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Abstract 
Glycosylation is a prevalent form of post translational modification, believed to 
occur on over 50% of human proteins. Homogeneous forms of glycoproteins are 
essential for developing an understanding of how activity is mediated at a structural 
level. As biological origins of glycoproteins give rise to complex mixtures of 
glycoforms, homogeneous glycoprotein production has become an important goal.  
As chemical protein synthesis is often limited to sequences of 30-50 residues, 
access to large native glycoproteins is currently restricted to fragment based 
approaches. Protein semi-synthesis enables the preparation of larger proteins 
which can be difficult to obtain through chemical synthesis alone. Consequently, a 
general semi-synthetic strategy towards N-glycoproteins has been proposed and 
demonstrated on Interferon-β-1 (IFNβ), a 166 residue glycoprotein. A three 
fragment strategy was designed, relying on the chemical synthesis of a short 
glycopeptide segment and recombinant expression of the two flanking domains. 
Homogeneity was established through the chemical synthesis of a glycopeptide 
containing a natively linked N-acetylglucosamine (GlcNAc), also enabling the 
selective transfer of complex oligosaccharides. After cloning and expression, the 
recombinant fragments were functionalised to allow assembly of the protein using 
Native Chemical Ligation. These desired protein modifications were achieved 
through the application of highly chemoselective reactions. These reactions were 
also applied towards the generation of N-glycopeptides compatible with the 
ligation strategy. Further to this, existing methods enabling the direct synthesis of 
functionalised N-glycopeptides were also explored. After glycopeptide synthesis, 
endoglycosidase A enabled the transfer of oligosaccharides to the N-
acetylglucosamine motif. This has allowed the preparation of the desired IFNβ 
glycopeptide as well as a glycosylated variant of glucagon like peptide-1. 
To expand the utility of endoglycosidase methodology, a novel sugar nucleotide 
was synthesised to facilitate the incorporation of a sialyl galactose mimic onto N-
glycans. The resulting oligosaccharides may serve as novel substrates for 
endoglycosidases in the preparation of N-glycoprotein mimics. 
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Abbreviations 
Ac acetyl 
Acm acetamidomethyl 
BAL backbone amide linker 
Boc tert-butyloxycarbonyl 
BOP benzotriazole-1-yl-oxy-tris(dimethylamino)phosphonium hexafluorophosphate 
CBD chitin binding domain 
CG carboxymethyl galactose 
CMP cytidine monophosphate 
CNX calnexin 
CRT calreticulin 
DCC N,N’-dicyclohexylcarbodiimide 
DCM dichloromethane 
DIC N,N’-diisopropylcarbodiimide 
DIPEA N,N-diisopropylethylamine 
DMF N,N-dimethylformamide 
DMC 2-chloro-1,3-dimethylimidazolinium chloride 
Dmmb 2-mercapto-4,5-dimethoxybenzyl 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
Dol-P dolichyl phosphate 
DTT dithiothreitol 
EDC N-ethyl-N’-(3-dimethylaminopropyl)carbodiimide 
EEDQ N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline 
Endo A endo-β-N-acetylglucosaminidase isolated from Arthrobacter Protophormiae 
EPL expressed protein ligation 
EPO erythropoietin 
ER endoplasmic reticulum 
ERGIC ER-Golgi intermediate compartment 
ESI electrospray ionisation 
FAB fast atom bombardment 
FMDV foot-and-mouth disease virus 
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Fmoc 9-fluorenylmethoxycarbonyl 
Gal galactose 
GDP guanosine diphosphate 
Glc glucose 
GlcNAc N-acetylglucosamine 
GLP-1 glucagon like peptide-1 
GlyCAM-1 glycosylation dependant cell adhesion molecule-1 
GST glutathione-S-transferase 
GT glycosyltransferase 
Gu.HCl guanidine hydrochloride 
HATU O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate 
hBNP human B-type natriuretic peptide 
HBTU O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate 
HFIP hexafluoroisopropanol 
HOAt 1-hydroxy-7-azabenzotriazole 
HOBt 1-hydroxybenzotriazole 
IFNβ Interferon β-1 
IPTG iso-propyl-β-ᴅ-thiogalactopyranoside 
LC-MS liquid chromatography mass spectrometry 
Lev levulinoyl 
LIC ligation independent cloning 
Man mannose 
MAP methionylaminopeptidase 
MCP-3 monocyte chemotactic protein-3 
MESNa sodium 2-mercaptoethanesulfonate 
MFD metal-free dethiylation 
MPA 3-mercaptopropionic acid 
MPAA 4-mercaptophenylacetic acid 
MS mass spectrometry 
NBS N-bromosuccinimide 
NCL native chemical ligation 
NDP nucleoside diphosphate 
NMP N-methyl-2-pyrrolidone 
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NMR nuclear magnetic resonance 
Npys 3-nitro-2-pyridinesulfenyl 
OST oligosaccharyltransferase 
Pbf 2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sulfonyl 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PG protecting group 
PMB para-methoxybenzyl 
PyBOP benzotriazole-1-yl-oxy-tris-pyrrolidinophosphoniumhexafluorophosphonate 
PyBrOP bromo-tris-pyrrolidino phosphonium hexafluorophosphate 
(RP)HPLC reversed phase high performance liquid chromatography 
RPM revolutions per minute 
RVG rabies virus glycoprotein 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SPPS solid phase peptide synthesis 
Su succinimide 
TBAB tetrabutylammonium bromide 
TBAHS tetrabutylammonium hydrogensulfate 
TBPP tetrabenzyl pyrophosphate 
tBu tert-butyl 
TCEP tris(2-carboxyethyl)phosphine 
TES triethylsilane 
TEV tobacco etch virus 
TFA trifluoroacetic acid 
TfOH triflic acid 
TIPS triisopropylsilane 
TLC thin layer chromatography 
TMS trimethylsilyl 
Tris tris(hydroxymethyl)aminomethane 
Trt trityl 
UDP uridine diphosphate 
UGGT UDP-glucose:glycoprotein glucosyltransferase 
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Amino acid single and three letter codes: 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Cysteine Cys C 
Glutamic acid Glu E 
Glutamine Gln Q 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
 
 
 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Selenocysteine Sec U 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
Unspecified amino acid  Xaa X 
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1 N-linked glycoproteins  
 
1.1 Introduction 
Glycosylation is a co and post-translational modification of proteins believed to 
occur on over 50% of proteins in humans, giving rise to important biological 
properties.1 This modification serves to assist protein folding, mediate both cell-cell 
recognition and immune defence whilst improving the therapeutic potential of the 
protein.2, 3 Carbohydrate structures also contribute to the hydrodynamic volume of 
glycoproteins, consequently prolonging circulation in vivo. In the absence of 
glycosylation, proteins can aggregate and fold incorrectly, rendering them unable to 
fulfil their functional role.3 Glycans also enhance the thermal stability of proteins, 
improve solubility and prevent degradation by proteolysis.4 
Glycosylation forms a covalent linkage between a carbohydrate and protein, most 
commonly to the amide nitrogen of an asparagine side chain. This N-linkage is 
observed at Asn-X-Ser or Asn-X-Thr motifs (where X is any amino acid except 
proline) and is largely abundant in eukaryotic cells. O-linked glycosylation is another 
prevalent form of glycosylation, formed through hydroxyl groups of serine or 
threonine residues.5  
Conversely to protein biosynthesis where assembly is template mediated, the 
oligosaccharide structures observed on complex N-linked glycoproteins are built up 
from smaller carbohydrate building blocks through a series of enzymatic steps.6 The 
vast assortment of building blocks and linkages can give rise to a number of possible 
glycan structures. Assembly of the glycan through a cascade of enzymatic steps is 
subject to substrate/acceptor competition, leading to varied incorporation of 
building blocks. As a consequence, glycoproteins are isolated as heterogeneous 
mixtures containing different ‘glycoforms’, exhibiting the same protein backbone 
but different glycosylation patterns.7  
 
Semi-synthesis of glycoproteins                                                      Bhavesh Premdjee 
 
18 
 
1.2 N-linked glycoprotein biosynthesis 
N-linked glycosylation is the attachment of a carbohydrate through the amido 
group of an asparagine and is found to be more prominent than O-linked 
glycosylation.8 In mammalian cells, the synthesis of the glycan commences on the 
cytosolic surface of the ER (Figure 1.1). Individual monosaccharide building blocks 
are added in a stepwise fashion to the lipid carrier, dolichylphosphate. The first 
seven sugars (two N-acetylglucosamine and five mannose residues) are 
enzymatically transferred by glycosyltransferases from sugar nucleotide precursors 
UDP-GlcNAc and GDP-Man. The next seven residues (four mannose and three 
glucose) are attached in the ER lumen from lipid derived intermediates, Dol-P-Man 
and Dol-P-Glc.  
 
Figure 1.1: N-glycoprotein biosynthesis in the ER 
The resulting oligosaccharide is then transferred to a growing polypeptide  by an 
oligosaccharyltransferase (OST) and covalently binds to the asparagine side chain.6 
In a recent study, the X-ray crystal structure of a bacterial OST has elucidated the 
critical residues involved in this reaction. The co-crystal structure with a model 
hexapeptide ‘DQNATF’ suggests that the β-hydroxyl of threonine forms three 
hydrogen bonds to a ‘WWD’ motif in the catalytic subunit of the OST (Figure 1.2 a).9 
Critical to the function of the OST, a divalent cation coordinates the catalytic 
residues D56, D154 and E319 to activate the acceptor asparagine (Figure 1.2 b and 
c). Interestingly, the amide is activated sufficiently to act as a nucleophile and 
attacks C-1 of the oligosaccharide to form the N-glycosidic bond. It was 
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consequently proposed that the unique reactivity of the amide arises from the 
twisting of the C-N bond. The rotation out of planarity is facilitated by hydrogen 
bonding with catalytic residues D56 and E319. 
 
Figure 1.2: Mechanism for glycan transfer in the ER
9 
sad 
Following attachment of the glycan to the growing polypeptide, terminal glucose 
residues are trimmed by glucosidases I and II, to form a high mannose 
intermediate, typically GlcMan9GlcNAc2.
10 The resulting intermediates are bound by 
specific lectins calnexin (CNX) and/or calreticulin (CRT) (Figure 1.3), bringing the 
glycoprotein into close proximity with cochaperone oxidoreductase ERp57.11-13 The 
oxidoreductase forms disulfide bonds with the substrate, enabling the formation of 
correctly paired disulfides through subsequent oxidation and isomerisation 
reactions.14 The cleavage of the final Glc residue by glucosidase II causes the 
complex to dissociate, releasing the glycoprotein. Correct folding is controlled by 
UDP-glucose:glycoprotein glucosyltransferase (UGGT), which transfers glucose units 
to misfolded glycoproteins, forcing re-entry to the CNX/CRT cycle for refolding.15 
This process is repeated until the protein is correctly folded or degraded. The 
correctly folded, deglucosylated high mannose intermediates are bound by lectins 
ERGIC-53 or VIPL, which facilitate transport to the Golgi complex.16 
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Figure 1.3: The Calreticulin-Calnexin cycle 
sad 
At the Golgi complex (Figure 1.4), the glycoprotein undergoes trimming of mannose 
residues. An additional N-acetylglucosamine is added, after which further mannose 
trimming takes place. During terminal glycosylation, additional sugar residues are 
added onto the glycan structure, including N-acetylglucosamine, galactose, sialic 
acid and fucose. Figure 1.4 shows one pathway in the final stages of glycosylation, 
but alternative terminal glycosylation patterns are known to occur as a result of 
varied incorporation of sugars, furnishing a range of glycans (Figure 1.5).17, 18 
 
Figure 1.4: N-glycoprotein biosynthesis in the Golgi 
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Figure 1.5: Examples of N-glycans isolated from human cells
18
 
sad 
To gain a reliable understanding of how glycoprotein activity is mediated at a 
structural level, it is critical that studies are performed on single homogeneous 
forms. Glycoproteins from natural biological sources are largely unsuitable, as the 
phenomenon of microheterogeneity gives rise to inseparable mixtures of 
glycoforms.19 Accordingly, much interest has grown in the chemical synthesis of 
homogenous glycoproteins.  
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1.3 Strategies towards the synthesis of homogeneous N-linked 
glycoproteins 
To meet the demand of homogeneous N-glycoprotein synthesis, it is essential that 
glycans are accessible as defined single structures. The synthesis of such elaborate 
structures has been achieved by total chemical synthesis,20-23 chemoenzymatic 
synthesis24, 25 and technologies have also been developed to allow isolation of 
complex glycans from natural sources.26 Once obtained, the incorporation of 
oligosaccharides into native N-glycoproteins is commonly achieved by one of three 
strategies (Figure 1.6). 
 
Figure 1.6: Retrosynthetic analysis highlighting synthetic routes towards N-glycoproteins 
The incorporation of complex glycans can be achieved by the insertion of suitably 
protected glycoamino acid “cassettes” during solid phase peptide synthesis (SPPS) 
(Figure 1.6 a). Pioneered by the Kajihara and Unverzagt groups, this has been 
developed to enable compatibility with Boc and Fmoc methods.27-29 During 
subsequent elongation steps, it is often necessary to protect carbohydrate 
hydroxyls by acetylation to prevent unwanted side reactions. However, it has been 
found that large acetylated glycans can impede peptide synthesis.30 As an 
alternative, the GlcNAc-Asn linkage is formed after the completion of peptide 
synthesis. This convergent strategy relies on the orthogonal deprotection of the 
aspartic acid residue at the desired site of glycosylation, followed by its reaction 
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with a glycosyl amine (Figure 1.6 b). Originally developed by Lansbury,31 this 
strategy has been applied to the synthesis of a number of N-glycoproteins.32-37 Until 
recently,38, 39 a major drawback encountered with this method was the formation of 
aspartimide by-products (Scheme 1.1).40, 41  
 
Scheme 1.1: Formation of aspartimide by-products from the cyclisation reaction with protein backbone 
Figure 1.6 c highlights a strategy that relies on the enzyme catalysed formation of 
the GlcNAcβ(1-4)GlcNAc chitobiose core present in N-glycans.42 
Endohexosaminidases have been shown to process sugar oxazolines as activated 
donors to promote transglycosylation reactions to GlcNAc.43-46  
Chemical assembly of proteins is most commonly achieved using solid phase 
synthesis, although is not routinely performed for sequences larger than 30 
residues. Therefore the synthesis of larger proteins relies heavily on methods which 
allow the conjugation of smaller fragments. The most distinguished method, Native 
Chemical Ligation (NCL) allows the chemoselective reaction of unprotected protein 
segments, resulting in the formation of a native amide bond. Fragment based 
approaches allow the incorporation of complex glycopeptides and have been 
successfully applied towards the synthesis of large glycoproteins which were 
otherwise inaccessible from traditional chemical methods. Despite impressive 
efforts,30, 47-49 homogeneous glycoprotein synthesis still presents a significant 
challenge and has not advanced at the same rate as unglycosylated protein 
synthesis. 
NCL can be extended to the semi-synthesis of proteins by ligating chemically 
synthesised fragments with proteins obtained from biosynthetic methods. 
Recombinant expression of unmodified proteins can obviate the laborious synthesis 
of large fragments, which can be difficult to obtain by chemical synthesis alone. 
Therefore a semi-synthetic strategy towards native N-glycoproteins may provide a 
significant advantage to existing methodology.  
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1.4 Chemical Protein Synthesis 
Traditionally, peptide syntheses were carried out using fully protected amino acids 
in organic solvents. However, during attempts to synthesise longer polypeptide 
chains, many shortcomings of the ‘solution phase’ strategy were realised. With 
increasing chain length, fully protected peptides suffered from poor solubility, 
subsequently leading to poor coupling reactions. Another difficulty encountered 
was the inability to purify and characterise the protected peptides.50 Multiple 
recrystallisations were not reliable enough to guarantee a pure product and 
characterisation would require deprotection of the peptide. Activation of the C-
terminal amino acid under basic conditions was also accompanied by racemisation. 
Despite the problems associated with solution phase peptide synthesis, short 
peptide sequences have been successfully synthesised employing this method.51 
 
1.5 Solid phase peptide synthesis 
In 1963, Bruce Merrifield introduced a remarkable concept which overcame 
difficulties encountered with solution phase synthesis.52 His strategy utilised an 
insoluble polymeric support to which a C-terminal amino acid was covalently 
attached. Removal of the N(α) amino protecting group could be achieved 
selectively, and the resin bound amino acid could be washed and isolated by 
filtration. The next N(α) amino protected, carboxyl activated residue could then be 
added, resulting in the formation of a peptide bond. After completion of the 
coupling, the excess amino acid and soluble by-products could simply be washed 
away to essentially yield a pure peptide. The process could then be repeated until 
the target peptide had been constructed. In the final step the peptide could be 
cleaved from the solid support, simultaneously removing any side chain protecting 
groups. This method has proved to be an extremely useful strategy, providing 
access to peptides of higher purity with better yields. Conveniently, this method is 
also suitable for automation by specialised machines. The most commonly utilised 
methods employ Boc (tert-butyloxycarbonyl) or Fmoc (9-fluorenylmethoxycarbonyl) 
for temporary protection of the N(α) amino group, with each strategy having 
advantages and limitations. 
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Scheme 1.2: Solid phase peptide synthesis 
Merrifield’s evolved SPPS method relied on N(α) Boc protection and benzyl-based 
protection for side chain functionalities. Boc removal is achieved with TFA and after 
neutralisation of the resulting ammonium salt, peptide elongation can be 
continued. Cleavage from the resin and concomitant deprotection of side chains is 
most commonly carried out by acidolysis using anhydrous hydrofluoric acid. This 
step highlights the major drawback of the Boc method, as the extreme toxicity and 
volatility of HF limits its use in laboratories without specialised equipment. 
Furthermore, repeated exposures to TFA and finally HF renders peptides with acid 
sensitive functionalities such as glycosidic linkages incompatible with this approach.  
Due to the complications of Boc SPPS, researchers sought an alternate strategy that 
would obviate the repeated exposure of peptides to acidic conditions and the use 
of hazardous reagents. This demand was met by the Fmoc group,53 and was first 
applied in SPPS by Meienhofer.54 The Fmoc strategy employs the use of orthogonal 
protecting groups, where the N(α) amino group is deprotected by mild treatment 
with piperidine. The peptide-resin linkage and side chain protecting groups are 
stable to these conditions and are only cleaved by TFA on completion of peptide 
synthesis. 
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1.6 Peptide bond formation 
The progression of SPPS has been closely reliant on reactions which allow rapid 
coupling of amino acids. Carboxylic acid and amine functionalities do not react with 
each other spontaneously, and in extreme cases can require high temperatures.55 
Therefore, in most cases amide bond formation is facilitated by the activation of 
carboxylic acids to promote acylation of the free amine. A vast number of reagents 
and methods have been developed, a selection of which will be elaborated upon in 
this chapter. First and foremost, it is important to appreciate that SPPS is usually 
carried out in the C → N direction to prevent undesired side reactions resulting 
from the activation of resin bound carboxyl groups (Scheme 1.3).56 Peptide 
synthesis in the N → C direction can result in attack of the activated carboxyl group 
by the adjacent amide bond, resulting in the formation of a diketopiperazine. 
Another possible side reaction commences with cyclisation to an oxazolone, which 
is followed by enolisation and the loss of the proton from the α-carbon. 
Accordingly, this pathway is capable of promoting racemisation, as the 
reprotonation step can take place from either face.  
 
 
Scheme 1.3: Diketopiperazine formation and racemisation during SPPS in the N → C direction  
N,N’-dicyclohexylcarbodiimide (DCC) was one of the first coupling reagents to find 
use in peptide synthesis.57 The reaction of DCC with carboxylic acids gives rise to a 
number of possible reaction pathways (Scheme 1.4). Initially an O-acylisourea is 
formed and this highly reactive intermediate is susceptible to direct aminolysis 
(path A). An excess of carboxylic acid leads to the formation of a symmetrical 
anhydride which is also capable of acylating an amine (path B). A drawback of this 
activation method is the rearrangement to the N-acylurea. This results in the 
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irreversible consumption of the carboxylic acid (path C). The by-product of the 
coupling reaction is N,N’-dicyclohexylurea, which is solubilised with TFA or 
methanol. Alternative carbodiimides have also been developed including N,N’-
diisopropylcarbodiimide (DIC) and N-ethyl-N’-(3- 
dimethylaminopropyl)carbodiimide (EDC).58 
 
 
Scheme 1.4: Carbodiimides in peptide coupling reactions 
ssad 
It was later discovered that the O-acylisourea intermediates were prone to 
oxazolone formation and subsequently gave rise to racemisation.59 This was shown 
to be minimised by the addition of 1-hydroxybenzotriazole (HOBt), which also 
improved yields.60 The protonation of the O-acylisourea by HOBt prevents the 
intramolecular rearrangement to the N-acylurea and generates the corresponding 
active ester. The reactivity is further enhanced by the ability to stabilise the 
approaching amino group by hydrogen bonding. A derivative of HOBt, 1-Hydroxy-7-
azabenzotriazole (HOAt) was found to be superior in terms of yield and ability to 
reduce racemisation.61 A number of alternative additives have also been developed 
for carbodiimide coupling.62 
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Scheme 1.5: HOBt assisted bond formation in DCC coupling 
The use of HOBt and HOAt inspired the development of other benzotriazole 
reagents for generation of active esters. Castro reported Benzotriazole-1-yl-oxy-
tris(dimethylamino)phosphonium hexafluorophosphate (BOP), which initially 
produces the acylphosphonium species before interception by HOBt to form the 
active ester (Scheme 1.6).63 The resulting hexamethylphosphoric triamide by-
product is extremely toxic and consequently BOP has been superseded by 
Benzotriazole-1-yl-oxy-tris-pyrrolidinophosphonium hexafluorophosphonate 
(PyBOP).64 
 
 
Scheme 1.6: BOP and PyBOP assisted amide bond formation 
The formation of active esters is also achieved through the use of 
uronium/aminium salts such as O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate (HBTU) (Scheme 1.7).65 A number of derivatives have been 
reported,62 though it has been suggested that their use does not result in significant 
differences.66 
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Scheme 1.7: HBTU activation of carboxylic acid 
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1.7 Peptide ligation 
Despite being an excellent tool, the efficiency of SPPS for peptide assembly 
decreases for longer sequences due to the accumulation of by-products and 
impurities. With many peptides and proteins of interest containing over 30 amino 
acids, researchers sought a method to overcome the shortcomings of SPPS. It was 
envisaged that the most promising strategy would enable smaller unprotected 
peptide fragments to be joined together chemoselectively.  
Schnolzer and Kent were able to first demonstrate chemoselective ligation of two 
unprotected peptides via a thioester linkage in the synthesis of HIV-1 protease.67 
Other chemical ligation strategies also emerged, all able to conjugate two 
unprotected peptides through a non-native peptide bond.68, 69 However peptides 
containing non-native structures were criticised and deemed unreliable for studies 
on protein structure and function. Hence, further investigations were made into a 
ligation strategy that would furnish a native peptide bond. 
 
1.8 Native Chemical Ligation  
In 1994, the Kent group reported the synthesis of proteins by Native Chemical 
Ligation.70 Based on a reaction first described by Wieland,71 this significant 
innovation allowed ligation of two unprotected peptide segments through a native 
peptide bond. Traditionally in the first step of NCL, a C-terminal peptide thioester 
undergoes transthioesterification with the thiol group of an N-terminal cysteine. 
The intermediate rearranges via a spontaneous intramolecular S→N acyl transfer, 
resulting in the formation of an amide bond (Scheme 1.8). The reaction is typically 
performed at neutral pH under denaturing conditions and can be catalytically 
enhanced by aryl thiols.72 The widespread use and success of NCL has also been 
accompanied by the development of a number of alternative ligation strategies.73-79 
However, the employment of mild aqueous conditions and remarkable 
chemoselective reactivity in the absence of protecting groups has distinguished NCL 
as the most popular method for assembling proteins from smaller fragments.  
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Scheme 1.8: Native Chemical Ligation  
ssad 
An important consideration for NCL strategies is the relatively low abundance of 
cysteine in protein sequences. Furthermore, the position of the Xaa-Cys junction is 
not always at a strategically favourable position. Although the substitution of 
cysteine for non-critical residues can be well tolerated without loss of protein 
activity,80 methods have been developed to overcome this limitation.  
One of the simplest innovations was the use of cysteine surrogates. After 
participation in NCL, these residues can be converted to native structures through 
desulfurisation or alkylation.81, 82 This potential of desulfurisation was first 
demonstrated by Yan and Dawson, who converted cysteine to alanine after ligation 
using Raney nickel or palladium/aluminium oxide (Scheme 1.9).83  
 
 
Scheme 1.9: Desulfurisation of cysteine to alanine after NCL  
Such conditions however, can lead to the hydrogenation of tryptophan and 
demethythiolisation of methionine. To avoid the use of metal-based catalysts, 
Danishefsky developed a free radical approach to desulfurisation using TCEP and 
water soluble VA-044 (2,2’-azobis(2-(2-imidazolin-2-yl)propane) dihydrochloride) as 
a radical initiator (Scheme 1.10).84  
 
 
Scheme 1.10: Proposed mechanism for VA-044/TCEP mediated desulfurisation 
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Metal-free dethiolation (MFD) was considered to be a milder treatment with 
improved selectivity and vastly expanded the applicability of ligation-desulfurisation 
methods. Consequently, various thiolated amino acids have been introduced to 
broaden the scope of NCL (Figure 1.7). The method was further extended by 
Dawson, who showed selenocysteine could be selectively deselenised to alanine in 
the presence of cysteine residues.85 A number of other selenol containing amino 
acid derivatives have also been developed for NCL.86 
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Figure 1.7: Thiolated amino acids used for ligation desulfurisation strategies 
ssad 
The low abundance of cysteine residues has also driven the investigation of thiol 
auxiliaries for NCL. Participation in the ligation reaction results in the formation of 
an amide linked product, after which the auxiliary is amenable to removal (Scheme 
1.11). A number of cleavable auxiliaries have been developed,102-106 although their 
use is limited to certain junctions.107 
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Scheme 1.11: Auxiliary mediated Native Chemical Ligation 
ssad 
The development of desulfurisation and auxiliary strategies has led to the 
widespread use of NCL. Most importantly these enabling technologies are 
compatible with glycosylated fragments and have been vital in the total chemical 
synthesis of glycoproteins.108 
The task of obtaining the C-terminal fragment for NCL is comparatively 
straightforward, only requiring an N-terminal amino acid (or auxiliary) with a thiol 
moiety. These building blocks can be incorporated during SPPS, although in the case 
of recombinant fragments are limited to cysteine. More often the challenge 
encountered when attempting to synthesise proteins through NCL, is obtaining the 
N-terminal fragment adorned with a C-terminal thioester.  
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1.9 Chemical peptide thioester synthesis 
Despite Boc SPPS facilitating the direct synthesis of peptide thioesters, the highly 
acidic conditions used in the final deprotection are often incompatible with 
glycosidic appendages.109 Until recently,48 this problem remained largely unresolved 
and consequently the Fmoc method has gained popularity for the synthesis of 
glycopeptides and their respective thioesters. However, thioesters are susceptible 
to nucleophilic attack during removal of the Fmoc group with piperidine, rendering 
direct synthesis unsuitable by routine protocols. Therefore, an important goal in the 
synthesis of glycoproteins has been the development of methods which enable the 
synthesis of glycopeptide thioesters via the Fmoc strategy.  
1.9.1 Direct synthesis of peptide thioesters via Fmoc method 
In an attempt to circumvent the cleavage of the thioester linkage, a number of 
researchers investigated the replacement of piperidine with less nucleophilic bases 
for Fmoc cleavage.110-112 Hojo demonstrated the applicability of this strategy 
towards the synthesis of a glycopeptide thioester bearing an N-linked 
pentasaccharide (Scheme 1.12).113 
 
 
Scheme 1.12: Fmoc SPPS of an N-linked glycopeptide thioester using bases with lower nucleophilicity 
ssad 
However, the use of bases with lower nucleophilicity can lead to racemisation of 
amino acids adjacent to the thioester. The thioester itself is also susceptible to 
aminolysis from adjacent residues during the first few cycles of peptide synthesis. 
This led researchers to investigate the direct thioesterification of fully protected 
peptides after assembly and cleavage from the resin. The use of highly acid-
sensitive resins facilitates the release of protected peptide acids, which can 
subsequently be activated and thioesterified.114-116 Kajihara successfully applied this 
concept towards the synthesis of a sialylglycopeptide thioester of monocyte 
chemotactic protein-3 (MCP-3).117, 118 The glycopeptide was synthesised on HMPB-
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PEGA resin, followed by treatment with acetic acid and trifluoroethanol to release 
the partially protected peptide. Subsequent activation of the C-terminal carboxylic 
acid and condensation with benzyl mercaptan afforded the thioester (Scheme 
1.13). 
 
 
Scheme 1.13: Kajihara’s thioesterification of a side chain protected sialylglycopeptide 
ssad 
This method has been further extended to obviate the use of thiols, by coupling 
amino acid thioesters (Scheme 1.14).119 However, these approaches can be 
complicated by the poor solubility of fully protected peptides.  
 
 
Scheme 1.14: Protected peptide coupling to amino acid thioesters 
ssad 
Another approach is the conversion of resin bound peptides to their corresponding 
thioester. This strategy relies on peptide attachment through a side chain and 
orthogonal protection of the C-terminal carboxylic acid in the form of an allyl 
ester.120-122 Following peptide synthesis, the removal of the allyl group allows 
thioesterification by coupling of a thiol or an amino acid thioester. Wong and co-
workers demonstrated this approach towards a glycosylated thioester 
corresponding to erythropoietin (EPO) residues 1-28 (Scheme 1.15).123  
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Scheme 1.15: Side chain anchoring strategy at threonine for the synthesis of EPO 1-28 thioester 
ssad 
The restriction of this methodology to amino acids with appropriate side chains is 
overcome by the use of the backbone amide linker (BAL). Originally applied to Fmoc 
SPPS by Barany,124 the amino group of the penultimate C-terminal residue was 
initially attached to the tris(alkoxy)benzaldehyde resin via a reductive amination. 
Peptide extension in the C → N direction followed by allyl deprotection allowed 
coupling of an amino acid thioester (Scheme 1.16). Difficulties encountered with 
this strategy are largely due to the inefficient acylation of the secondary amine. 
 
 
Scheme 1.16: BAL strategy applied to the synthesis of peptide thioesters via Fmoc SPPS 
ssad 
More recently, a linker developed by Raz and Rademann, showed that by using a 
tert-butyl thiol moiety it was possible to synthesise peptide thioesters that were 
stable to secondary amines (Scheme 1.17).125 Steric hindrance and electron 
donation contribute to the stabilisation of the structure, although is still able to 
undergo thiolysis to afford the thioester. 
 
Scheme 1.17: Peptide thioester synthesis on a tert-butyl thiol linker 
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1.9.2 Fmoc peptide thioester synthesis enabled by post SPPS activation of 
specialised linkers 
An alternative to the synthesis of peptide thioesters via the Fmoc approach utilises 
specialised linkers, which upon activation are susceptible to nucleophilic attack. 
One example of this is the use of a modified sulfonamide ‘safety catch’ linker in 
which the C-terminus of the peptide is attached to an N-acyl sulfonamide resin.126 
This functionality exhibits stability to acid and base, and is activated for cleavage 
with iodoacetonitrile or trimethylsilyldiazomethane prior to thiolysis. The method 
was extended by Unverzagt, who incorporated a double linker to allow convenient 
monitoring of peptide synthesis in the preparation of a glycopeptide derived from 
RNAse (Scheme 1.18).127 
 
Scheme 1.18: Unverzagt’s safety-catch linker in the synthesis of a glycopeptide thioester 
ssad 
The use of the ‘safety catch’ strategy has successfully been applied to the synthesis 
glycopeptide thioesters,127-129 although low loading of the first amino acid can lead 
to decreased yields.130  
Camarero demonstrated that Fmoc SPPS could be carried out on an aryl hydrazide 
linker and subsequent oxidation to the acyl diazene could be followed by 
displacement with an amino acid thioester (Scheme 1.19).131 Although successfully 
applied to the synthesis of a peptide thioester corresponding to the N-terminal SH3 
domain of the c-Crk adaptor protein, undesired oxidation is observed at cysteine 
and methionine residues. 
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Scheme 1.19: Camarero’s aryl hydrazine linker for Fmoc SPPS of peptide thioesters 
ssad 
Blanco-Canosa and Dawson later showed the utility of aromatic N-acyl ureas to 
thioesterify peptides.132 Peptides could be assembled by Fmoc SPPS on a 3,4-
diaminobenzoyl linker and formation of the N-acylbenzimidazolone was induced by 
4-nitrophenyl chloroformate. Following ring closure under basic conditions, 
thiolysis of the activated peptide allows the formation a thioester (Scheme 1.20). 
 
Scheme 1.20: Fmoc synthesis of rabies virus glycoprotein thioester with Dawson’s Dbz linker 
ssad 
The backbone pyroglutamylimide linker was also shown to facilitate thioester 
formation by Tofteng et al.133 Deprotection of the C-terminal glutamic acid side 
chain followed by activation with PyBrOP and microwave irradiation, allows 
pyroglutamylimide formation prior to thiolysis (Scheme 1.21). 
 
 
Scheme 1.21: Pyroglutamylimide strategy for the synthesis of peptide thioesters 
Semi-synthesis of glycoproteins                                                      Bhavesh Premdjee 
 
39 
 
1.9.3 Fmoc SPPS of latent thioesters 
Another recent development in Fmoc SPPS of thioesters, is the use of surrogates in 
the form of acyl hydrazides. The utility of peptide hydrazides for ligation was 
originally investigated by Ramage,134 although necessitated the protection of 
primary amino groups. The use of peptide hydrazides was further investigated by 
Liu, who showed that it was possible to selectively oxidise unprotected peptide 
hydrazides and convert the corresponding acyl azide to the thioester (Scheme 
1.22).135 Peptide hydrazides can be synthesised by Boc and Fmoc methods and also 
exhibit enhanced stability compared to thioesters. The ability to use peptide 
hydrazides as latent thioesters can be highly advantageous in convergent 
strategies.136 
 
 
Scheme 1.22: Fmoc SPPS of a peptide hydrazide and conversion to a thioester 
  
Semi-synthesis of glycoproteins                                                      Bhavesh Premdjee 
 
40 
 
1.9.4 Peptide thioester formation via O→S acyl transfer 
In recent years, the use of acyl transfer has gained considerable interest for the 
synthesis of thioesters. In 2004, Danishefsky showed that installation of a 2-
mercaptophenyl ester at the C-terminus of a peptide could facilitate thioester 
formation via O→S acyl transfer and be used directly in ligation reactions (Scheme 
1.23).34 
 
Scheme 1.23: The use of α-2-mercaptophenyl esters for thioester formation via O→S acyl transfer 
ssad 
Botti also showed O→S acyl transfer of peptide esters to generate the 
corresponding thioester under ligation conditions.137 This methodology was applied 
to glycopeptides by Zheng et. al, where thiolysis allows aryl thioester formation 
directly from the solid support (Scheme 1.24).138  
 
Scheme 1.24: Synthesis of glycopeptide thioesters via O→S acyl transfer  
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1.9.5 Peptide thioester formation via N→S acyl transfer 
Many research groups have shown the use of N→S acyl transfer in the formation of 
peptide thioesters. The N→S acyl transfer mechanism has been shown to occur in 
nature, facilitating splicing reactions between inteins and N-exteins (see section 
1.10.1.1). The resulting S-acyl intermediates can subsequently be intercepted by a 
thiol or used directly in ligation. 
In a study investigating the use of the 2-mercapto-4,5-dimethoxybenzyl (Dmmb) 
group as a glycine auxiliary, it appeared that removal under acidic conditions 
triggered an N→S acyl shift to generate an internal thioester bond (Scheme 1.25).139 
 
 
Scheme 1.25: Vorherr’s observation of N→S acyl transfer on attempted auxiliary removal 
ssad 
Inspired by this observation, Vorherr and Aimoto evaluated the use of a C-terminal 
Dmmb group to form thioesters. After peptide assembly, TFA cleavage allowed 
removal of the side chain protecting groups and initiation of the N→S acyl transfer. 
This was followed by treatment with 2-mercaptoethanesulfonic acid to intercept 
the S-acyl intermediate resulting in the formation of the thioester (Scheme 1.26).140 
 
Scheme 1.26: Dmmb mediated thioester formation via N→S acyl transfer 
The reaction was shown to proceed without any evidence of racemisation and can 
be performed at 37 °C to increase the rate of thioester formation. 
In 2004, Muir observed that a protein splicing reaction was enhanced by ground 
state destabilisation of a non-planar scissile amide bond.141 Encouraged by this and 
a previous report which suggested that N-acyloxazolidinones were capable of 
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distorting amide planarity,142 Otaka attempted the preparation of thioesters via a 
mercaptomethylated N-acyloxazolidinone derivative.143 Fmoc SPPS required the use 
of Aimoto’s reagent mixture112 to prevent breakdown of the N-acyloxazolidinone. 
After cleavage from the resin and removal of the PMB group, N→S acyl transfer was 
induced in the ligation buffer (pH 7.6) in the presence of an N-terminal cysteine 
peptide affording full length hBNP (human B-type natriuretic peptide) (Scheme 
1.27). 
 
Scheme 1.27: N-acyloxazolidinone synthesis of thioesters and use in NCL 
A drawback of this method is its incompatibility with piperidine during Fmoc 
deprotection. This led to the pursuit of more robust acyl transfer devices, which 
were compatible with Fmoc SPPS. Peptide N-sulfanylethylanilides were investigated 
as it was suspected that adjacent positioning of an aromatic ring would lead to 
activation of the amide bond. N→S acyl transfer was promoted with  
4 M HCl/DMF and TCEP (1% w/v) at 37 °C for 8 hours, before thiolysis with MESNa. 
Further developments of this method allowed the acyl transfer reaction to be 
performed on-resin, allowing the crude release of peptide thioesters upon 
treatment with a thiol in aqueous buffer (Scheme 1.28).144 
 
Scheme 1.28: N-sulfanylethylanilides mediating on-resin thioester formation 
In an extension of this work, Melnyk and Liu independently reported the use of 
Bis(2-sulfanylethyl) amides to synthesise peptides for ligation.145-147 The installation 
of two thiol groups obviates an isomerisation step to form the energetically 
unfavourable cis conformation. Therefore, this motif undergoes N→S acyl transfer 
more readily, as one of the sulfhydryl groups is always anti to the carbonyl oxygen 
and hence able to promote the intramolecular reaction (Scheme 1.29). 
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Scheme 1.29: Application of bis(2-sulfanylethyl) amides for thioester synthesis and direct use in NCL 
Hojo and Nakahara later investigated the use of thiolated proline derivative as a 
post SPPS thioesterification device.148 The reaction was expected to proceed via the 
formation of a diketopiperazine, which is particularly known to occur at C-terminal 
Pro-Pro dipeptides (Scheme 1.30). 
 
 
Scheme 1.30: Diketopiperazine formation towards enhanced thioester formation 
ssad 
However, the expected transformation did not occur under the reaction conditions 
and it was suspected that the reverse S→N acyl shift was favoured over 
diketopiperazine formation. Consequently, the reaction was attempted in the 
presence of 3-mercaptopropionic acid (MPA) in an attempt to form the thioester 
via intermolecular exchange. Although this method successfully generated the 
thioester, acceptable reaction rates necessitated the use of microwave irradiation. 
The reaction was subsequently applied towards the synthesis of a glycopeptide 
thioester (Scheme 1.31). 
 
Scheme 1.31: N-glycopeptide thioester formation using a mercaptomethylated proline derivative 
 ssad 
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The need for microwave irradiation and the laborious preparation of the 
mercaptomethyl proline derivative led the authors to investigate alternative 
devices for N→S acyl transfer.149 It was postulated that the intramolecular 
rearrangement was favoured by the increased lability of the tertiary amide bond 
when the C-terminal residue was proline. Accordingly, a number of N-alkyl cysteine 
derivatives were prepared and evaluated for thioester formation. Encouragingly, 
the N-alkyl cysteine derivatives could be thioesterified at room temperature with 
lower concentrations of MPA without the need of microwave irradiation. 
Conversion to the thioester was found to proceed quicker when bulky groups were 
used to alkylate the nitrogen, however steric hindrance resulted in poor coupling of 
the next amino acid. N-ethyl cysteine provided the best overall yield and has 
consequently been utilised for the synthesis of glycopeptide thioesters (Scheme 
1.32).150 
 
Scheme 1.32: N-alkyl cysteine mediated thioesterification of glycopeptides  
ssad 
Tam later developed an alternative mercaptomethylated proline surrogate in the 
form of a thiazolidine.151 The shorter preparation of the acyl transfer device relied 
on the intermolecular cyclisation of a resin bound cysteine with 2-(tritylthio) 
acetaldehyde. After Fmoc SPPS, the peptide was cleaved from the resin with TFA, 
TfOH and thiocresol, leading to concomitant thioester formation (Scheme 1.33). 
 
Scheme 1.33: Mercaptomethylated thiazolidine mediated thioester formation 
ssad 
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Kawakami and Aimoto showed that it was possible to form thioesters through use 
of an autoactivating cysteine-proline ester. Originally reported by Zanotti et al.152 
N→S acyl shift is followed by diketopiperazine formation, thereby preventing the 
reverse reaction. The resulting diketopiperazine can be transthioesterified to 
generate peptide thioesters, or can be used directly in NCL reactions (Scheme 
1.34).153 The reaction occurs under neutral conditions at room temperature and 
presents a mild method of peptide thioesterification. 
 
Scheme 1.34: Cysteine-proline ester mediated ligation  
ssad 
Recently, Liu introduced the concept of Fmoc synthesis of thioesters using a C-
terminal enamide.154 The clever design of the linker in this strategy allows thioester 
formation to take place via N→S acyl transfer, with the reverse reaction prevented 
by enamine hydrolysis. This essentially allows thioester formation to take place 
during cleavage from the resin without the need for any non-standard 
manipulations and has been successfully used to generate glycopeptide thioesters 
(Scheme 1.35). 
 
 
Scheme 1.35: Enamide mediated thioester formation 
Crucially, the methylation of the C-terminal amide nitrogen prevents thiazole 
formation, which was found to predominate in earlier studies. The major limitation 
of this method, is the multistep procedure required for the synthesis of the 
enamide building block. 
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The use of N→S acyl transfer for the synthesis of peptide thioesters is usually 
facilitated by incorporation of unnatural motifs preinstalled during SPPS. However, 
Macmillan observed that this transformation could also be achieved by a C-terminal 
cysteine residue (Scheme 1.36).155 Thioester formation via N→S acyl shift was found 
to be efficient at Gly-Cys, His-Cys and Cys-Cys junctions and has been shown to be 
compatible with thioester synthesis of O-linked glycopeptides.156  
 
Scheme 1.36: Cysteine promoted thioester formation via N→S acyl shift  
 
The commercial availability of preloaded cysteine resins makes this a 
straightforward and accessible strategy towards synthesising peptide thioesters via 
the Fmoc method. The methodology also allows the convenient synthesis of cyclic 
peptides, allowing thioester formation and irreversible cyclisation to take place 
concomitantly under the same reaction conditions.157 The concept was also 
extended to C-terminal selenocysteine residues, where it was shown that N→Se 
acyl transfer could also lead to accelerated formation of thioesters.158  
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1.10 Production of recombinant proteins compatible with NCL 
The use of recombinant DNA technology in the overexpression of proteins has 
provided an indispensable tool towards the study of protein structure and function. 
One of the most widely used hosts for protein expression is E. coli, which can be 
grown rapidly at high density to provide unmodified proteins.159 The ability to 
access large recombinant fragments led to an interest in their use for protein semi-
synthesis. However, the most commonly available expression systems are restricted 
to unmodified protein structures, prompting researchers to investigate techniques 
which enable their selective functionalisation. For protein semi-synthesis, particular 
emphasis has been geared towards methods which enable their compatibility with 
Native Chemical Ligation. 
1.10.1 Production of recombinant protein thioesters for NCL 
 Intein mediated production of recombinant protein thioesters 1.10.1.1
One of the first methodologies explored for the thioesterification of recombinant 
proteins exploited the unique reactivity of protein splicing elements. These proteins 
are able to undergo intramolecular rearrangements to excise an internal sequence 
(intein), whilst subsequently linking the resulting external sequences (exteins). The 
first step in the splicing mechanism most commonly involves an N→S acyl transfer 
at the junction between the N-extein and intein. The resulting “S-peptide” 
intermediate can undergo transthioesterification by the side chain of cysteine at 
the intein-C-extein junction. Finally, the intein is excised from the branched 
intermediate through asparagine mediated succinimide formation and the thioester 
linked exteins undergo an S→N acyl transfer to form a native amide linkage 
(Scheme 1.37).160 
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Scheme 1.37: Mechanism of protein cis-splicing 
ssad 
The use of intein technology was initially exploited for the single step purification of 
recombinant proteins using a C-terminal chitin binding domain (CBD) for chitin 
affinity chromatography. Mutated versions of inteins were designed to only allow 
the initial N→S acyl transfer to proceed, with the resulting intermediate susceptible 
to intermolecular transthioesterification by a thiol (Scheme 1.38). This effectively 
allows the protein of interest to be cleaved at the splice junction.161  
 
 
 
 
 
Scheme 1.38: Intein mediated purification of proteins via thiolysis 
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Cleavage of the intein fusion with β-mercaptoethanol or dithiothreitol ultimately 
results in a C-terminal carboxylic acid via hydrolysis of the thioester. Inspired by the 
fact that the reaction proceeded through a transthioesterification, Muir and co-
workers explored the possibility of intercepting the S-peptide intermediate with 
synthetic peptides through NCL. This was successfully demonstrated when 
thiophenol was included in the cleavage buffer, suggesting formation of the aryl 
thioester was necessary before ligation with a cysteinyl peptide.162 This 
methodology was successfully used to generate semi-synthetic tail-phosphorylated 
C-terminal Src kinase (Csk) (Scheme 1.39) and the technology was accordingly 
named “Expressed Protein Ligation” (EPL). Alternatively, the intein fusion can also 
be cleaved with a thiol such as MESNa, which provides a thioester with improved 
stability to hydrolysis and can hence be used in NCL at a later stage. EPL has since 
been applied towards a number of semi-synthetic strategies, enabling access to 
modified proteins.91, 128, 130, 163-169 
 
Scheme 1.39: Expressed protein ligation - semi-synthesis of tail-phosphorylated Csk 
Further developments of EPL included the discovery of “split” inteins. In this 
subclass, inteins are expressed as two fragments (N-intein and C-intein), which are 
able to spontaneously and non-covalently assemble to initiate protein trans-splicing 
(Scheme 1.40).170 
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Scheme 1.40: Split intein mediated protein trans-splicing 
ssad 
In 2011, Liu and Cotton independently reported the cleavage of intein fusions with 
hydrazine.135, 171 This reaction affords the corresponding acyl hydrazide, a latent 
thioester surrogate which can subsequently participate in EPL. Hydrazinolysis of C-
terminal intein fusions has also shown to proceed more efficiently, with improved 
yields compared to thioester formation. 
Although the application of EPL has been effective in a number of studies, it is 
important to note that efficient cleavage of the fusion protein relies on a correctly 
folded intein structure. In the case of hydrophobic sequences or unstructured 
fragments, the poor solubility of the target protein can render the intein fusion 
insoluble. As a consequence, certain sequences may be unsuitable for EPL, although 
it has been demonstrated that after successful refolding of an insoluble fusion, the 
resulting protein can be susceptible to thiolysis.172 
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 Protein thioester synthesis enabled by sortase  1.10.1.2
Sortase’s are transpeptidases involved in the anchoring of surface proteins to the 
cell wall and found in most Gram-positive bacteria.173 Sortase A recognises the 
motif ‘LPXTG’ (where X is any amino acid), and a cysteine residue within the active 
site acts as a nucleophile cleaving at the Thr-Gly junction. The resulting S-acyl 
intermediate can be intercepted by an N-terminal amino group of a sequence 
containing one to five glycine residues, affording the ligated product (Scheme 1.41). 
 
Scheme 1.41: Sortase A catalysed ligation 
ssad 
Recently, Pentelute reported that by using Sortase A, it was possible to append 
synthetic oligoglycine thioesters to recombinant proteins, potentially allowing 
ligation of fragments at a later stage (Scheme 1.42).174 This strategy could be 
particularly beneficial for ligations involving insoluble C-terminal sequences, which 
are unsuitable for direct sortase ligation. 
 
Scheme 1.42: Recombinant thioester synthesis enabled by sortase A 
ssad 
A further extension of sortase A in the production of recombinant proteins for use 
in NCL was demonstrated by Liu. It was shown that recombinant sequences bearing 
the LPXTG motif could be cleaved with hydrazine at the Thr-Gly junction in the 
presence of sortase A to form the acyl hydrazide (Scheme 1.43).175 The irreversible 
reaction prevents further recognition by sortase and hence limits background 
hydrolysis of the thioester linked intermediate. 
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Scheme 1.43: Recombinant hydrazide synthesis enabled by sortase A 
ssad 
Although successfully utilised for peptide ligation79, 176 and protein semi-
synthesis,177 the broad application of sortase is currently limited by the 
requirement of recognition motifs. Future investigations may yield evolved forms of 
the enzyme, which may exhibit wider tolerance for recognition sequences, 
consequently expanding its utility. 
 Recombinant production of protein hydrazides via oxoester moiety  1.10.1.3
In 2008, Schultz showed that the use of genetic code expansion with unique codons 
and a corresponding orthogonal tRNA–aminoacyl-tRNA synthetase pair178, 179 could 
be used to introduce α-hydroxy acids into proteins expressed in E. coli with site 
specificity.180 This results in the incorporation of a backbone ester linkage, which 
was shown to be vulnerable to selective hydrolysis under slightly basic conditions. 
Inspired by this, Liu showed that it was also possible to cleave such linkages with 
aqueous hydrazine to provide thioester synthons in the form of acyl hydrazides 
(Scheme 1.44).181 
 
Scheme 1.44: Genetic incorporation of oxoesters to facilitate site selective hydrazinolysis 
ssad 
This strategy may exceed some of the limitations found with intein based 
technologies, as successful cleavage should not depend on the expression of 
correctly folded structures. However, the encoding of unnatural amino acids can 
significantly lower yields of the expressed protein. 
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1.10.2 Production of recombinant proteins functionalised with an N-terminal 
cysteine for NCL 
 Methionylaminopeptidase generation of an N-terminal cysteine 1.10.2.1
In prokaryotes and eukaryotes, protein translation is initiated by the incorporation 
of a methionine residue. As a consequence, the generation of C-terminal fragments 
for NCL relies on the cleavage of a leader sequence. In E. coli, most cytosolic 
proteins do not exhibit an N-terminal methionine, as it is excised by 
methionylaminopeptidase (MAP).182, 183 With this in mind, Muir showed that 
inclusion of a Met-Cys leader motif could allow the expression of proteins 
containing an N-terminal cysteine and applied this to the circularisation of the c-Crk 
SH3 domain in vivo (Scheme 1.45).184   
 
Scheme 1.45: Expression of a protein with an N-terminal cysteine followed by NCL in vivo 
ssad 
However, the expression of proteins with a Met-Cys leader sequence can result in 
diminished translation efficiency.185 Furthermore, MAP cleavage of the N-terminal 
methionine does not always proceed.186 This led researchers to investigate the use 
of proteases to unmask N-terminal cysteine residues.  
 Protease generation of an N-terminal cysteine 1.10.2.2
Verdine showed that insertion of a Factor Xa protease recognition sequence (IEGR) 
preceding the protein of interest, could facilitate enzymatic cleavage to reveal an N-
terminal cysteine (Figure 1.8 a).187 An extension of this method was introduced by 
Wong, who showed that the use of Tobacco Etch Virus (TEV) protease could be 
utilised in a similar manner.188 TEV protease offers a significant advantage, as its 
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extended recognition sequence ENLYFQ(G/S) improves selectivity and is relatively 
inexpensive as it can be produced “in house” by expression in E. coli. TEV cleavage 
takes place between the final two amino acids of the recognition sequence and 
tolerates cysteine as the seventh residue (Figure 1.8 b).189  
Leatherbarrow later showed that the 3C protease from Foot-and-mouth disease 
virus could also cleave between the final two residues in the recognition sequence 
PAKQX to generate N-terminal cysteinyl proteins for NCL (Figure 1.8 c).190 
a 
 
b 
 
c 
 
Figure 1.8: Protease cleavage for release of N-terminal cysteines 
ssad 
 Intein mediated generation of an N-terminal cysteine 1.10.2.3
As discussed earlier, the natural ability of an intein to splice at its N-terminal 
junction with an extein is useful for the generation of recombinant protein 
thioesters. Similarly, the splicing activity at the C-terminus of an intein can be 
exploited to functionalise proteins with an N-terminal cysteine. A study by Evans et 
al. demonstrated this approach to be feasible and consequently showed that 
addition of a C-terminal intein could lead to cyclisation or polymerisation of the 
expressed protein corresponding to CDR-H3 (Scheme 1.46).191 
 
 
Semi-synthesis of glycoproteins                                                      Bhavesh Premdjee 
 
55 
 
 
Scheme 1.46: N-terminal intein fusion for the expression of N-terminal cysteinyl proteins 
ssad 
 Chemical approaches for the generation of an N-terminal cysteine 1.10.2.4
The use of a protease or an intein fusion to generate recombinant fragments with 
an N-terminal cysteine, rely on the expressed proteins to be soluble in buffers 
compatible with cleavage. In 2004, Macmillan designed a semi-synthetic strategy 
towards erythropoietin (EPO).192 Residues 29-166 were expressed with a 
polyhistidine tag and Factor Xa recognition sequence preceding the desired N-
terminal cysteine. The resulting protein could only be solubilised through the use of 
denaturants or detergents. It was found that the employment of these reagents 
compromised protease activity and formation of the desired product was not 
observed. Instead, a chemical approach was investigated adopting the use of 
cyanogen bromide, which had previously been demonstrated to selectively cleave 
proteins at the C-terminus of methionine residues (Scheme 1.47).193 
 
 
Scheme 1.47: Liberation of an N-terminal cysteine via CNBr cleavage 
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The reaction typically employs the use of formic acid or TFA, which efficiently 
solubilises difficult sequences and masks the reactivity of basic residues. Selectivity 
is also ensured by the mutation of native methionine residues within the protein of 
interest. 
 
Scheme 1.48: Proposed mechanism of CNBr cleavage 
ssad 
An inherent drawback of this approach, is the highly toxic nature of cyanogen 
bromide and requirement to mutate native methionine residues. However, this is 
the only method which can be universally applied to any protein of interest.  
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1.11 Summary 
Chemical protein synthesis relies on the platforms of solid phase peptide synthesis 
and Native Chemical Ligation, which have enabled the synthesis of large proteins 
through convergent strategies. The chemoselective reaction of NCL requires the 
synthesis of C-terminal thioesters, which can be accessed directly through Boc 
SPPS. However, posttranslational modifications are often incompatible with harshly 
acidic hydrogen fluoride used during this method, which is also accompanied by 
significant hazards of its own. 
The Fmoc method has consequently gained popularity, although thioesters are 
prone to nucleophilic attack during piperidine treatment used to remove the Fmoc 
group. As a result, much effort has aimed to address the general incompatibility of 
Fmoc SPPS with direct thioester synthesis. A number of strategies have 
consequently been developed to facilitate the synthesis of peptide thioesters using 
Fmoc SPPS. These methods have been extended to the synthesis of glycopeptide 
thioesters, enabling homogeneous glycoprotein synthesis to be attained through 
NCL. It is important to note that in all cases, homogeneity is established by the 
employment of chemical methods to access defined glycosylated protein 
fragments.  
The compatibility of NCL with expressed proteins has provided a useful extension of 
this methodology. Recombinant expression of unmodified proteins allows access to 
fragments which are not limited in size and can present a significant advantage over 
chemical synthesis. However, for recombinant proteins to participate in expressed 
protein ligation, they usually require a processing step which enables the formation 
of the required functionality. The exploitation of various biological technologies can 
provide access to the desired functionality, but often fall short in the case of 
particularly hydrophobic sequences. On the other hand, chemoselective treatments 
can overcome these limitations, as reactions can be performed under conditions 
which are usually incompatible with biological systems. 
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1.12 Project Aims 
This study has aimed to establish a routine method of homogeneous native 
glycoprotein assembly through semi-synthesis. For demonstration of this strategy, 
efforts were focussed on Interferon β-1, a 166 residue glycoprotein currently used 
for the treatment of multiple sclerosis. Due to the position of glycosylation, a three 
fragment semi-synthetic strategy for IFNβ was designed (Figure 1.9). 
 
Figure 1.9: Sequence analysis of IFNβ and design of a semi-synthetic strategy 
ssad 
To facilitate the NCL strategy, cysteine residues were introduced by substitution at 
residues 78 and 94. A T77G mutation was also incorporated as NCL is known to be 
more efficient with glycine thioesters.194 It was envisaged that the chemical 
synthesis of a glycopeptide corresponding to residues 78-93 would establish 
homogeneity. The incorporation of N-acetylglucosamine at the site of glycosylation 
also enables a selective enzymatic transfer of a glycan with endoglycosidase A. 
After expression of recombinant fragments corresponding to residues 1-77 and 94-
166 in E. coli, functionalisation of these proteins enables participation in NCL 
reactions. Sequential ligation reactions in the N → C or C → N direction would allow 
access to the complete protein backbone, allowing investigation into enzymatic 
transfer of a glycan in the final stages of glycoprotein assembly (Scheme 1.49).  
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Scheme 1.49: Proposed assembly of semi-synthetic IFNβ 
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2 Synthesis of N-linked glycopeptides for semi-
synthesis of Interferon β-1   
 
2.1 Strategies for incorporation of GlcNAc into N-glycopeptides  
A critical step in the synthesis of homogeneous N-glycoprotein synthesis is the 
formation of the GlcNAc-Asparagine linkage. For the purpose of this study where 
the GlcNAcβ(1-4)GlcNAc chitobiose core is formed by endoglycosidase A, methods 
allowing the introduction of N-acetylglucosamine into peptides were of particular 
interest. The stepwise strategy relies on the incorporation of suitably protected 
glycoamino acids during SPPS (Scheme 2.1 a),195, 196 whereas the convergent 
strategy relies on coupling between GlcNAc and the side chain of a peptide (Scheme 
2.1 b). A complication often observed with this approach is the formation of 
aspartimide by-products.31, 197, 198 
 
Scheme 2.1: Methods of GlcNAc incorporation into peptides 
ssad 
It has also recently been shown that the N-glycosylation enzyme Pg1B can be used 
to incorporate GlcNAc at certain sequences.199, 200 However, the requirement of the 
D/E-X-N-X-S/T motif prevents broader application and is further complicated by the 
need for complex unnatural substrates. 
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2.2 Synthesis of glycoamino acid for Fmoc SPPS 
The glycoamino acid was synthesised from N-acetylglucosamine, initially treated 
with acetyl chloride according to the procedure reported by Horton.201 Acetylation 
at all the hydroxyl groups of the sugar is followed by loss of acetic acid from the 
anomeric carbon. The reaction proceeds via an oxocarbenium ion intermediate, 
which is intercepted by chloride ions to form the α-glycosyl chloride 2, favoured by 
the anomeric effect. Following this step, the α-chloride was converted to the 
glycosyl azide under phase transfer conditions to give the β-azide 3 in excellent 
yield.202 Subsequent reduction of the azide with a platinum (IV) catalyst yielded the 
free amine 4, which could then be coupled to the side chain of aspartic acid.203 This 
process of forming the native N-glycosidic linkage was assisted by the coupling 
reagent EEDQ.204 After tert-butyl deprotection of the α-carboxyl group with TFA, 
the glycoamino acid 6 was ready to be used in Fmoc SPPS (Scheme 2.2). 
 
Scheme 2.2: Glycoamino acid synthesis 
 
2.3 Synthesis of glycopeptides for NCL 
2.3.1 Native N-glycopeptide thioester synthesis via N→S acyl transfer 
In a model study for thioester formation of N-glycopeptides, the peptide 
corresponding to EPO residues 22-28 was assembled with a C-terminal cysteine on 
NovaSyn TGT resin. The glycoamino acid 6 was incorporated at position 24, the 
native site of glycosylation. The peptide was assembled in a stepwise fashion using 
10 equivalents of protected amino acids (except 5 equivalents for the glycoamino 
acid), employing 0.45 M HBTU/HOBt in DMF to assist peptide bond formation. After 
cleavage from the resin, the glycopeptide 7 was purified by (RP)HPLC (Figure 2.1). 
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Figure 2.1: Fmoc SPPS of model glycopeptide corresponding to EPO residues 22-28-Cys 
ssad 
The glycopeptide 7 was treated with MESNa (10% w/v) and TCEP (0.5% w/v) in 0.1 
M sodium phosphate buffer (pH 5.8) at 55 °C for 48 hours to afford the C-terminal 
thioester 8 (Scheme 2.3). The reaction was monitored by analytical (RP)HPLC and 
indicated a smooth transition to the thioester (Figure 2.2), confirmed by LC-MS 
(Figure 2.3) and NMR after purification (Figure 2.4).  
 
Scheme 2.3: Thioester formation of model glycopeptide via N→S acyl transfer 
 
 
Figure 2.2: Analytical (RP)HPLC data with UV absorption at 230nm monitoring formation of thioester (spectra 
timepoints offset by increments of 0.5 mins) 
 
 
 Figure 2.3: ES+ mass spectrum of glycopeptide thioester 8 
 
retention time (mins) 
8 
7 
Deacetylated 
derivatives of 
7 and 8 
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Figure 2.4: 
1
H NMR (D2O) comparison of the cysteinyl peptide 7 (upper trace) and MESNa thioester 8 (lower 
trace) showing the appearance of MESNa CH2’s and the absence of the cysteine CH2 β 
During thioester formation, it was postulated that the free cysteine released could 
reverse the reaction through NCL back to the starting material. To test this theory, 
the peptide concentration in the reaction was lowered from 1 mg/mL to 0.2 mg/mL. 
It was envisaged that the cysteine residue released upon thioester formation would 
remain at a relatively lower concentration, reducing the extent of the reverse 
reaction. The other reaction components were kept constant to ensure thioester 
formation could take place at the same rate and after purification, improved yields 
were attained (~ 40%). 
2.3.2 Native Chemical Ligation of model glycopeptide thioester 
To confirm the successful formation of the desired thioester, the purified 
glycopeptide was ligated to a recombinant protein corresponding to EPO residues 
29-166 (donated by Dr Derek Macmillan). The ligation reaction was carried out in  
6 M Guanidine hydrochloride (Gu.HCl) buffered with 0.3 M sodium phosphate (pH 
7.0). The inclusion of mercaptophenyl acetic acid (100 mM) catalyses the reaction 
by forming the corresponding aryl thioester in situ and LC-MS indicated completion 
2 x MESNa CH2 
Cysteine CH2 β 
ppm 
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of the ligation reaction within 3 hours. A final treatment of hydrazine hydrate in the 
presence of DTT afforded the deacetylated glycoprotein 10 (Scheme 2.4). 
 
 
Scheme 2.4: Model glycopeptide thioester ligation 
 
 
Figure 2.5: ES+ mass spectrum and deconvoluted mass of EPO 22-166 
 
2.3.3 Native N-glycopeptide thioester synthesis via N→Se acyl transfer 
With the successful application of N→S acyl transfer towards glycopeptide 
thioesters, the use of selenocysteine was explored to generate thioesters via N→Se 
acyl shift.158 The model glycopeptide was resynthesised with a C-terminal 
selenocysteine, which was concomitantly protected with the 3-nitro-2-
pyridinesulfenyl (Npys) group during cleavage from solid support (Scheme 2.5).205 
20+ 
19+ 
18+ 17+ 
16+ 
15+ 
11+ 
10+ 
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Scheme 2.5: Synthesis of Fmoc-Sec(PMB)-OH and incorporation into model glycopeptide 
ssad 
N→Se acyl shift mediated thioester formation of the glycopeptide was attempted 
as before with MESNa (10% w/v) and TCEP (0.5% w/v) in 0.1 M sodium phosphate 
buffer (pH 5.8) at 55 °C (Scheme 2.6). From previous experiments with 
selenocysteine, it was suspected that oxygen could promote TCEP mediated 
deselenisation and hence the reaction mixture was degassed prior to the addition 
of TCEP.85 Although a small amount of the thioester was detected by LC-MS after  
48 hours, a significant amount of peptide was still found to have irreversibly 
deselenised to 15c (Figure 2.6).  
 
Scheme 2.6: Thioester formation of model glycopeptide via N→Se acyl transfer 
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Figure 2.6: ES+ mass spectrum showing progress of thioester formation via N→Se acyl transfer after 48 hours. The 
major species corresponds to the deselenised peptide 15c. 
The use of ascorbate, which had recently been shown to prevent TCEP-mediated 
desulfurisation, was also unable to improve the outcome of the reaction.206  
15c 1+ 
15c Na+ 
8 Na+ 8 1+  
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2.3.4 Synthesis of IFNβ 78-93 glycopeptide 
With the N→S acyl transfer method still a promising method of generating 
glycopeptide thioesters, attention was focussed on the synthesis of the IFNβ 78-93. 
The peptide was synthesised using Fmoc SPPS on preloaded Cys-NovaSyn TGT resin 
(0.05 mmol scale) and acetamidomethyl protection was employed for the N-
terminal cysteine. Residues 81-93 were assembled through automated synthesis, 
using 10 equivalents for each coupling. A small amount of resin was cleaved, 
allowing the efficiency of peptide synthesis to be determined by LC-MS. 
Encouragingly, the major species corresponded to the expected peptide.  
The manual coupling of the glycoamino acid was attempted and subsequently 
followed by a microscale cleavage to assess coupling efficiency. LC-MS revealed that 
the coupling had only been partially efficient and so the coupling of the glycoamino 
acid was repeated. Once again, analytical scale cleavage indicated poor coupling of 
the glycoamino acid. In an attempt to progress this coupling step, the use of 
stronger coupling reagents PyBOP and HATU were evaluated. Disappointingly, 
neither seemed to improve coupling efficiency and it was considered that peptide 
aggregation could be the cause of poor coupling reactions. To overcome this, a 
commercially available pseudoproline dipeptide was incorporated instead of Glu-
Thr at positions 81-82. Pseudoprolines have been reported to prevent the 
formation of secondary structures during peptide synthesis by introducing kinks 
into the peptide chain. Upon cleavage with TFA, the structure reverts to the native 
dipeptide (Scheme 2.7).207 
 
Scheme 2.7: Pseudoproline dipeptides and their conversion to native structures upon treatment with TFA 
ssad 
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Pleasingly, the incorporation of the Fmoc-Glu(OtBu)-Thr(psiMe,Mepro)-OH  
pseudoproline alleviated the difficulties encountered earlier. Following the final 
couplings and cleavage from the resin, the crude glycopeptide was deacetylated 
with aqueous hydrazine (5% v/v). (RP)HPLC afforded the desired product 16 (6%), 
confirmed by mass spectrometry (Figure 2.7).  
 
Figure 2.7: ES+ mass spectrum confirming successful synthesis of IFNβ 78-93 glycopeptide 16 
 
  
2+ 
3+ 
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2.3.5 Application of N→S acyl transfer towards IFNβ 78-93 glycopeptide 
thioester 
Following glycopeptide assembly, the application of the thioester formation via 
N→S acyl transfer was investigated. Unlike the model EPO sequence, this peptide 
necessitated the use of chaotropes to remain in solution, although previous studies 
had shown that 6 M Gu.HCl was compatible with thioester forming reactions.130, 208 
Peptide 16 was subjected to a treatment of MESNa (10% w/v) and TCEP (0.5% w/v) 
in 6 M Gu.HCl/0.1 M sodium phosphate buffer (pH 5.8) at 55 °C and monitored via 
LC-MS over 48 hours (Figure 2.8). 
 
 
Scheme 2.8: Thioester formation of IFNβ 78-93 glycopeptide via N→S acyl transfer 
 
Figure 2.8: ES+ mass spectrum analysis of thioester formation of IFNβ 78-93 after 48 hours 
sad 
LC-MS analysis suggested that thioester formation over 48 hours was slower 
compared to previous experiments. This was consistent with previous observations 
within the research group, where the use of 6 M Gu.HCl was found to slow the rate 
of reaction. Peptide aggregation was also observed over the course of the reaction 
and was believed to contribute to slower conversion. Although the reaction was 
slow, the product was isolated by (RP)HPLC, albeit in low yield (<5%).  
3+ 
2+ 
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2.3.6 N→S acyl transfer in the synthesis of glycopeptide hydrazides 
At the time of this study, independent investigations by the groups of Liu and 
Cotton suggested that hydrazine could intercept S-acyl intermediates to form acyl 
hydrazides.135, 171 Peptide hydrazides exhibit improved stability towards hydrolysis 
and can be converted to the corresponding thioester under mild conditions. This 
led to an investigation of whether the inclusion of hydrazine in an N→S acyl transfer 
reaction could allow the generation of the corresponding peptide hydrazide. It was 
hypothesised that the improved stability of the product would allow it to 
accumulate under the reaction conditions, thus enabling the reaction to be carried 
out over extended periods of time.  
Preliminary studies were performed on model peptide “MEELYKSHC” (Scheme 2.9) 
using hydrazinium acetate as the source of hydrazine, in the presence and absence 
of MESNa (Figure 2.9).209 
 
Scheme 2.9: Hydrazinolysis of model peptide MEELYKSHC 
N2H4·HOAc  T (°C) MESNa  MEELYKSHC (%)* 
[% w/v]   [% w/v] 24 h 48 h 
5 60 10 5 0 
5 50 10 27 5 
5 40 10 28 19 
0 50 10 33 30 
5 50 5 33 21 
2.5 50 10 -
†
 5 
5 50 0 -
†
 30 
 
Figure 2.9: Conditions used to investigate hydrazinolysis via N→S acyl transfer 
*Reaction progress was judged by the quantity of starting material remaining, determined by (RP)HPLC 
†Not determined 
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Although reactions were conducted in 0.1 M sodium phosphate buffer (pH 5.8), it is 
important to note that the final pH of the reaction mixture was found to be 
approximately 7, potentially slowing the process of N→S acyl transfer. 
Hydrazinolysis proceeded smoothly over a range of temperatures and was found to 
be more efficient compared to direct thioester formation. Interestingly, when 
MESNa was excluded from the reaction there was no evidence of hydrazide 
formation by LC-MS. Instead, the predominant species indicated the formation of 
peptide dimers and oxidation of methionine. 
To ensure compatibility of this reaction with N-glycopeptides, the hydrazinolysis of 
a glycopeptide corresponding to EPO residues 1-28 was investigated. The peptide 
was treated with MESNa (10% w/v), hydrazinium acetate (5% w/v) and TCEP (0.5% 
w/v) in 3 M Gu.HCl/0.1 M sodium phosphate buffer (pH 5.8) at 55 °C. Conversion to 
the hydrazide 19 was monitored by LC-MS and took place over 48 hours (Figure 
2.10). 
 
 
Scheme 2.10: Hydrazinolysis of EPO 1-28 glycopeptide via N→S acyl transfer 
 
Figure 2.10: ES+ mass spectrum analysis of hydrazinolysis of EPO 1-28 over 48 hours  
3+ 
4+ 
4+ 
3+ 
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2.3.7 Application of N→S acyl transfer towards IFNβ 78-93 glycopeptide 
hydrazide  
Following this success, the hydrazide forming reaction was applied to the 
glycopeptide corresponding to IFNβ 78-93. The reaction was conducted in 6 M 
Gu.HCl/0.1 M sodium phosphate buffer (pH 5.8) in the presence of MESNa (10% 
w/v), hydrazinium acetate (5% w/v) and TCEP (0.5% w/v). To minimise peptide 
aggregation, the reaction temperature was lowered to 45 °C. LC-MS analysis 
showed transition to the hydrazide 20a over 120 hours and the product was 
successfully isolated by (RP)HPLC. 
 
 
Scheme 2.11: Hydrazinolysis of IFNβ 78-93 glycopeptide via N→S acyl transfer 
 
Figure 2.11: ES+ mass spectrum analysis of hydrazinolysis of IFNβ 78-93 over 120 hours 
 
  
2+ 
3+ 
3+ 
2+ 
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2.3.8 Direct synthesis of IFNβ 78-93 glycopeptide hydrazide by SPPS 
Despite the novel hydrazinolysis reaction providing the desired product, existing 
methods allowed the direct synthesis of peptide hydrazides by Fmoc SPPS.135, 210 
Often during the synthesis of peptide thioesters with an N-terminal cysteine, 
protection is necessary to prevent the undesired cyclisation of the peptide.157 
However, for the synthesis a latent peptide thioester in the form of a hydrazide, it 
was envisaged that N-terminal cysteine protection would not be necessary, 
consequently avoiding an additional deprotection and purification step during 
protein assembly. 
In the first instance, NovaSyn TGT alcohol resin 21 (0.21 mmol/g) was converted to 
the chloride derivative 22 followed by displacement with hydrazine (Scheme 2.12). 
 
 
Scheme 2.12: Synthesis of NovaSyn TGT hydrazine resin 
sad 
Fmoc-His(Trt)-OH was double-coupled with HBTU/HOBt and loading was 
determined by Fmoc analysis to be 0.04 mmol/g. The remainder of the sequence 
was completed by manual synthesis as before, using 10 equivalents of each Fmoc 
amino acid and HBTU/HOBt (except for Fmoc-Glu(OtBu)-Thr(psiMe,Mepro)-OH  and 
the glycoamino acid where 5 equivalents were used). Cleavage from the resin was 
enabled by a treatment of TFA/thioanisole/water/phenol/EDT (82.5:5:5:5:2.5) and 
after precipitation in ether, the crude glycopeptide was deacetylated with aqueous 
hydrazine (5%). Disappointingly, the overall yield after purification by (RP)HPLC was 
~ 1 mg (5%). 
At this point, the preparation of a hydrazine functionalised Wang (para-
alkoxybenzyl alcohol) resin was investigated according to a procedure reported by 
Liu.135 Commercially available Wang resin (1.3 mmol/g loading) was initially treated 
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with para-nitrophenyl chloroformate, followed by hydrazine hydrate to afford the 
hydrazine functionalised Wang resin 26 (Scheme 2.13). 
 
Scheme 2.13: Synthesis of hydrazine functionalised Wang resin 
Fmoc-His(Trt)-OH was coupled to the resin and loading was determined to be 0.67 
mmol/g. In the first attempt to synthesise the IFNβ 78-93 glycopeptide, analytical 
cleavage was performed after coupling of residue 85. Unexpectedly, LC-MS analysis 
suggested that peptide synthesis was not entirely efficient, with a number of 
deletions observed (Figure 2.12). 
 
Figure 2.12: ES+ mass spectrum of crude IFNβ 85-93 hydrazide 
The poor coupling efficiencies were attributed to the high loading of the resin. 
During the second attempt to synthesise the peptide, the hydrazine resin was 
loaded with a mixture of Fmoc-His(Trt)-OH and Boc-Ala-OH (1:2). The inclusion of 
Boc protected alanine in the first coupling prevents further elongation during Fmoc 
SPPS, thus effectively lowering the loading of the resin. The new resin loading was 
determined by Fmoc analysis to be 0.15 mmol/g and peptide elongation was 
continued as before. Finally, the peptide hydrazide was cleaved from the resin, 
deacetylated and purified by (RP)HPLC with a final yield of 6% (Figure 2.13). 
 
IFNβ 85-93Hyd 1+ 
IFNβ 85-93Hyd 2+ 
-E, -N, -L, -L 1+ 
-E, -N, -L 1+ 
-E, -N 1+ 
-E 1+ 
-E, -N 2+ 
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Figure 2.13: ES+ of purified IFNβ 78-93 glycopeptide hydrazide 
sad 
To enable a flexible approach to IFNβ assembly, the glycopeptide was also 
synthesised with an Acm protected N-terminal cysteine. For the synthesis of this 
glycopeptide hydrazide, commercially available trityl chloride resin (1.4 mmol/g) 
was functionalised according to an updated protocol reported by Liu.210 After 
treatment with hydrazine hydrate and coupling of Fmoc-His(Trt)-OH, the loading 
was found to have decreased to 0.45 mmol/g. Wary of previous difficulties 
associated with higher resin loading, the second coupling was performed with a 
mixture of Fmoc-Tyr(OtBu)-OH and Boc-Ala-OH (1:1). Resin loading was determined 
to have decreased to 0.18 mmol/g, and the synthesis of the peptide was completed 
as before.  
 
Figure 2.14: ES+ of purified IFNβ 78-93 glycopeptide hydrazide (Acm protected) 
2+ 
3+ 
3+ 
2+ 
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2.4 Conclusions 
In summary, the novel application of N→S acyl transfer towards the synthesis of 
native N-linked glycopeptide thioesters and hydrazides has been demonstrated. 
This methodology is particularly amenable to soluble peptide sequences, but 
difficulties were encountered with hydrophobic segments. In the case of such 
sequences, hydrazinolysis via N→S acyl transfer offers a significant advantage. The 
peptide hydrazide product can accumulate without breakdown over extended 
periods of time, which is often necessitated due to lower reaction temperatures 
and the use of denaturants. 
The expanding use of peptide hydrazides as thioester surrogates has gained 
significant popularity due to its compatibility with Fmoc SPPS. The direct synthesis 
of peptide hydrazides is facilitated by the use of functionalised resins and was 
shown to be compatible with the Fmoc synthesis of native N-glycopeptides. 
Importantly, this platform provides a convenient and attractive route towards 
peptide thioester surrogates and will undoubtedly broaden the scope of protein 
assembly through NCL.  
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3 Expression and functionalisation of proteins 
for the semi-synthesis of Interferon β-1   
 
3.1 Introduction 
The development of recombinant methods allowing expression of protein in a 
bacterial host has provided an indispensable tool for obtaining large unmodified 
proteins. Recombinant DNA technology allows a gene corresponding to a desired 
protein to be inserted into a bacterial vector. Following transformation into a 
bacterial host, the protein can be overexpressed in a controlled manner. For the 
semi-synthesis of Interferon β-1 through NCL, both an N-terminal fragment with a 
C-terminal thioester and a C-terminal fragment with an N-terminal cysteine (Figure 
3.1) were required. 
 
 
Figure 3.1: Recombinant fragments required for the semi-synthesis of IFNβ 
 
3.2 Cloning and expression of IFNβ fragments for semi-synthesis 
3.2.1 Cloning of IFNβ 1-77 intein fusion 
With the previously mentioned technologies in mind (section 1.10.1.1), the proteins 
corresponding to IFNβ 1-77 and 94-166 were cloned into the relevant expression 
vectors. The sequence corresponding to IFNβ residues 1-77 was cloned into vector 
pTYB1 (Figure 3.2), which allows expression of IFNβ 1-77 with a C-terminal intein-
chitin binding domain fusion.161 
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Figure 3.2: pTYB1 vector map 
ssad 
The gene corresponding to IFNβ 1-77 was cloned between the NdeI and SapI 
restriction sites (Figure 3.3) present in the multiple cloning site.  
  
Figure 3.3: NdeI and SapI recognition sequences and cleavage positions 
ssad 
This strategy ensured that the expressed protein would be capable of splicing at the 
correct position, resulting in a product free of any vector encoded amino acids. 
NdeI and SapI are restriction enzymes that cleave double stranded DNA to produce 
sticky ends, enabling efficient DNA ligation (Figure 3.4). Primers were designed for 
the amplification of the gene corresponding to IFNβ 1-77 and also to introduce the 
T77G mutation (see section 8.3 for details). 
pTYB1 
7477 bp 
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Figure 3.4: NdeI/SapI cloning strategy of IFNβ 1-77 gene into vector pTYB1 
ssad 
PCR was conducted from a plasmid containing the IFNβ gene cloned into pKYB1 
(donated by Dr Derek Macmillan). The vector and PCR product were treated with 
restriction endonucleases NdeI and SapI to prepare sticky ends for subsequent 
ligation. After purification by preparative agarose gel, DNA ligation was attempted, 
followed by transformation into competent cells. Disappointingly, multiple 
attempts to clone the gene corresponding to IFNβ 1-77 into pTYB1 were 
unsuccessful, determined by DNA sequencing and agarose gel analysis. It was 
postulated that poor ligation efficiency could be attributed to the unusual activity 
of SapI, which cleaves outside of its recognition sequence. As a consequence, the 
pTYB1 cloning site: 
5’        Intein 3’ 
… CAT ATG GCT … GGC TCT TCC TGC TTT GCC AAG GGT ACC … 
… GTA TAC CGA … CCG AGA AGG ACG AAA CGG TTC CCA TGG … 
3’ NdeI   SapI     KpnI 5’ 
 
pTYB1 cloning site after treatment with NdeI/SapI: 
5’        Intein 3’ 
… CA       TGC TTT GCC AAG GGT ACC … 
… GTA T       AAA CGG TTC CCA TGG … 
3’         KpnI 5’ 
 
PCR amplified gene corresponding to IFNβ 1-77: 
5’   IFNβ 1-77     3’ 
… CAT ATG AGC … GGC TGC GGA AGA GCA … 
… GTA TAC TCG … CCG ACG CCT TCT CGT … 
3’ NdeI     SapI 5’ 
        
PCR amplified gene corresponding to IFNβ 1-77 after treatment with NdeI/SapI: 
5’   IFNβ 1-77  3’ 
 T ATG AGC … GGC   
  AC TCG … CCG ACG  
3’      5’ 
 
DNA ligation product: 
5’   IFNβ 1-77 Intein 3’ 
… CAT ATG AGC … GGC TGC TTT GCC AAG GGT ACC … 
… GTA TAC TCG … CCG ACG AAA CGG TTC CCA TGG … 
3’ NdeI        KpnI 5’ 
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recognition site remains intact after cleavage, possibly resulting in a poor turnover 
rate and inefficient cleavage by SapI. At this stage, an alternative ligation at the 
KpnI site was considered. The reverse primer was redesigned to encode the KpnI 
recognition sequence (Figure 3.5) and the N-terminal residues of the intein lost 
during KpnI digest of the vector, resulting in the originally desired construct (Figure 
3.6). 
 
Figure 3.5: KpnI recognition sequence and cleavage position 
ssad 
 
Figure 3.6: NdeI/KpnI cloning strategy of IFNβ 1-77 gene into vector pTYB1 
pTYB1 cloning site: 
5’        Intein 3’ 
… CAT ATG GCT … GGC TCT TCC TGC TTT GCC AAG GGT ACC … 
… GTA TAC CGA … CCG AGA AGG ACG AAA CGG TTC CCA TGG … 
3’ NdeI   SapI     KpnI 5’ 
 
pTYB1 cloning site after treatment with NdeI/KpnI: 
5’          3’ 
… CA        C … 
… GTA T      CA TGG … 
3’      5’ 
 
PCR amplified gene corresponding to IFNβ 1-77: 
5’   IFNβ 1-77 Intein 3’ 
… CAT ATG AGC … GGC TGC TTT GCC AAG GGT ACC … 
… GTA TAC TCG … CCG ACG AAA CGG TTC CCA TGG … 
3’ NdeI        KpnI 5’ 
 
PCR amplified gene corresponding to IFNβ 1-77 after treatment with NdeI/KpnI: 
5’   IFNβ 1-77 Intein 3’ 
 T ATG AGC … GGC TGC TTT GCC AAG GGT AC  
  AC TCG … CCG ACG AAA CGG TTC C   
3’          5’ 
      
DNA ligation product: 
5’   IFNβ 1-77 Intein 3’ 
… CAT ATG AGC … GGC TGC TTT GCC AAG GGT ACC … 
… GTA TAC TCG … CCG ACG AAA CGG TTC CCA TGG … 
3’ NdeI        KpnI 5’ 
 
Intein codons lost from KpnI digest 
are accounted for in the reverse 
primer, leading to their 
incorporation in the PCR product 
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After PCR amplification, the product and vector were treated with NdeI/KpnI. The 
DNA ligation was attempted and subsequently transformed into cloning hosts. After 
colony screening, successful cloning was confirmed by sequencing.  
3.2.2 Expression of IFNβ 1-77 intein fusion 
The plasmid was transformed into BL21(DE3) cells to enable protein expression, 
which was carried out at 30 °C for 5 hours. Analysis of the soluble fraction and 
whole cell lysate (WCL) prepared by Bugbuster Protein Extraction Reagent 
(Millipore) was carried out by SDS-PAGE (Figure 3.7). A number of conditions for 
sample preparation were evaluated, to ensure that cleavage of the intein was not 
induced by DTT or heat. 
 
 
 
  
Figure 3.7: SDS-PAGE analysis after expression of IFNβ 1-77 intein fusion 
A band corresponding to the expected mass of the IFNβ 1-77 intein fusion 27 (~ 66 
kDa) was observed, but it was found that the majority of this protein was not 
soluble. Nonetheless, the soluble fraction was passed down a chitin column and 
thiolytic cleavage was attempted with MESNa. After 24 hours at 4 °C, the column 
was eluted and analysed by SDS-PAGE. Unfortunately, product isolation was 
unsuccessful and instead the decision was made to investigate the refolding of the 
IFNβ 1-77 intein fusion from the insoluble fraction. 
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Insoluble material remaining from the initial lysis and centrifugation step was 
resuspended in binding buffer containing 6 M Gu.HCl, 500 mM NaCl and 20 mM Tris 
(pH 8.0) and stirred vigorously at room temperature for 30 minutes. The remaining 
insoluble cell debris was pelleted by centrifugation and the supernatant containing 
the solubilised protein was dialysed against 8 M urea containing 10 mM DTT, 500 
mM NaCl, 20 mM Tris (pH 8.5). Refolding was attempted by slowly reducing the 
concentration of urea according to a protocol reported by New England Biolabs, 
with all buffers containing 500 mM NaCl, 20 mM Tris (pH 8.5) allowing at least 12 
hours for each step. Dialysis into 6 M urea, 1 mM DTT was followed by 4 M urea, 1 
mM DTT and finally 2 M urea, 1 mM reduced glutathione and 1 mM oxidised 
glutathione. At this stage formation of a precipitate was observed, which was 
separated by centrifugation and separated into two batches. The first batch was 
kept in 2 M urea to allow the investigation of Sce VMA intein cleavage, which has 
been reported to take place under these conditions.211 The remainder was dialysed 
into the final renaturation buffer containing 1 mM reduced glutathione and 0.1 mM 
oxidised glutathione. Once again precipitate was formed and removal was achieved 
by centrifugation. The remaining fractions were analysed by SDS-PAGE (Figure 3.8). 
 
Figure 3.8: SDS-PAGE analysis after attempted refolding 
ssad  
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It appeared that in the absence of urea, a significant amount of the fusion protein 
had precipitated out. Therefore, purification and cleavage was attempted in 2 M 
urea, initially passing the fraction through a chitin column. The column was washed 
and then flushed with buffer containing MESNa. The immediate flow through was 
collected and then the resin was incubated with MESNa for 24 hours. Flow through 
wash fractions and chitin beads were analysed by SDS-PAGE (Figure 3.9). 
 
Figure 3.9: Attempted purification and cleavage of IFNβ 1-77 intein fusion in 2 M urea 
ssad 
From SDS-PAGE analysis, it was evident that the protein did not bind effectively to 
the resin. The poor affinity can be attributed to the presence of urea, which is likely 
to denature the chitin binding domain to some extent. 
3.2.3 Cloning and expression of IFNβ 1-77 thioredoxin intein fusion 
In another attempt to express a soluble and active form of the IFNβ 1-77 intein 
fusion, an N-terminal fusion protein was considered. Attention was drawn to the 
thioredoxin, which has previously been shown to improve the solubility and yield of 
proteins expressed in E. coli.212 The pTYB1 construct was subcloned with the intein-
chitin binding domain fusion into a pET32 Xa/LIC vector (Figure 3.10) using ligation 
independent cloning (LIC).213 
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Figure 3.10: pET32 Xa/LIC vector map 
ssad 
For ligation independent cloning into pET32 Xa/LIC, the direct annealing of the PCR 
product into the vector is facilitated by GTP-free overhangs of 15 nucleotide bases. 
This strategy obviates the requirement for restriction digests and ligation reactions 
and overhangs are generated by T4 DNA polymerase which exhibits 3’-5’ 
exonuclease activity. After annealing of the insert, the plasmid is transformed into 
E. coli and circularisation of the plasmid via formation of phosphodiester bonds, 
takes place within the cell. 
pET32 Xa/LIC 
5926 bp 
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Figure 3.11: Ligation independent cloning with Xa/LIC strategy 
ssad 
After verifying the new construct, the protein was expressed at 30 °C for 5 hours at 
an analytical scale. The whole cell lysate and soluble fraction were analysed by SDS-
PAGE (Figure 3.12), which unfortunately indicated that the thioredoxin fusion 28 
was also insoluble. 
 
 
 asd 
Figure 3.12: SDS-PAGE analysis after expression of IFNβ 1-77 thioredoxin intein fusion 84. Although the 
desired protein had been expressed, it appeared to be insoluble. 
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3.2.4 Cloning of IFNβ 1-77 with C-terminal Gly-Cys 
It was concluded that an intein based strategy was unlikely to be successful towards 
obtaining the thioester of IFNβ 1-77. At this point, it was decided to investigate the 
formation of a thioester via an N→S acyl transfer reaction. The gene corresponding 
to IFNβ 1-77 was cloned into pET16b (Figure 3.13) which introduces an N-terminal 
His10 tag, allowing the protein of interest to be purified using Ni
2+ affinity 
chromatography.214 
 
Figure 3.13: pET16b vector map 
The gene was inserted between NdeI and BamHI (Figure 3.14), with the reverse 
primer designed to encode a C-terminal Gly-Cys motif followed by a stop codon. 
 
Figure 3.14: BamHI recognition sequence and cleavage position 
pET16b 
5711 bp 
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Figure 3.15: NdeI/BamHI cloning strategy of IFNβ 1-77 gene into vector pET16b 
 
3.2.5 Expression of IFNβ 1-77 with C-terminal Gly-Cys 
After sequencing, the pET16b plasmid encoding IFNβ 1-77 was transformed into 
BL21(DE3) cells for protein expression. The His10 tagged protein was found to be 
insoluble, but was nonetheless purified under denaturing conditions (Figure 3.16) 
and identified by LC-MS (Figure 3.17). 
  
pET16b cloning site: 
5’ His10 tag Factor Xa       3’ 
… … … ATC GAA GGT CGT CAT ATG CTC GAG GAT CCG … 
… … … TAG CTT CCA GCA GTA TAC GAG CTC CTA GGC … 
3’   Ile Glu Gly Arg NdeI  BamHI 5’ 
 
pET16b cloning site after treatment with NdeI/BamHI: 
5’ His10 tag Factor Xa       3’ 
… … … ATC GAA GGT CGT CA    GAT CCG … 
… … … TAG CTT CCA GCA GTA T    GC … 
3’   Ile Glu Gly Arg      5’ 
 
PCR amplified gene corresponding to IFNβ 1-77: 
5’   IFNβ 1-77     3’ 
… CAT ATG AGC … GGC TGT TAA GGA TCC … 
… GTA TAC TCG … CCG ACA ATT CCT AGG … 
3’ NdeI   Gly Cys Stop BamHI 5’ 
 
PCR amplified gene corresponding to IFNβ 1-77 after treatment with NdeI/BamHI: 
5’   IFNβ 1-77     3’ 
… T ATG AGC … GGC TGT TAA G  … 
…  AC TCG … CCG ACA ATT CCT AG … 
3’    Gly Cys Stop  5’ 
 
DNA ligation product: 
5’ His10 tag Factor Xa   IFNβ 1-77     3’ 
… … … ATC GAA GGT CGT CAT ATG AGC … GGC TGT TAA GGA TCC … 
… … … TAG CTT CCA GCA GTA TAC TCG … CCG ACA ATT CCT AGG … 
3’   Ile Glu Gly Arg NdeI   Gly Cys Stop BamHI 5’ 
 
Semi-synthesis of glycoproteins                                                      Bhavesh Premdjee 
 
88 
 
 
 
Figure 3.16: SDS-PAGE of His10 tagged IFNβ 1-77 after purification 
 
 
Figure 3.17: ES+ mass spectrum and deconvoluted mass of His10 tagged IFNβ 1-77  
3.2.6 C-terminal chemical functionalisation of IFNβ 1-77 via N→S acyl transfer 
From previous experience functionalising the C-terminus of insoluble proteins 
(Section 2.3.7), it was decided to apply the hydrazide forming reaction to His10 
tagged IFNβ 1-77 (Scheme 3.1). The reaction was followed by LC-MS over 72 hours 
and formation of the hydrazide 30 was observed (Figure 3.18). 
 
 
Scheme 3.1: Hydrazinolysis of His10 tagged IFNβ 1-77 via N→S acyl transfer 
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Figure 3.18: ES+ mass spectrum analysis of hydrazinolysis of His10 tagged IFNβ 1-77 over 72 hours 
ssad 
Although hydrazide formation occurred, there was an evident loss of quality in the 
mass spectrum signal over time. Consistent with previous observations, it also 
appeared that the rate of reaction decreased after the initial 48 hours of the 
reaction. The decreased reaction rate was attributed to the oxidation of the protein 
and reagents, where resulting disulfide formation blocks N→S acyl transfer. 
Due to the protein’s insolubility, removal of the His10 tag would be ineffective with 
Factor Xa and hence the possibility of CNBr cleavage was considered. As this 
strategy necessitates the removal of any native methionine residues, it was also 
reasoned that this could reduce the formation of an additional species 
corresponding to mass difference of +16, which was attributed to methionine 
oxidation. 
 
Figure 3.19: Sequence analysis of His10 tagged IFNβ 1-77 highlighting mutations for CNBr strategy 
ssad 
The internal methionine residues were mutated to leucine through site directed 
mutagenesis and the protein was expressed as before. After purification, the 
protein was subjected to hydrazinolysis conditions and checked by LC-MS after 48 
hours (Figure 3.20). 
8+ 
9+ 12+ 13+ 
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Scheme 3.2: Hydrazinolysis of His10 tagged IFNβ 1-77 (CNBr mutant) via N→S acyl transfer 
  
 
Figure 3.20: ES+ mass spectrum analysis of hydrazinolysis of His10 tagged IFNβ 1-77 (CNBr mutant) over 48 h 
Encouragingly, conversion to the hydrazide 32 appeared to have proceeded by 
approximately 60% after 48 hours, with less evidence of competing side reactions. 
According to the previous rationale that reaction progress was slowed by oxidation 
of MESNa and the protein, the use of fresh reagents was considered to enable 
further hydrazinolysis. The sample was exhaustively buffer-exchanged to ensure 
maximum removal of expended reagents and then resubjected to the hydrazide 
forming conditions. 
 
Figure 3.21: ES+ mass spectrum analysis of hydrazinolysis of His10 tagged IFNβ 1-77 (CNBr mutant) after 96 h 
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LC-MS analysis revealed that further hydrazinolysis appeared to take place, 
although a small amount of inseparable starting material remained. However, it 
was reasoned that any residual cysteinyl protein would not interfere with 
forthcoming ligation steps. The His10 tag was retained to aid subsequent 
purification steps. 
3.2.7 Cloning and expression of IFNβ 94-166 allowing formation of N-terminal 
cysteine 
The gene corresponding to IFNβ 94-166 was also cloned into pET16b to allow 
expression with a His10 tag. As pET16b encodes a Factor Xa cleavage site preceding 
a methionine residue, an additional IEGR recognition sequence was introduced 
before the desired N-terminal cysteine during PCR.  
 
Figure 3.22: NdeI/BamHI cloning strategy of IFNβ 94-166 gene into vector pET16b 
pET16b cloning site: 
5’ His10 tag Factor Xa       3’ 
… … … … … CAT ATG CTC GAG GAT CCG … 
… … … … … GTA TAC GAG CTC CTA GGC … 
3’     NdeI  BamHI 5’ 
 
pET16b cloning site after treatment with NdeI/BamHI: 
5’ His10 tag Factor Xa      3’ 
… … … … … CA    GAT CCG … 
… … … … … GTA T    GC … 
3’          5’ 
 
PCR amplified gene corresponding to IFNβ 94-166: 
5’   Additional Factor Xa site IFNβ 94-166    3’ 
… CAT ATG ATC GAA GGT CGT TGT … AAC TAA GGA TCC … 
… GTA TAC TAG CTT CCA GCA ACA … TTG ATT CCT AGG … 
3’ NdeI Ile Glu Gly Arg Cys   Stop BamHI 5’ 
 
PCR amplified gene corresponding to IFNβ 94-166 after treatment with NdeI/BamHI: 
5’   Additional Factor Xa site IFNβ 94-166    3’ 
… T ATG ATC GAA GGT CGT TGT … AAC TAA G  … 
…  AC TAG CTT CCA GCA ACA … TTG ATT CCT AG … 
3’  Ile Glu Gly Arg Cys   Stop  5’ 
 
DNA ligation product: 
5’ His10 tag Factor Xa   Additional Factor Xa site IFNβ 94-166    3’ 
… … … … … CAT ATG ATC GAA GGT CGT TGT … AAC TAA GGA TCC … 
… … … … … GTA TAC TAG CTT CCA GCA ACA … TTG ATT CCT AGG … 
3’     NdeI Ile Glu Gly Arg Cys   Stop BamHI 5’ 
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The protein was expressed in BL21(DE3) cells and SDS-PAGE analysis revealed that 
His10 tagged IFNβ 94-166 was also insoluble. In an attempt to solubilise this 
fragment, the gene was subcloned into pET32 Xa/LIC in the hope that an N-terminal 
thioredoxin fusion would be soluble. Disappointingly, after expression at 30 °C it 
appeared that the thioredoxin fusion 33 was also insoluble (Figure 3.23). 
 
 
 
Figure 3.23: SDS-PAGE of thioredoxin His6 tagged IFNβ 94-166 after expression 
With the fusion protein insoluble and unsuitable for Factor Xa treatment, the pET16 
plasmid was redesigned to produce a protein suitable for CNBr cleavage. The 
methionine residues were mutated to leucine and a methionine substitution was 
introduced preceding the desired N-terminal cysteine (Figure 3.24) through site 
directed mutagenesis. 
 
Figure 3.24: Sequence analysis of His10 tagged IFNβ 94-166 highlighting mutations for CNBr strategy 
The modified construct was used to express the His10 tagged protein, which was 
purified by Ni2+ affinity chromatography under denaturing conditions as before. LC-
MS confirmed successful expression of His10 tagged IFNβ 94-166 (Figure 3.25). 
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Figure 3.25: ES+ mass spectrum and deconvoluted mass of His10 tagged IFNβ 94-166 (CNBr mutant) 
 
3.2.8 N-terminal chemical functionalisation of IFNβ 94-166 via CNBr treatment 
CNBr treatment of the protein was performed according to the protocol reported 
by Richardson and Macmillan.215 Although the use of 80% formic acid enabled the 
complete solubilisation of the fusion protein, LC-MS disappointingly indicated 
deterioration of the sample after treatment with CNBr overnight. After a number of 
unsuccessful attempts, an alternative protocol for CNBr cleavage reported by 
Andreev et. al was investigated.216 This method relies on solubilisation of proteins 
in 6 M Gu.HCl, with 0.1 M HCl to prevent reactions at basic residues (Scheme 3.3). 
Pleasingly, LC-MS of the crude sample after CNBr treatment suggested quantitative 
conversion to the desired product 35 (Figure 3.26). The crude mixture was 
subjected to another round of Ni2+ affinity chromatography, enabling the separation 
of the product from any His10 tagged proteins. 
 
 
Scheme 3.3: CNBr treatment of His10 tagged IFNβ 94-166 
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Figure 3.26: ES+ mass spectrum and deconvoluted mass of IFNβ 94-166 (CNBr mutant) 
 
3.3 Conclusions 
A number of methods have been explored towards the functionalisation of IFNβ 
fragments to enable a semi-synthetic strategy. Unfortunately, the highly 
hydrophobic sequences in both recombinant segments have rendered some of 
these strategies incompatible. Consequently, novel and existing chemoselective 
reactions have been applied to achieve the desired protein modifications. The novel 
application of N→S acyl transfer towards the C-terminal functionalisation of 
recombinant protein hydrazides was demonstrated. Importantly, this methodology 
represents the first demonstration of C-terminal hydrazinolysis to an insoluble 
recombinant protein. This may expand the applicability of semi-synthetic strategies 
towards particularly hydrophobic sequences, where intein and sortase technologies 
are largely unsuitable. As the desired protein fragments were armed with the 
appropriate functional groups, investigations were able to proceed towards protein 
assembly via NCL.  
11+ 
10+ 
9+ 
8+ 
7+ 
6+ 
 
Semi-synthesis of glycoproteins                                                      Bhavesh Premdjee 
 
95 
 
4 Application of Native Chemical Ligation 
towards the assembly of semi-synthetic IFNβ  
 
4.1 NCL of His10 tagged IFNβ 1-77 hydrazide with 78-93 glycopeptide  
In the first approach to assemble semi-synthetic IFNβ, a ligation between the N-
terminal fragment hydrazide was conducted with the glycopeptide segment 
containing a free N-terminal cysteine and a C-terminal hydrazide (Scheme 4.1).  
 
Scheme 4.1: NCL of His10 tagged IFNβ 1-77 hydrazide with 78-93 glycopeptide hydrazide 
sad 
It was envisaged that this strategy would allow the resulting product to be used in 
the next ligation without the need for an additional deprotection step. The ligation 
was attempted following the protocol reported by Liu,135 where the treatment of 
the N-terminal hydrazide with sodium nitrite in 6 M Gu.HCl, 0.2 M Na Phosphate 
(pH 3.0-4.0) results in the formation of the acyl azide. After the oxidation step, the 
pH was raised to 7.0 by addition of neutral ligation buffer containing 
mercaptophenyl acetic acid and the glycopeptide hydrazide. This step allows the 
thioester to be formed in situ, with subsequent participation in the ligation 
reaction.  
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The reaction was allowed to proceed overnight, followed by concentration in a 
molecular weight cut off device and was subsequently reduced with TCEP. 
Discouragingly, LC-MS analysis of the crude reaction mixture showed an abundance 
of the hydrolysed N-terminal fragment, with little accumulation of the ligated 
product (Figure 4.1). Purification of the ligated product 36 was attempted by 
(RP)HPLC, but isolation of the semi-synthetic glycoprotein was not successful. 
 
 
 
Figure 4.1: ES+ deconvoluted mass spectrum of attempted His10 IFNβ 1-93 formation. Ligated product was 
detected, although the major species correspond to cysteinyl protein 31 and hydrolysis of the hydrazide. 
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4.2 NCL of IFNβ 78-93 glycopeptide hydrazide with 94-166 
In an alternate strategy towards semi-synthetic IFNβ, the ligation between the C-
terminal fragment and the Acm protected glycopeptide hydrazide (Scheme 4.2) was 
performed. The ligation was carried out as before and LC-MS analysis revealed that 
complete consumption of the C-terminal fragment 35 took place within 3 hours. 
The semi-synthetic glycoprotein 37a was subsequently purified by (RP)HPLC. 
 
 
Scheme 4.2: NCL of IFNβ 78-93 glycopeptide hydrazide with 94-166 (CNBr mutant) 
 
 
Figure 4.2: ES+ mass spectrum and deconvoluted mass of IFNβ 78-166 glycopeptide (Acm protected) 
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4.2.1 Acm deprotection of IFNβ 78-166 glycopeptide  
In preparation for the next ligation, the N-terminal cysteine was unmasked by Ag+ 
mediated Acm deprotection according to a procedure reported by Danishefsky 
(performed by Dr Derek Macmillan).217 After reduction with DTT, the protein 37b 
was purified by (RP)HPLC and confirmed to be the product by LC-MS (Figure 4.3). 
 
Figure 4.3: ES+ mass spectrum and deconvoluted mass of IFNβ 78-166 glycopeptide 
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4.3 NCL of His10 tagged IFNβ 1-77 hydrazide with 78-166 glycopeptide  
The final ligation was attempted, with initial diazotisation of the N-terminal 
hydrazide as before. Addition of MPAA and the C-terminal fragment was followed 
by adjustment of the final pH to 7.0 and the ligation was allowed to proceed 
overnight (performed by Dr Ben Cowper). 
 
 
Scheme 4.3: NCL of His10 tagged IFNβ 1-77 hydrazide with semi-synthetic glycopeptide 94-166 
sad 
After analysis by LC-MS no trace of the expected product was found, but instead 
the major species was found to correspond to the N-terminal fragment MPAA 
thioester (Figure 4.4). Purification was attempted by (RP)HPLC, but disappointingly 
attempts to isolate the product 38 were unsuccessful. The failed ligation was 
attributed to an insufficient concentration of the C-terminal fragment.  
 
Figure 4.4: Deconvoluted mass spectrum analysing attempted NCL of His10 tagged IFNβ 1-77 hydrazide with 
semi-synthetic glycopeptide 
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4.4 Conclusions 
Unfortunately, the first attempt to assemble semi-synthetic IFNβ by Native 
Chemical Ligation was ineffective. Nonetheless, the foundations have been laid to 
enable this goal to be achieved in the near future. For these studies, it is critical that 
large amounts of material are accessible. The low expression efficiency of IFNβ 
fragments in E. coli may be overcome by the use of a fermenter, which will allow 
protein expression to be conducted with much larger culture volumes.  
Most importantly this study has shown that the necessary fragments were 
accessible, overcoming the limitations of existing methodology. Hence, this strategy 
should still enable a universal application to virtually any N-glycoprotein of interest. 
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5 Enzymatic transfer of oligosaccharides to 
N-glycopeptides  
 
5.1 Introduction 
In the early 1970’s, a family of enzymes were identified with the capability of 
selectively cleaving the GlcNAcβ(1-4)GlcNAc chitobiose core of N-glycans.218-220 
endo-β-N-acetyl-glucosaminidases were initially exploited for truncating N-
glycoproteins and for the release of glycans for analysis.221 However, it was later 
discovered that the enzyme catalysed cleavage could also be accompanied by a 
transglycosylation reaction, wherein the released glycan is transferred to another 
substrate.222-224 The ability to transfer large oligosaccharides en bloc in a single step 
with remarkable regio- and stereoselectivity, has led researchers to investigate the 
use of endoglycosidases in the synthesis of N-glycoproteins (Figure 5.1). In 
particular, Endo M from Mucor hiemalis and Endo A from Arthrobacter 
protophormiae have been exploited in such endeavours, due to their synthetic 
transglycosylation efficiency. Endo M recognises both complex-type and high 
mannose N-glycans as native substrates, whereas Endo A is specific for the high 
mannose subtype.  
 
 
Figure 5.1: Endoglycosidase catalysed reactions 
Semi-synthesis of glycoproteins                                                      Bhavesh Premdjee 
 
102 
 
Both Endo A and Endo M fall into the GH85 subfamily of glycosyl hydrolases, and 
are understood to operate via a two-step acid/base catalysed reaction involving a 
glutamic acid and an asparagine residue within the active site (Scheme 5.1). The 
mechanism of transglycosylation is presumed to take place through an oxazoline or 
oxazolinium intermediate, which is formed by neighbouring group participation 
from the acetamide of the second GlcNAc residue.  
 
 
Scheme 5.1: Proposed mechanism for GH85 endoglycosidase mediated hydrolysis and transglycosylation 
sad 
A complication encountered with endoglycosidase mediated synthesis is the natural 
hydrolytic activity of these enzymes, which often leads to poor overall yields as the 
transglycosylated product is also recognised as a substrate.225 Furthermore, 
transglycosylation reactions with un-activated donors (in the form of N-
glycopeptides) are generally inefficient and require high concentrations of the 
acceptor to be effective.225, 226 In an attempt to favour the synthetic reaction, 
researchers have sought methodologies which overcome the low transglycosylation 
efficiency of these enzymes, whilst minimising product hydrolysis. Consequently, 
two major routes have been explored, utilising activated glycosyl donors in the 
form of oxazolines and the evaluation of mutant enzymes. 
5.1.1 Oxazolines as activated glycosyl donors for “transglycosylation” reactions 
With the assumption that transglycosylation mediated reactions proceed via an 
oxazolinium intermediate, Shoda surveyed the ability of various endoglycosidases 
to process a disaccharide oxazoline as an activated substrate for glycosylation.43 
Interestingly, transfer to a GlcNAc acceptor (Scheme 5.2) was observed with Endo A 
and Endo M, with the desired regio- and stereoselectivity confirmed by NMR. This 
prompted the investigation of a number of other glycosyl oxazolines as substrates 
for endoglycosidase mediated synthesis.45, 227-231 
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Scheme 5.2: Shoda’s investigation of a disaccharide oxazoline as a substrate for transfer 
sad 
Importantly, these studies have revealed that endoglycosidases are able to transfer 
a wide range of glycosyl oxazolines, regardless of their native substrate specificity. 
Accordingly, application of this methodology can result in reduced product 
hydrolysis, as the transglycosylated product is not recognised by the enzyme. A 
noteworthy example of this was demonstrated by Wang, where it was shown that 
Endo A could transfer a complex sialoglycan to a GlcNAc-pentapeptide without 
product hydrolysis (Scheme 5.3).231 
 
Scheme 5.3: Transfer of a complex type glycan oxazoline with Endo A  
sad 
5.1.2 Endoglycosidase mutants 
In an alternative approach to abolish the hydrolytic activity of these enzymes, 
several research groups have examined endoglycosidase mutants which are able to 
transglycosylate sugar oxazolines but are unable to hydrolyse the chitobiose core. 
These investigations have also yielded mutants that have improved 
transglycosylation efficiency compared to the wild type. A common starting point 
for these studies involves the mutagenesis of the critical residues involved in 
endoglycosidase mediated hydrolysis.  
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Wang and Yamamoto evaluated the mutation of asparagine at residue 175 in Endo 
M, which was understood to be critical to the hydrolysis reaction by assisting 
formation of the oxazoline intermediate (Scheme 5.1). It was found that an N175A 
mutation allowed the transfer of a high mannose glycan oxazoline to a GlcNAc-
pentapeptide to take place without significant hydrolysis of the product (Scheme 
5.4).232 The enzyme also permitted transfer of a complex type oxazoline with 
excellent conversion (Scheme 5.5).231 Encouraged by these findings, Wang 
subsequently considered the mutation of the analogous residues in Endo A.230 The 
N171A mutant was found to transfer high mannose glycan oxazolines without 
product hydrolysis, but disappointingly was unable to process complex type glycan 
oxazolines.  
 
Scheme 5.4: Transfer of high mannose glycan oxazolines with endoglycosidase mutants  
 
Scheme 5.5: Transfer of complex type glycan oxazolines with endoglycosidase mutants  
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Fairbanks postulated that minimised Endo A hydrolysis could also be attained 
through removal of a glutamic acid residue from the active site. It was reasoned 
that the acidic functionality promotes formation of the oxazolinium intermediate by 
protonation of the outgoing anomeric oxygen in the first step of hydrolysis. The 
glutamate is then capable of acting as a general base, deprotonating water to 
promote hydrolysis (Scheme 5.1). Accordingly, an E173Q mutation was introduced 
under the rationale that non-acidic glutamine would be unable to catalyse the 
hydrolytic reaction. It was hoped that the synthetic reaction could still be 
accommodated by hydrogen bonding or deprotonation of the incoming 
nucleophile. An E173H mutation was also investigated, as histidine can act as a 
general acid or base. The pKa of glutamic acid is ~ 4.1, whereas histidine is ~ 6.0 
and hence it was supposed that the E173H mutant could potentially exhibit reduced 
hydrolytic activity.233 The mutant enzymes were subjected to glycosylation assays 
with a tetrasaccharide oxazoline donor and Cbz-Asn(GlcNAc)-OMe (Scheme 5.6). 
 
Scheme 5.6: Tranfer of tetrasaccharide oxazoline to Cbz-Asn(GlcNAc)-OMe with Endo A variants 
sad 
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Results showed that whilst oxazolines were processed with the wild type and both 
mutants, the synthetic reaction proceeded at different rates with varied amounts of 
product hydrolysis (Figure 5.2). The wild type enzyme rapidly transferred the 
tetrasaccharide, although was followed by gradual hydrolysis of the product. The 
E173Q mutant was able to catalyse the reaction, albeit slowly but without evidence 
of product hydrolysis. Finally, the E173H mutant was capable of processing the 
tetrasaccharide oxazoline efficiently and although product hydrolysis took place, it 
was significantly slower compared to the wild type. 
 
Figure 5.2: Time correlations of product yield for glycosylations of Cbz-Asn(GlcNAc)-OMe with tetrasaccharide 
oxazoline and Endo A variants 
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5.2 Synthesis of a tetrasaccharide oxazoline donor 
As part of a collaborative investigation, the glycosyl donor was provided by Dextra 
Laboratories, a specialist in the manufacturer of complex carbohydrates. The 
oxazoline was synthesised in a convergent manner, initially synthesising suitably 
protected monosaccharides A-C (Scheme 5.7). To begin with, the disaccharide core 
D was synthesised from GlcNAc acceptor A and Glc donor B. The donor was 
orthogonally protected as a levulinic acid ester at the 2-position, facilitating 
selective deprotection and epimerisation to convert glucose to mannose later in the 
synthesis. This strategy was adopted from a procedure described by Ajisaka and 
obviates a difficult step in the direct formation of a β-mannoside.234-236 Selective 
deprotection of the silyl protecting group was followed by glycosidation with Donor 
C to construct the Manα(1-3)Man linkage. After Lev removal, the free hydroxyl 
group was converted to the triflate and nucleophilically displaced with 
tetrabutylammonium acetate, resulting in inversion of configuration at C-2 to 
provide the desired trisaccharide H containing the Manβ(1-4)GlcNAc linked core. 
The benzylidene acetal was regioselectively opened using triethylsilane and PhBCl2, 
leaving the 6-hydroxyl group free to act as an acceptor.237 Glycosidation of I with 
trichloroacetimidate C allowed construction of the Manα(1-6)Man linkage to afford 
J. After a series of steps to remove the protecting groups, the fully deprotected 
tetrasaccharide M was converted to the corresponding oxazoline O using 2-chloro-
1,3-dimethylimidazolinium chloride (DMC).238 The resulting product was found to 
contain significant amounts of an inseparable triethylammonium species and 
subsequently as a precaution, an alternative method was investigated from the 
unprotected tetrasaccharide. Reacetylation to N was followed by treatment with an 
equimolar mixture of TMSBr and BF3OEt2 to form the protected oxazoline
239 and 
the final deacetylation was achieved by a treatment of sodium methoxide in 
methanol. 
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Scheme 5.7: Synthesis of tetrasaccharide oxazoline 
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5.3 Preparation of Endo A for transfer reactions 
5.3.1 Cloning of Endo A E173Q mutant 
With the tetrasaccharide oxazoline as the first substrate for glycosylation reactions, 
interest was drawn to the methodology reported by Fairbanks who had previously 
investigated a similar transformation.233 The E173Q mutant was of particular 
interest, as it was reported that no hydrolysis of the product was observed. Site 
directed mutagenesis was used to introduce the E173Q substitution into a plasmid 
containing the Endo A gene in vector pGEX2T (donated by Dr Derek Macmillan). 
After DNA sequencing verified that the desired mutation was introduced, both the 
wild type and mutant plasmids were transformed into BL21(DE3) cells. 
5.3.2 Expression of Endo A wild Type and E173Q mutant 
Expression of the GST (glutathione S-transferase) tagged proteins was carried out at 
30 °C for 5 hours and the enzymes were purified using glutathione affinity 
chromatography. SDS-PAGE analysis confirmed that both fusion proteins had been 
purified successfully although also suggested that a significant amount of protein 
did not bind to the column (Figure 5.3). 
 
 
Figure 5.3: SDS-PAGE analysis of column fractions after purification of GST tagged Endo A WT and E173Q 
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5.3.3 Removal of GST tag 
Proteins expressed from vector pGEX2T encode a Thrombin recognition sequence 
(LVPRGS) between GST and the target protein. After expression and the first round 
of purification, the Endo A fusion proteins were treated with thrombin. Following 
protease cleavage, the mixtures were passed down a glutathione column to bind 
GST and any remaining uncleaved protein. The flow-through was collected and 
after analysis by SDS-PAGE (Figure 5.4), the purified enzymes were dialysed into 
transglycosidation assay buffer and concentrated in a molecular weight cut off 
device. 
 
 
 
 
Figure 5.4: Thrombin cleavage of GST-Endo A fusions 
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5.4 Endo A transfer assays 
5.4.1 Endo A activity assays with RNAse B 
With the endoglycosidase enzymes in hand, their hydrolytic activity was evaluated 
against commercially available RNAse B, a high mannose glycoprotein (Scheme 5.8).  
 
Scheme 5.8: Deglycosylation of RNAse B to assess hydrolytic activity of Endo A variants 
sad 
Endo A wild type, E173Q and their GST variants were tested at different 
concentrations, followed by SDS-PAGE to assess the extent of deglycosylation 
(Figure 5.5). 
 
Figure 5.5: SDS-PAGE analysis of deglycosylation assay with RNAse B 
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As expected, the wild type Endo A appeared exceptionally capable of hydrolysing 
the substrates, even at a relatively lower concentration. The GST-tagged protein 
was also able to promote the deglycosylation reaction, concurrent with previous 
findings.240 Unexpectedly, the E173Q mutants also appeared to catalyse hydrolysis 
of the high mannose glycan to some extent, which contradicted earlier  
reports.233, 241 
5.4.2 Model transfer assays 
To initially survey the activity of the expressed endoglycosidases, it was decided to 
investigate the transfer of the tetrasaccharide oxazoline to the glycopeptide 
corresponding to IFNβ 78-93 (Chapter 2). However, the insolubility of this peptide 
in glycosylation buffer prompted the investigation of an alternative model system. 
Glucagon like peptide-1 (GLP-1) 7-36 has recently gained widespread attention as a 
potential therapeutic for the treatment of type 2 diabetes and affects glucose 
control by stimulating insulin secretion, suppressing glucagon secretion and 
lowering appetite. However, it has a relatively short half-life of two minutes as it is 
rapidly degraded in vivo by dipeptidyl peptidase-4.242 Although GLP-1 is not 
naturally glycosylated, a recent study showed that the addition of carbohydrate 
moieties prolonged the half-life of the peptide in vivo, thus increasing its potential 
for therapeutic applications.243  
Therefore a study on the endoglycosidase mediated transfer of the Man3GlcNAc 
oxazoline was performed with an analogue of GLP-1 7-36, incorporating GlcNAc-Asn 
in place of lysine at residue 34. This introduction was made in accordance with the 
previous study by Ueda et al. which showed that glycosylation at this position was 
the most beneficial.243 
The glycopeptide was synthesised by Native Chemical Ligation from two fragments 
using Liu’s hydrazide activation method.135 The glutamine residue at position 23 
was chosen as the ligation junction and was substituted with cysteine. It was 
envisaged that chemoselective treatment of the peptide with iodoacetamide after 
the ligation would convert the cysteine to a glutamine like residue (Scheme 5.9). 
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Scheme 5.9: Synthesis of a glycosylated GLP-1 analogue 
sad 
The transfer of the glycan was performed according to a protocol described by 
Wang, which was also attempted using a tetrasaccharide oxazoline (Scheme 5.10).45 
Initially, the activity of the E173Q mutant was assessed, following the reaction 
progress by analytical (RP)HPLC (Figure 5.6).  
 
 
Scheme 5.10: Endo A E173Q mediated transfer to GLP-1 with Man3GlcNAc oxazoline 
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Figure 5.6: Analytical (RP)HPLC data with UV absorption at 230nm monitoring Endo A E173Q mediated 
transfer to GLP-1 
Over 24 hours, a peak which eluted 1.0 minute earlier than the starting material 
was observed and assumed to be the more hydrophilic product. However, the rate 
of reaction was disappointing and it was concluded that background hydrolysis of 
the donor oxazoline would overall limit the maximum obtainable yield. This 
prompted the investigation of wild type Endo A, which was carried out under the 
same conditions and monitored by (RP)HPLC (Figure 5.7).  
retention time (mins) 
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Figure 5.7: Analytical (RP)HPLC data with UV absorption at 230nm monitoring Endo A (wild type) mediated 
transfer to GLP-1. * The time point corresponding to t = 0 h was injected shortly after addition of the reaction 
components. 
sad 
Remarkably, the first analytical time point (which was taken immediately after the 
addition of reaction components) suggested an almost instantaneous 
transformation to the desired pentasaccharide. Over the next 4 hours, it appeared 
that the newly formed product slowly reverted back to the starting material. LC-MS 
analysis confirmed successful transformation to the desired product, which was 
subsequently purified by RP(HPLC) (Figure 5.8). 
 
Figure 5.8: ES+ mass spectrum of GLP-1 pentasaccharide analogue 
 
3+ 
4+ 
 
retention time (mins) 
Semi-synthesis of glycoproteins                                                      Bhavesh Premdjee 
 
116 
 
 IFNβ transfer assays 5.4.2.1
Inspired by the rapid transfer observed in model studies, the procedure was applied 
towards the IFNβ 78-93 glycopeptide (Scheme 5.11). 
 
 
Scheme 5.11: Endo A (wild type) mediated transfer to IFNβ 78-93 with Man3GlcNAc oxazoline 
sad 
With the previous experiment suggesting that maximum yield was obtained in the 
early stages, the glycosylation reaction was allowed to proceed for 15 minutes 
before analysis by LC-MS (Figure 5.9). Once again, formation of the pentasaccharide 
was observed and the mixture was immediately purified by (RP)HPLC. 
 
Figure 5.9: ES+ mass spectrum of IFNβ 78-93 pentasaccharide analogue 
  
2+ 
3+ 
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5.5 Conclusions 
Endoglycosidase A was successfully used to form a novel analogue of GLP-1 bearing 
an N-linked pentasaccharide. Although biological activity has yet to be evaluated, 
the new analogue may extend the half-life of GLP-1 in vivo and may hold 
therapeutic potential. The endoglycosidase strategy was also applied towards an 
IFNβ glycopeptide, demonstrating the potential compatibility of this approach with 
the semi-synthetic strategy described in Chapter 4. 
Disappointingly, the E173Q mutant of Endo A did not appear to catalyse 
glycosylation efficiently. Subsequent investigations may benefit from the 
employment of alternative mutants such as the E173H mutant variant. 
Nonetheless, the wild type enzyme was capable of furnishing the desired products, 
albeit with accompanied hydrolysis after extended reaction times. 
By demonstrating the feasibility of this strategy, it is envisaged that future studies 
will allow the extension of this methodology to a number of alternative glycosyl 
donors and enzymes, allowing the production of a range of glycosylated peptides 
and proteins. 
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6 Synthesis of 3-carboxymethyl galactose 
uridine diphosphate 
 
6.1 Introduction 
To further expand the utility of endoglycosidase mediated transfer of complex 
glycans for the semi-synthesis of N-glycoproteins, it was decided to investigate the 
compatibility of this methodology with novel glycoprotein analogues. Given the 
importance of sialic acid in complex glycans to prolong the activity of glycoproteins 
in vivo, it was decided to investigate non-hydrolysable mimics of the sialyl 
galactose. In the absence of sialic acid, glycoproteins are removed from circulation 
via the asialoglycoprotein receptor in the liver and are subsequently degraded.244 
Therefore it was postulated that a non-hydrolysable mimic may present a method 
of extending the half-life of N-glycoproteins. Previous studies had indicated that 
sialyl LewisX (SLex) analogues retaining the negative carboxylate moiety were still 
able to bind to E-selectin.245-247 This observation was consistent with the crystal 
structure of SLex bound to E-selectin, which revealed the critical residues involved 
in this interaction (Figure 6.1).248 
 
Figure 6.1: Interaction between sialyl galactose of SLe
x
 and E-selectin revealed by an X-ray crystal structure
248
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Based on these findings, a non-hydrolysable sialyl galactose mimic was designed, 
retaining the important carboxyl motif (Figure 6.2). The incorporation of this motif 
into glycosyl oxazolines provides a novel substrate for Endo A, potentially 
generating novel N-glycoproteins which may exhibit prolonged activity in vivo. 
 
Figure 6.2: Rationale for 3-carboxymethyl galactose as a sialyl galactose mimic  
sad 
It was reasoned that the most convenient method of mimic incorporation would be 
through the use of a commercially available glycosyltransferase, thus avoiding the 
laborious synthesis of the complex glycan. This strategy could also allow for 
glycoproteins to be “remodelled” by treating complex type glycans with sialidases 
and galactosidases before transfer of the mimic to the terminal N-
acetylglucosamine acceptor. The formation of the lactosamine linkage usually relies 
on a β-1,4 galactosyltransferase, which processes galactose in the activated form of 
a UDP sugar nucleotide.  Accordingly, the initial investigation focussed on the 
synthesis of 3-carboxymethyl galactose uridine diphosphate (Figure 6.3) to facilitate 
the incorporation of the mimic through the use of a galactosyltransferase.  
 
 
Figure 6.3: 3-carboxymethyl galactose uridine diphosphate 
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6.1.1 Glycosyltransferases 
Glycosyltransferases (GTs) are a class of enzymes capable of forming glycosidic 
bonds with precise regio- and stereoselectivity, playing a vital role in the 
biosynthesis of oligosaccharides and glycoconjugates.249 GTs utilise activated 
glycosyl donors containing a good leaving group at the anomeric position to 
facilitate transfer. Depending on the nature of this leaving group, eukaryotic GTs fall 
into two families – the Leloir type and the non-Leloir type (Scheme 6.1).250 Most 
mammalian GTs belong to the Leloir type subfamily and require nucleotide donors 
such as UDP-Glc, UDP-Gal, UDP-GlcNAc, GDP-Man and CMP-Sialic acid. Not only 
does the nucleotide serve the role of a leaving group, it is also important for GT 
recognition.251 The active site of a GT binds the reacting donor and acceptor in a 
very specific manner, ensuring regio- and stereoselectivity in the glycosylation 
reaction. For certain GTs, a divalent cation such as Mn2+ is also important in aiding 
the loss of the leaving group.252 
 
Scheme 6.1: Glycosidic bond formation using GTs 
GTs are also classified as inverting or retaining, according to the stereochemistry 
observed at the anomeric centre after glycosidic bond formation. Whilst the 
mechanism of inverting GTs is well established (Scheme 6.2),253, 254 the mechanism 
for retaining GTs is less understood. 
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For inverting GTs, basic carboxylate side chains from Asp or Glu facilitate 
nucleophilic attack by the glycosyl acceptor. The leaving group of the sugar 
nucleotide facilitates the formation of an oxocarbenium intermediate, enabling the 
glycosidation reaction to take place. The result of this process gives rise to inversion 
of stereochemistry at the anomeric position of the donor. 
 
 
Scheme 6.2: Mechanism for inverting GTs 
sad 
For retaining GTs, it has been suggested that the reaction occurs via a double 
displacement SN2 with net retention of configuration (Scheme 6.3).
251, 255, 256 This 
reaction is initiated by direct attack of a carboxylate residue from Asp or Glu at the 
anomeric centre of the donor. The enzyme-donor intermediate is then displaced by 
another SN2 process by the glycosyl acceptor, giving net retention of stereochemical 
configuration in the product. 
 
Scheme 6.3: Suggested double displacement mechanism for retaining GTs
41
 
sad 
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6.2 Synthesis of UDP 3-carboxymethyl galactose 
The most popular method of preparing nucleoside diphosphate (NDP) sugars 
exploits the formation of the pyrophosphate bond. Coupling a sugar phosphate and 
a nucleoside monophosphate preserves the anomeric configuration of the sugar, 
whereas glycosylation of NDPs can lead to loss of stereocontrol at the anomeric 
centre.257 Activated nucleoside monophosphates are commercially available in the 
form of morpholidates and hence efforts have been driven towards the synthesis of 
a 3-carboxymethyl galactose (3-CG) phosphate.  
In the first step of 3-CG phosphate synthesis, the thiophenyl glycoside of galactose 
was formed. The thioglycoside enables protection of the anomeric carbon, 
exhibiting stability to a wide range of conditions and can be selectively removed by 
mild hydrolysis.258 Initially, ᴅ-Galactose 49 was peracetylated with acetic anhydride 
in the presence of catalytic perchloric acid, providing the α-configured anomer. 
Thioglycosidation of the peracetylated sugar was performed using thiophenol and 
catalytic boron trifluoride diethyl etherate to give the β-thioglycoside in moderate 
yield.259 Deacetylation with a catalytic amount of sodium methoxide in methanol 
afforded the deprotected thioglycoside 52.  
 
Scheme 6.4: Synthesis of thioglycoside 52 
sad 
The hydroxyl group at C-3 was selectively activated for alkylation by reaction of the 
thioglycoside with dibutyl tin oxide. The cis relationship of the hydroxyl groups at C-
3 and C-4, allows the formation of a stannylene acetal and the more reactive 
equatorial C-3 can react with tert-butyl bromoacetate. The free hydroxyls at C-2, C-
4 and C-6 were subsequently reacetylated with acetic anhydride and pyridine, 
before treatment of 54 with N-bromosuccinimide in aqueous acetone to selectively 
cleave the thiophenyl glycoside. The anomeric mixture was deprotonated with LDA 
prior to treatment with tetrabenzyl pyrophosphate, resulting in formation of the α-
phosphate 56 exclusively (Scheme 6.5). 
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Scheme 6.5: Synthesis of 3-carboxymethyl galactose phosphate 
sad 
Following phosphorylation, the benzyl groups were removed by hydrogenation in 
the presence of a palladium catalyst. As the resulting phosphate 57 was expected to 
be highly acidic, the reaction was quenched with triethylamine to prevent the 
unwanted cleavage of the tert-butyl ester. The formation of the pyrophosphate 
bond was conducted in DMF over 24 hours with the commercially available UMP 
morpholidate, followed by ion exchange to the sodium salt (Scheme 6.6).260, 261 The 
presence of the pyrophosphate linkage was confirmed by 31P NMR (Figure 6.4). 
 
Scheme 6.6: Deprotection of sugar monophosphate 56 and formation of the pyrophosphate bond 
 
Figure 6.4: 
31
P NMR (D2O) comparison of commercially purchased UDP-Gal and sugar nucleotide 58 
confirming successful pyrophosphate bond formation. The pyrophosphate linkage gives rise to two doublets 
which arise from phophorus-phosphorus coupling. 
 
ppm 
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Subsequently, the removal of the tert-butyl protecting group was investigated using 
various concentrations of aqueous TFA. Initial experiments using 5% or 20% TFA 
showed that cleavage of the ester was sluggish. Over extended periods of time, 31P 
NMR revealed cleavage of the pyrophosphate bond, indicated by the presence of a 
singlet corresponding to monophosphate 57. This led to attempted tert-butyl ester 
cleavage with higher concentrations of TFA. Indeed the use of 95% TFA resulted in 
rapid removal of the tert-butyl group, although hydrolysis of the pyrophosphate 
was still observed. With the incompatibility of the pyrophosphate bond with tert-
butyl ester cleavage, an alternative protecting group strategy was investigated. 
 
Scheme 6.7: Unsuccessful cleavage of tert-butyl ester with TFA 
It was postulated that carboxylate protection with a benzyl group would allow 
simultaneous deprotection during debenzylation of the protected sugar 
monophosphate (Scheme 6.8). Despite the presence of a free carboxyl group, 
previous studies have shown that this functionality is compatible with 
pyrophosphate formation.262, 263 
 
Scheme 6.8: Alternative protection strategy of the carboxylate as a benzyl ester facilitates concomitant 
removal during deprotection of the sugar monophosphate 
In an initial attempt to synthesise the benzyl protected derivative, it was decided to 
alkylate thioglycoside 52 with benzyl bromoacetate via the stannylene acetal as 
before (Scheme 6.9). 
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Scheme 6.9: Proposed synthesis of benzyl protected thioglycoside 
Surprisingly, the use of benzyl bromoacetate as an alkylating reagent did not 
successfully lead to the formation of the desired product. However, this 
observation was consistent with a previous study which also reported inefficient  
alkylation of a thiogalactoside with benzyl bromoacetate.247 
As a result, the benzyl protected thioglycoside was synthesised from derivative 54, 
substituting tert-butyl protection in the form of a benzyl ester. Cleavage of the tert-
butyl group took place quantitatively in 20% TFA and the free carboxylate was 
esterified by treatment with caesium carbonate and benzyl bromide.264 Following 
hydrolysis of thioglycoside 59 and subsequent phosphorylation, debenzylation of 61 
was achieved by hydrogenation as before. 
 
Scheme 6.10: Synthesis of sugar nucleotide via benzyl protection strategy 
Unfortunately, the critical formation of the pyrophosphate linkage proved 
unsuccessful using the debenzylated sugar monophosphate and UMP 
morpholidate. Despite a number of attempts, no product was detected by TLC or 
crude 31P NMR, even after extensive drying of reaction components by co-
evaporation with dry pyridine and addition of molecular sieves. 
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At this point, it was hypothesised that a strategy relying on tert-butyl ester removal 
after glycosyl transfer (Scheme 6.11) could prove more feasible and the previous 
strategy was revisited.  
 
Scheme 6.11: Alternative strategy relying on tert-butyl deprotection following glycosyl transfer 
ad 
Consequently, efforts were directed towards the removal of the remaining sugar 
acetate groups from sugar nucleotide 58. The sensitivity of the pyrophosphate 
motif led to the exploration of protocols which had previously been shown to be 
compatible with sugar nucleotides. The deprotection was first attempted in a 
mixture of methanol/water/triethylamine (5:2:1) according to the procedure 
described by Marchesan and Macmillan.265 These relatively mild conditions are 
popular for deacetylation, as they are typically high yielding and product 
purification is achieved by extraction followed by lyophilisation of the aqueous 
layer. Unfortunately, cleavage of the acetate groups proceeded much slower than 
expected and was accompanied by pyrophosphate cleavage. Zemplen deacetylation 
with sodium methoxide in methanol was also found to be ineffective due to the 
poor solubility of the sugar nucleotide in methanol. Later, the use of aqueous 
lithium hydroxide and hydrazine hydrate was attempted, but these conditions also 
resulted in the breakdown of the sugar nucleotide or inefficient deacetylation. 
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Conditions  Observations 
MeOH/H2O/Et3N 
(5:2:1) 
Inefficient deacetylation after 24 hours, pyrophosphate 
cleavage occurs slowly 
MeOH/H2O/Et3N 
(7:3:1) 
Inefficient deacetylation after 5 days, pyrophosphate 
cleavage occurs slowly 
0.1 M LiOH  Inefficient deacetylation after 24 hours, pyrophosphate 
cleavage occurs slowly 
1 M LiOH Quantitative deacetylation accompanied by pyrophosphate 
cleavage within 4 hours 
1% Hydrazine 
hydrate 
Inefficient deacetylation after 24 hours, pyrophosphate 
cleavage occurs slowly 
5% Hydrazine 
hydrate 
Quantitative deacetylation accompanied by pyrophosphate 
cleavage within 2 hours 
NaOMe in methanol Sugar nucleotide insoluble in methanol, inefficient 
deacetylation over 24 hours 
 
Figure 6.5: Reaction conditions and outcomes for attempted deacetylation of sugar nucleotide 58 
This further prompted a redesign of the approach to the final product. Removal of 
the protecting groups before pyrophosphate formation could potentially obviate 
the difficulties encountered previously. However, it was also found when 
attempting the coupling in the absence of acetate groups, formation of the desired 
product was not observed. 
 
Scheme 6.12: Attempted synthesis of sugar nucleotides with deacetylated sugar monophosphate 
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Finally, the previous attempts to deacetylate the sugar nucleotide using 
methanol/water/triethylamine (5:2:1) were re-examined. Although previous 
experiments had shown the reaction was slow, pyrophosphate cleavage did not 
occur to the same extent as observed under the alternative conditions. The 
reaction was allowed to proceed for 7 days, resulting in quantitative deacetylation 
albeit accompanied with hydrolysis of the pyrophosphate linkage. Removal of the 
acetate groups was confirmed by 1H NMR (Figure 6.6), and 31P NMR indicated the 
presence of 62 (Figure 6.7). 
 
Scheme 6.13: Deacetylation of sugar nucleotide 58 
 
Figure 6.6: 
1
H NMR (D2O) comparing sugar nucleotide 58 (upper) with crude deacetylated mixture (lower) 
after treatment with MeOH/H2O/Et3N (5:2:1) for 7 days. From comparison of the spectra, efficient 
deacetylation was confirmed by the absence of 3 x CH3 singlets. 
2 x CH3 
CH3 
ppm 
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Figure 6.7: 
31
P NMR comparing (upper to lower) sugar monophosphate 57 (CDCl3), uridine monophosphate 
(D2O), sugar nucleotide 58 (D2O) and crude deacetylated mixture (D2O). Comparison of the spectra confirms 
the presence of a pyrophosphate linkage in the crude deacetylated mixture, although appears to be 
accompanied by species corresponding to monophosphates. 
  
ppm 
Pyrophosphate 
linkage still present 
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6.3 Synthesis of GlcNAc benzyl glycoside 
To initially survey the ability of a glycosyltransferase to accept UDP 3-
carboxymethyl galactose 62 as a substrate, the benzyl glycoside of N-
acetylglucosamine was chosen as a glycosyl acceptor. It was envisaged that the 
benzyl group incorporated a UV chromophore, allowing visualisation during 
(RP)HPLC analysis of transfer assays. The glycoside was synthesised from 
phthalamido protected GlcNAc 63266 (provided by Dr Derek Macmillan) furnishing 
the benzyl glycoside 64 in 45% yield over 3 steps. Subsequent Zemplen 
deacetylation afforded the desired unprotected glycoside 65. 
 
Scheme 6.14: Synthesis of GlcNAc benzyl glycoside 65 
 
6.4 Conclusions 
The latter stages of sugar nucleotide synthesis have presented significant problems 
when investigating protecting group removal as the pyrophosphate linkage appears 
vulnerable to both acidic and basic conditions. The coupling of unprotected sugar 
phosphates was accordingly investigated, however disappointingly failed to yield 
the product.  
The objective of this study was to synthesise a novel sugar nucleotide analogue and 
assess its ability to be transferred by a galactosyltransferase. With this in mind, this 
study has still provided a source of sugar nucleotide 62 which can be tested as a 
substrate. A suitable glycosyl acceptor 65 has also been synthesised for use in the 
initial transfer assays. Future studies may yield a more efficient synthesis of the 
sugar nucleotide and access to purer samples. In time, this should allow the crucial 
evaluation of a sialyl galactose mimic on glycoproteins in vivo. 
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7 Final conclusions and outlook 
 
7.1 Semi-synthesis of N-linked glycoproteins 
A semi-synthetic strategy towards N-glycoproteins was directed towards Interferon 
β-1, a 166 residue cytokine bearing a single site of N-glycosylation. IFNβ 
represented an ideal target for the demonstration of this methodology, as the 
central position of glycosylation necessitated the expression of two flanking protein 
sequences, each requiring distinct functionalisation. By meeting this criterion, the 
developed methodology may potentially be applied to any N-glycoprotein of 
interest. 
The application of N→S acyl transfer has allowed the preparation of N-glycopeptide 
thioesters for participation in protein assembly through Native Chemical Ligation. 
This was successfully demonstrated on a model glycopeptide corresponding to EPO 
residues 22-28, which was subsequently able to ligate with a recombinant protein. 
However, the elevated temperature required to drive formation of a thioester was 
found to be incompatible with hydrophobic sequences. When applied to the 
thioester formation of the glycopeptide corresponding to IFNβ 78-93, aggregation 
was observed, ultimately leading to poor conversions. Although temperature could 
be lowered to minimise aggregation, longer reaction times would result in 
hydrolysis of the thioester. The utility of peptide hydrazides and their use in NCL led 
to the exploration of hydrazine in the acyl transfer reaction. Pleasingly, this reaction 
afforded the respective hydrazide, which exhibited stability over longer reaction 
periods. This allowed the functionalisation of hydrophobic sequences, overcoming 
the earlier encountered difficulties. Whilst these studies were intriguing, the impact 
of this reaction for the functionalisation of synthetic peptides was limited, as 
peptide hydrazides can be prepared directly on specialised resins. 
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The true potential of this reaction was unlocked when exploring the 
functionalisation of recombinant proteins. Despite intein and sortase technologies 
offering access to recombinant protein thioesters (and hydrazides), these methods 
are typically limited to soluble protein sequences. The developed hydrazinolysis 
reaction can be performed in the presence of chaotropes and is potentially 
applicable to any sequence of interest. Accordingly, the highly insoluble N-terminal 
fragment (IFNβ 1-77) was converted to the corresponding C-terminal hydrazide.  
The C-terminal fragment (IFNβ 94-166) was also found to be highly insoluble, 
excluding the protein from a number of existing functionalisation methods. The 
liberation of an N-terminal cysteine was eventually achieved using a highly 
chemoselective treatment of cyanogen bromide, although this required mutation of 
methionine residues from within the sequence. 
With all the appropriately functionalised fragments in hand, IFNβ assembly was 
attempted using the hydrazide ligation methodology developed by Liu. The ligation 
was successfully conducted between the glycopeptide and C-terminal fragment, 
allowing the isolation of a semi-synthetic glycoprotein corresponding to IFNβ 78-
166. Although the final ligation step was attempted, the final product 
corresponding to full length IFNβ was not observed. Future studies with larger 
amounts of material may enable optimisation of this step, allowing the preparation 
of full length IFNβ. 
In spite of this outcome, the study has demonstrated the potential of the 
hydrazinolysis reaction, importantly overcoming the limitations of current 
methodologies. This should permit a widespread application of the semi-synthetic 
strategy towards any protein of interest. 
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7.2 Glycosylation with Endohexosaminidases 
In recent years, the use of endoglycosidases for the glycosylation of proteins has 
proved an invaluable tool. Nonetheless, the use of this methodology requires 
access to complex glycans, where preparation is typically restricted to specialist 
laboratories. As a consequence, the use of this technology has been limited to a 
small number of research groups around the world. In this study, a tetrasaccharide 
oxazoline was successfully synthesised and transferred to glycopeptides bearing a 
natively linked N-acetylglucosamine acceptor. This led to the preparation of a 
glycosylated analogue of GLP-1, as well as IFNβ 78-93 for use in our semi-synthetic 
strategy. The first demonstration of endoglycosidase technology within this 
research group should undoubtedly pave the way towards future studies with a 
range of glycans and enzyme variants to generate homogenous N-glycoproteins.  
 
7.3 3-carboxymethyl galactose as a sialyl galactose mimic 
The synthesis of 3-carboxymethyl galactose uridine diphosphate for the preparation 
of sialyl galactose mimics through glycosyl transfer has proved challenging in the 
final stages, as the pyrophosphate bond was found to be compromised upon 
removal of the protecting groups. Attempting formation of the pyrophosphate in 
the absence of protecting groups was met with considerable difficulty and 
unsuccessful isolation of the product. Consequently, carboxylate protection was 
retained with the intention that deprotection could be performed after glycosyl 
transfer. However, it is still unknown if the presence of the tert-butyl group will be 
tolerated in this reaction, in which case it may be necessary to investigate an 
alternative method of protection. The deacetylation step was examined under a 
number of conditions, but a clean conversion to the desired product without 
breakdown of the pyrophosphate has not been discovered. Future studies may 
uncover an improved procedure for deacetylation, accompanied by an efficient 
method for purification of the sugar nucleotide. In the meantime, the crude 
deacetylated mixture may provide a suitable source of the glycosyl donor. It is 
envisaged that successful transfer of the mimic will provide novel glycan substrates 
for Endo A and the preparation of N-glycoproteins with enhanced stability in vivo.  
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8 Experimental 
8.1 General experimental 
Chemicals were obtained from Novabiochem, Sigma-Aldrich, Fischer Scientific and 
AGTC Bioproducts, used without further purification unless mentioned otherwise. 
Petroleum Spirit refers to petroleum ether that boils in the range 40-60 °C. Flash 
chromatography was carried out with silica gel 40-63 μm (VWR). Analytical TLC was 
performed on Merck Silica gel 60 F254 aluminium sheets (0.25 mm layer coating) 
and was visualised with short wavelength (366 nm) ultraviolet light. Staining was 
performed with a solution of anisaldehyde, using heat to visualise spots. Anhydrous 
magnesium sulfate was used to dry organic extracts.  
Proton NMR (1H NMR) were recorded at 500 MHz or 600 MHz on Bruker AMX500 
and AMX600 instruments respectively. 13C NMR experiments were run on the same 
instruments at 125 MHz or 150 MHz respectively. 31P NMR was recorded at 121 on 
a Bruker AMX300. All NMR experiments were conducted at room temperature. 
Chemical shifts (δ) are recorded in parts per million (ppm) and reported with 
reference to the solvent peak. CDCl3 refers to fully deuterated chloroform, MeOD 
(CD3OD) refers to fully deuterated methanol, D2O to fully deuterated water and 
DMSO-d6 refers to fully deuterated dimethyl sulfoxide. Coupling constants (J) are 
reported in hertz, calculated from observed chemical shifts. LC-MS was conducted 
on a Waters UPLC/SQD-LC mass spectrometer with a linear gradient from 95% of 
solvent A (water with 0.1% formic acid) to 95% solvent B (acetonitrile with 0.1% 
formic acid) over 4 minutes at a flow rate of 0.6 mL/min. FAB and ESI mass 
spectrometry experiments were performed Dr Lisa Haigh or Dr Vincent Gray from 
the Department of Chemistry at UCL. Melting points were determined using an SRS 
Digimelt melting point apparatus. Infrared spectra were recorded on a Bruker Alpha 
Platinum ATR FT-IR spectrometer. 
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8.1.1 HPLC purification methods 
Analytical (RP)HPLC was carried out using a Phenomenex SphereClone™ 5 µm 
ODS(2) 80 Å, LC Column (diameter = 250 mm × 4.6 mm): flow rate 1.0 mL/min, 
detection at 230, 254 and 280 nm using a gradient of 95% water (0.1% TFA)/5% 
acetonitrile (0.1% TFA), to 5% water (0.1% TFA)/95% acetonitrile (0.1% TFA), over 
45 min, using a Dionex Ultimate 3000. 
Semi-preparative (RP)HPLC method 1 was carried out using a Phenomenex Luna 5 
µm C18 100 Å, LC Column (diameter = 250 mm × 10.0 mm): flow rate 4.0 mL/min, 
detection at 230, 254 and 280 nm (Dionex UVD170U) using a gradient of 95% water 
(0.1% TFA)/5% acetonitrile (0.1% TFA), to 40% water (0.1% TFA)/60% acetonitrile 
(0.1% TFA), over 45 min, using a P680 HPLC pump and a Foxy Jr fraction collector. 
Semi-preparative (RP)HPLC method 2 was carried out using a Phenomenex Jupiter 4 
µm Proteo 90 Å, LC Column (diameter = 250 mm × 10.0 mm): flow rate 4.0 mL/min, 
detection at 230, 254 and 280 nm (Dionex UVD170U) using a gradient of 95% water 
(0.1% TFA)/5% acetonitrile (0.1% TFA), to 70% water (0.1% TFA)/30% acetonitrile 
(0.1% TFA), over 5 min, to 30% water (0.1% TFA)/70% acetonitrile (0.1% TFA), over 
35 min, using a P680 HPLC pump and a Foxy Jr fraction collector. 
Preparative (RP)HPLC was carried out using a Phenomenex Jupiter 4 µm Proteo 90 
Å, LC Column (diameter = 250 mm × 21.2 mm): flow rate 10.0 mL/min, detection at 
230, 254 and 280 nm using a gradient of 95% water (0.1% TFA)/5% acetonitrile 
(0.1% TFA), to 40% water (0.1% TFA)/60% acetonitrile (0.1% TFA), over 45 min, 
using a Dionex Ultimate 3000 equipped with a fraction collector unless specified 
otherwise. 
Solvents were removed on an Edwards Modulyo freeze dryer equipped with an 
RV12 vacuum pump for 24-48 hours. 
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8.1.2 General microbiology 
Standard techniques were performed as described in Molecular Cloning - A 
Laboratory Manual (Sambrook and Russell, 3rd edition, 2001, Cold Spring Harbour 
Press). Standard sterile technique was maintained during all microbiological work. 
All media and glassware were sterilised in an autoclave at 121 °C for 15 minutes. 
Agarose gels were prepared by dissolving agarose (1.0 g) in TAE buffer (100 mL) 
with microwave heating. Ethidium bromide (5 µL) was added to the agarose 
solution, which was subsequently poured into the electrophoresis chamber to set. 
Gels were run at 110 volts and visualised with UV light. SDS-PAGE was carried out 
using the Novex NuPAGE gel system (Life technologies) using 4% polyacrylamide for 
the stacking gel and 12-14% for the resolving gel. Samples in Gu.HCl were 
precipitated by a 10 fold addition of acetone/methanol (1:1) and storage at -20 °C 
for 5 minutes. The proteins were pelleted by centrifugation at 13000 RPM before 
resuspension in SDS-PAGE loading buffer. DNA sequences were verified by the 
sequencing service at the Wolfson Institute of Biomedical Research. Cell cultures 
were grown in shaker incubators at 175 RPM. 
Preparation of Escherichia coli competent cells 
LB medium 10 mL was seeded with the appropriate cell line and grown overnight 
with shaking at 37 °C. An aliquot of the overnight culture (100 µL) was used to seed 
fresh LB medium (10 mL) and grown to an absorbance of OD600 ~ 0.2. The cells 
were collected by centrifugation at 3000 RPM for 15 minutes (4 °C). The 
supernatant was discarded and the cells were suspended in fresh ice cold 
transformation buffer (50 mM CaCl2, 10 mM Tris, pH 8.0, 4.0 mL). The cells were 
left on ice for 30 minutes, with occasional agitation. The cells were then collected 
by centrifugation at 3000 RPM for 15 minutes (4 °C). The supernatant was 
discarded and the cells were resuspended in 400 µL of ice cold transformation 
buffer. 
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Transformation of plasmids into Escherichia coli cells 
A 100 µL aliquot of competent cells was transferred to a sterile microcentrifuge 
tube (1.5 mL) and left on ice for 30 minutes. The respective DNA (2.5 µL) was 
added; the tube was gently tapped and then left on ice for another 30 minutes. The 
sample was then heat shocked for 30 seconds at 42 °C on an Eppendorf 
thermomixer and then LB medium (1 mL) was added. The sample was then 
incubated for 1 hour at 37 °C and then collected by centrifugation at 3000 RPM for 
15 minutes (4 °C). The supernatant was discarded and the cells were resuspended 
in fresh LB medium (100 µL). The cells were then spread to dryness on LB-agar 
plates with 100 µg/ml ampicillin and grown inverted at 37 °C overnight. 
Restriction endonuclease digestions 
Unless specified otherwise, the typical DNA digest was performed as follows: 
PCR product or vector 40 µL 
Compatible 10 x buffer 5 µL 
Restriction endonuclease I 1 µL  
Restriction endonuclease II 1 µL  
Distilled sterile water 3 µL  
DNA digests were performed at 37 °C overnight 
Protein and DNA quantification 
Single stranded or double stranded DNA concentrations were determined on an 
Eppendorf BioPhotometer using the appropriate function. Protein absorbance was 
measured on the same machine and quantified by the Beer-Lambert Law where:  
A280 = ε.c.l 
The molar extinction coefficient was predicted using the ProtParam tool from 
Expasy (web.expasy.org/protparam). 
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8.2 Chapter 2 experimental details 
2-acetamido-2-deoxy-3, 4, 6-tri-O-acetyl-α-ᴅ-glucopyranosyl chloride 2 
 
 
N-acetyl glucosamine 1 (10.2 g, 46.0 mmol) was added to stirring acetyl chloride (20 
mL) in a flask equipped with a drying tube. The suspension was stirred for 18 hours 
and formed an amber coloured solution, to which chloroform (80 mL) was added. 
The resulting solution was poured into ice (80 g) and water (20 mL) with stirring. 
The organic layer was run into saturated aqueous sodium bicarbonate (80 mL) with 
neutralisation being completed in a separating funnel. The organic layer was then 
dried over magnesium sulfate for 15 minutes before being filtered with suction. The 
yellow solution was then evaporated to dryness in vacuo to afford the crude 
product as a light brown solid, which was subsequently purified by flash 
chromatography over silica (100% ethyl acetate) to give the product as an off white 
solid (5.96 g, 36%). Rf 0.69 (100% ethyl acetate). 
1H NMR (500 MHz, CDCl3) δ 6.18 
(1H, d, J = 3.7, H1), 5.83 (1H, d, J = 8.5, NH), 5.32 (1H, t, J = 10.4, H3), 5.21 (1H, t, J = 
9.5, H4), 4.55 - 4.51 (1H, m, H2), 4.30 - 4.25 (2H, m, H6a and H5), 4.13 (1H, dd, J = 
12.5, 2.0, H6b), 2.10 (3H, s, CH3), 2.05 (6H, s, 2 x CH3), 1.98 (3H, s, CH3).
 13C NMR 
(125 MHz, CDCl3) δ 171.6, 170.7, 170.2, 169.2 (4 x C=O), 93.7 (C1), 71.0 (C5), 70.2 
(C3), 67.0 (C4), 61.2 (C6), 53.6 (C2), 23.2, 20.8, 20.6, 20.5 (4 x CH3). IR υmax (cm
-1) 
neat 3240 (NH), 1737 (C=O), 1641 (C=O). FAB+ MS (m/z) calculated for C14H20NO8Cl 
365.09 found [MNa]+ 388.08. m.p. 122-124 °C (lit. 124-125 °C).203 
2-acetamido-2-deoxy-3, 4, 6-tri-O-acetyl-β-ᴅ-glucopyranosyl azide 3 
 
 
A mixture of glycosyl chloride 2 (5.75 g, 15.7 mmol), TBAHS (5.35 g, 15.7 mmol) and 
sodium azide (3.07 g, 47.2 mmol) in dichloromethane (50 mL) with saturated 
aqueous sodium bicarbonate (50 mL) were stirred vigorously at room temperature 
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for 4 hours. To the biphasic mixture was added ethyl acetate (125 mL) and the 
organic layer was separated. The aqueous layer was extracted with ethyl acetate (2 
x 100 mL) before the combined organic extracts were washed with saturated 
aqueous sodium bicarbonate (100 mL) and water (100 mL). It was then washed with 
saturated aqueous sodium chloride (100 mL) before being dried over magnesium 
sulfate. The organic mixture was then collected under vacuum and the volatile 
solvents were removed in a rotary evaporator. The pure product was recrystallised 
from diethyl ether to afford the products as an off white solid (5.58 g, 95%). Rf 0.41 
(100% ethyl acetate). 1H NMR (500 MHz, CDCl3) δ 5.73 (1H, d, J = 8.8, NH), 5.24 (1H, 
t, J = 9.6, H3), 5.09 (1H, t, J = 9.6, H4), 4.75 (1H, d, J = 9.3, H1), 4.26 (1H, dd, J = 12.4, 
4.8, H6a), 4.16 (1H, dd, J = 12.4, 2.0, H6b), 3.92 (1H, q, J = 9.2, H2), 3.80 - 3.77 (1H, 
m, H5), 2.10 (3H, s, CH3), 2.04 (3H, s, CH3), 2.03 (3H, s, CH3), 1.97 (3H, s, CH3). 
13C 
NMR (125 MHz, CDCl3) δ 171.1, 170.8, 170.5, 169.4 (4 x C=O), 88.5 (C1), 74.1 (C5), 
72.2 (C3), 68.1 (C4), 62.0 (C6), 54.2 (C2), 23.3, 20.8, 20.7, 20.6 (4 x CH3). IR υmax (cm
-
1) neat 3350 (NH), 2103 (N3), 1742 (C=O), 1662.6 (C=O). ESI
+ MS (m/z) calculated for 
C14H20N4O8 372.13 found [MNa]
+ 395.12. m.p. 170-172 °C (lit. 166-168 °C).267  
2-acetamido-2-deoxy-3, 4, 6-tri-O-acetyl-β-ᴅ-glucopyranosyl amine 4 
 
 
Glycosyl azide 3 (2.01 g, 5.39 mmol) and platinum (IV) oxide (100 mg) were added 
to a 3 necked flask, which was evacuated and purged with nitrogen gas 3 times. Dry 
tetrahydrofuran (36 mL) was added and flask was evacuated and purged twice with 
hydrogen gas. The mixture was stirred under hydrogen at room temperature and 
monitored by thin layer chromatography. After 3 hours TLC indicated complete 
consumption of the azide and the reaction mixture was filtered through celite. The 
product was evaporated to dryness to yield the amine as a grey powder (1.43 g, 
97%). 1H NMR (500 MHz, CDCl3) δ 5.66 (1H, d, J = 8.8, NH), 5.13 - 5.01 (2H, m, H3, 
H4), 4.21 (1H, dd, J = 12.3, 4.9, H6a), 4.12 - 4.09 (2H, m, H1, H6b), 4.02 (1H, q, J = 9.4, 
H2), 3.65 - 3.62 (1H, m, H5), 2.09 (3H, s, CH3), 2.04 (3H, s, CH3), 2.03 (3H, s, CH3), 
1.99 (3H, s, CH3). 
13C NMR (125 MHz, CDCl3) δ 171.7, 170.9, 170.8, 169.4 (4 x C=O), 
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86.5 (C1), 73.5 (C3), 72.9 (C5), 68.5 (C4), 62.5 (C6), 55.0 (C2), 23.4, 20.9, 20.8, 20.7 
(4 x CH3). IR υmax (cm
-1) neat 3400 (NH), 3343 (NH), 1736 (C=O), 1659 (C=O). ESI+ MS 
(m/z) calculated for C14H22N2O8 346.14 found [MNa]
+ 369.13. m.p. 155-157 °C (lit. 
159 °C).203 
N-α-fluorenylmethoxycarbonyl-N-β-(2-N-acetylamido-2-deoxy-β-ᴅ-
glucopyranosyl)-tert-butyloxy-L-asparagine 5 
 
 
Glycosyl amine 4 (500 mg, 1.44 mmol), Fmoc-Asp-OtBu (594 mg, 1.44 mmol) and N-
ethoxycarbonyl-2-ethoxy-1, 2-dihydroquinoline (357 mg, 1.44 mmol) were stirred in 
dichloromethane (45 mL) under nitrogen at room temperature for 4 hours. The 
crude mixture was concentrated in vacuo to afford a grey solid to which a mixture 
(1:1) of hot ethyl acetate and petroleum sprit (20 mL) was added. The suspension 
was filtered and the product was collected as a grey solid which was dried under 
vacuum to yield 821 mg (77%). Rf 0.5 (100% ethyl acetate). 
1H NMR (500 MHz, 
CDCl3) δ 7.75 (2H, d, J = 7.5, 2 x Ar-H), 7.59 (2H, d, J = 7.4, 2 x Ar-H), 7.39 (2H, t, J = 
7.3, 2 x Ar-H), 7.31 - 7.28 (3H, m, 2 x Ar-H, NH), 6.21 (1H, d, J = 8.3, NH), 5.96 (1H, d, 
J = 8.6, NH), 5.11 - 5.03 (3H, m, H1, H3, H4), 4.55 - 4.49 (1H, m, CHα), 4.43 - 4.40 (1H, 
m, CH), 4.30 - 4.17 (3H, m, 2 x CH, H6a), 4.14 - 4.12 (2H, m, CH, H2), 3.74 (1H, dd, J = 
9.7, 2.0, H5), 2.84 (1H, dd, J = 16.4, 4.2, CHβ), 2.70 (1H, dd, J = 16.3, 3.9, CHβ), 2.06 
(3H, s, CH3), 2.05 (3H, s, CH3), 2.04 (3H, s, CH3), 1.94 (3H, s, CH3), 1.44 (9H, s, 
C(CH3)3). 
13C NMR (125 MHz, CDCl3) δ 172.4, 172.0, 171.2, 170.8, 170.1, 169.4, 
156.2 (7 x C=O), 144.0, 141.3 (4 x Ar-qC), 127.8, 127.2, 125.2, 120.0 (8 x Ar-C), 82.3 
(C(CH3)),  80.2, 73.6, 73.0, 67.7 (4 x CH), 67.2 (CH2), 61.8 (CH2), 60.5, 53.4 (2 x CH), 
51.1 (CHα), 47.2 (CH), 38.1 (CH2β), 28.0 (C(CH3)), 23.1, 20.8, 20.7, 20.6 (4 x CH3). IR 
υmax (cm
-1) neat 3308 (NH), 1738 (C=O), 1658 (C=O). FAB+ MS (m/z) calculated for 
C37H45N3O13 739.30 found [MNa]
+ 762.29. m.p. 208-211 °C (lit. 214-215 °C).204 
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N-α-fluorenylmethoxycarbonyl-N-β-(2-N-acetylamido-2-deoxy-β-ᴅ-
glucopyranosyl)-L-asparagine 6 
 
 
Glycoamino acid (5) (500 mg, 680 µmol) was treated with 95% trifluoroacetic acid 
(10 mL) and stirred at room temperature for 3 hours. TLC analysis indicated 
completion of the reaction and the solvent was removed in vacuo to yield the 
product as a grey solid (462 mg, 100%). Rf 0.18 (100% ethyl acetate). 
1H NMR (500 
MHz, DMSO-d6) δ 8.57 (1H, d, J = 9.2, NH), 7.87 (3H, d, J = 8.0, 2 x Ar-H, NH), 7.69 
(2H, d, J = 7.4, 2 x Ar-H), 7.45 (1H, d, J = 11.5, NH), 7.40 (2H, t, J = 7.4, 2 x Ar-H), 7.31 
(2H, t, J = 7.4, 2 x Ar-H), 5.17 (1H, t, J = 9.9, H1), 5.08 (1H, t, J = 9.9, H3), 4.80 (1H, t, J 
= 9.8, H4), 4.38 (1H, q, J = 8.7, CHα), 4.30 - 4.15 (4H, m, H6a, CH, CH2), 3.93 (1H, dd, J 
= 10.7, 1.6, H6b), 3.86 (1H, q, J = 9.7, H2), 3.80 (1H, dd, J = 9.9, 1.5, H5), 2.64 (1H, dd, 
J = 16.3, 5.4, CHβ), 2.48 (1H, dd, overlapped by DMSO signal CHβ), 1.98 (3H, s, CH3), 
1.95 (3H, s, CH3), 1.89 (3H, s, CH3), 1.70 (3H, s, CH3). 
13C NMR (125 MHz, DMSO-d6) δ 
173.0, 171.5, 170.0, 169.8, 169.5, 169.3, 155.8 (7 x C=O), 143.8, 140.7 (4 x Ar-qC), 
127.6, 127.1, 125.2, 120.1 (8 x Ar-C), 78.1 (C1), 73.4 (C3), 72.3 (C5), 68.4 (C4), 65.7 
(C6), 52.1 (C2), 50.0 (CH), 46.6 (CH), 36.8 (CHβ), 22.6, 20.5, 20.4, 20.3 (4 x CH3). IR 
υmax (cm
-1) neat 3308 (NH), 1743 (C=O), 1693 (C=O), 1659 (C=O). ESI+ MS (m/z) 
calculated for C33H37N3O13 683.23 found [MNa]
+ 706.22. m.p. 209-211 °C (lit. 210 
°C).204 
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General peptide synthesis 
Protected amino acids and resins for Fmoc peptide synthesis were purchased from 
Novabiochem or AGTC Bioproducts as: Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-
Asn(Trt)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Cys(Acm)-OH Fmoc-
Glu(OtBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Gly-OH, Fmoc-His(Trt)-OH, Fmoc-Ile-OH, 
Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Phe-OH, Fmoc-Pro-OH, Fmoc-Ser(OtBu)-
OH, Fmoc-Thr(OtBu)-OH, Fmoc-Trp(Boc)-OH, Fmoc-Tyr(OtBu)-OH, Fmoc-Val-OH 
unless specified otherwise. 
For manual syntheses, steps were performed in sintered 12 mL ISOLUTE SPE syringe 
tubes (Biotage). For a 0.05 mmol scale synthesis, couplings were performed using 
10 equivalents of the amino acid dissolved in DMF (1.1 mL), 10 equivalents of 
HBTU/HOBt (1.1 mL from a 0.45 M stock in DMF) and 17.5 equivalents of DIPEA 
(150 µL) for at least 4 hours with agitation at 430 RPM. Deprotection was carried 
out with 3.0 mL of 20% piperidine in DMF (v/v) for 15 minutes. Washings between 
each step were carried out with DMF (3 x 5.0 mL) and DCM (2 x 5.0 mL). Automated 
peptide synthesis was carried out on an ABI 433A synthesiser (Applied Biosystems) 
using the FastMoc protocol. Resin loading could be determined by quantification of 
the Fmoc-fulvene adduct at 290 nm. Deprotection of a small but accurately 
weighed amount of resin was conducted with 20% piperidine in DMF (3.0 mL, v/v). 
The fulvene adduct was quantified by the equation: 
 
 
Peptides were cleaved from the resin using the Reagent K cocktail 
(TFA/phenol/water/thioanisole/EDT, 82.5:5:5:5:2.5, v/w/v/v/v) for 4-5 hours unless 
specified otherwise. After filtration of the resin, peptides were precipitated in cold 
diethyl ether (60 mL). Crude peptides were obtained by centrifugation at 3000 RPM 
for 15 minutes at 4 °C. The ethereal layer was decanted and the crude peptide was 
resuspended in fresh diethyl ether before being pelleted again by centrifugation. 
Crude peptide pellets were typically resuspended in the minimum volume of water 
with up to 35% acetonitrile before purification by (RP)HPLC. 
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AEN(GlcNAc(OAc)3)ITTGC (EPO 22-28 Cys) 7 
 
Glycopeptide 7 was assembled on Fmoc-Cys(Trt)-NovaSyn TGT resin (0.20 mmol/g 
loading) (500 mg, 0.10 mmol) according to the general peptide synthesis protocols. 
An exception to this was the glycoamino acid 6 coupling, for which only 5 
equivalents were employed. The peptide was cleaved with TFA/EDT/Water 
(95:2.5:2.5, v/v/v, 4.0 mL) for 5 hours, filtered and washed with neat TFA (1.0 mL) 
and the crude peptide was precipitated. The peptide was purified using semi-
preparative (RP)HPLC method 1, (tr 22.3 min). The collections were lyophilised to 
afford 7 as a fluffy white solid (30.2 mg, 53%). ESI+ LC-MS (m/z) calculated for 
C45H72N10O22S 1136.45 found [MH]
+ 1137.25. 
AEN(GlcNAc(OAc)3)ITTG-SCH2CH2SO3H (EPO 22-28 thioester) 8 
 
Glycopeptide 7 (5 mg) was dissolved in sodium phosphate buffer (0.1 M, pH 5.8), 
containing MESNa (10% v/v) and TCEP (0.5% v/v). The samples were agitated at 500 
RPM in 5 x 1.5 mL microcentrifuge tubes in an Eppendorf Thermomixer at 55 °C for 
48 hours. The reaction was monitored by analytical (RP)HPLC at set intervals of 0, 6, 
24 and 48 hours before purification by semi-preparative (RP)HPLC method 1 (tr  20.8 
min) to yield a white solid (1 mg, 20%). ESI+ LC-MS (m/z) calculated for 
C44H71N9O23S2 1157.41 found [MH]
+ 1158.39. 
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EPO22-166 (GlcNAc at residue 24) 10 
 
 
EPO 29-166 9 (2.5 mg) was dissolved in 6 M Gu.HCl containing 0.3 M sodium 
phosphate buffer (pH 5.8, 0.5 mL). To the protein solution was added 20 µL of 1 M 
TCEP (neutralised to pH 7.0 with NaOH) and 50 µL of 1 M MPAA (neutralised to pH 
7.0 with NaOH) to give final concentrations of 40 mM and 100 mM respectively. 
The resulting mixture was added to glycopeptide thioester 8 (2 mg) in a 
microcentrifuge tube and shaken at 500 RPM under N2 at room temperature on an 
Eppendorf Thermomixer. After 3 hours, LC-MS indicated consumption of the 
protein EPO 29-166 and formation of the ligation product. The reaction mixture was 
subsequently diluted by the addition of cold distilled water (8.0 mL) and stored at 4 
°C overnight. A white precipitate formed and was collected by centrifugation at 
3000 RPM for 10 minutes. The process was repeated, resuspending the protein in 
cold distilled water (8.0 mL) allowing precipitation at 4 °C overnight. The crude 
protein was then collected by centrifugation and subsequently treated with 
hydrazine hydrate (5%) and DTT (50 mM) in 6 M Gu.HCl (3.0 mL) at room 
temperature with gentle agitation. After 1 hour, LC-MS indicated complete 
deacetylation of the starting material and the protein 10 was isolated through 
precipitation as before. ESI+ LC-MS (m/z) average mass calculated for 
C720H1164N204O213S3 16182.38 found [MH17]
17+ 952.81. 
Product protein sequence: 
AEN(GlcNAc)ITTGCCAEHCSLNENITVPDTKVNFYAWKRLEVGQQAVEVWQGLALLSEAVLR
GQALLVKSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAIKPPDAASAAPLRTITADTFRKL
FRVYSNFLRGKLKLYTGEACRTGDR 
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Para-methoxybenzyl chloride 12 
 
 
Para-methoxybenzyl alcohol (13.82 g, 0.1 mol) was stirred in dry diethyl ether (150 
mL) at 0 °C. To the stirred solution was added thionyl chloride (15 mL, 0.2 mol) 
dropwise and after complete addition was stirred vigorously at room temperature. 
After 3 hours, TLC indicated completion of the reaction and saturated sodium 
bicarbonate solution was added until the pH reached 8. The mixture was extracted 
with chloroform (3 x 100 mL) and washed with water (100 mL) followed by brine 
(100 mL). The organic phase was dried over magnesium sulfate before 
concentration in vacuo to yield a clear oil (11.24 g, 72%). Rf 0.82 (3:1 petroleum 
spirit/ethyl acetate). 1H NMR (500 MHz, CDCl3) δ 7.34 (2H, d, J = 8.6, Ar-H), 6.91 (2H, 
d, J = 8.6, Ar-H), 4.60 (2H, s, CH2), 3.84 (3H, s, CH3). 
13C NMR (125 MHz, CDCl3) δ 
130.5 (Ar-CH), 114.5 (Ar-CH), 55.7 (CH3), 46.7 (CH2). ESI
+ MS (m/z) calculated for 
C8H9OCl 156.03 found [M-Cl]
+ 121.03. 
Para-methoxybenzyl selenocysteine 13 
 
 
Selenocystine 11 (480 mg, 1.44 mmol) was stirred in 0.5 M NaOH (1.3 mL) in an ice 
bath. Sodium borohydride (450 mg, 11.9 mmol) was added in small portions 
cautiously and the mixture was stirred until the yellow colour had disappeared. 
Further 2 M NaOH (3.9 mL) was added, followed by dropwise addition of para-
methoxybenzyl chloride 12 (1.22 g, 7.82 mmol) and the resulting mixture was 
stirred vigorously at 4 °C for 4 hours. The mixture was acidified with concentrated 
HCl and the precipitated product was collected by filtration. The crude product was 
washed with diethyl ether (25 mL) and water (5.0 mL) before being dried in a 
desiccator overnight to yield a white solid (620 mg, 75%). 1H NMR (600 MHz, 
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DMSO-d6) δ 7.25 (2H, d, J = 8.6 Ar-H), 6.86 (2H, d, J = 8.6, Ar-H), 6.64 (2H, br, NH2), 
3.97 (1H, br, CH), 3.83 - 3.81 (2H, m, CH2), 3.73 (3H, s, CH3), 2.88 (2H, m, CH2). ESI
+ 
MS (m/z) calculated for C11H15NO3Se 288.20 found [MH]
+ 289.16. m.p. 169-172 °C 
(lit. 173-176 °C).268 
N-α-fluorenylmethoxycarbonyl para-methoxybenzyl selenocysteine 14 
 
 
Fmoc succinimide (724 mg, 2.15 mmol) was dissolved in acetonitrile (3.0 mL) and 
added to an ice cooled suspension of para-methoxybenzyl selenocysteine 13 in 
water (4.0 mL) and triethylamine (300 µL, 2.15 mmol). Further triethylamine (300 
µL) was added to maintain a pH above 8 and the mixture was stirred at room 
temperature for 2 hours. The mixture was acidified with 1 M HCl dropwise, and the 
product was extracted with ethyl acetate (50 mL). The organic extract was washed 
with 1 M HCl (2 x 30 mL) and brine (30 mL) before being dried over magnesium 
sulfate. After concentration in vacuo the crude product was triturated with a 
minimum volume of diethyl ether and dried under vacuum to yield an off-white 
solid (827 mg, 75%). Rf 0.2 (19:1 chloroform/methanol).
 1H NMR (500 MHz, CDCl3) δ 
7.90 (2H, d, J = 7.5, Ar-H), 7.82 - 7.69 (3H, m, 2 x Ar-H, NH), 7.42 (2H, t, J = 7.5, Ar-
H), 7.38 - 7.27 (2H, m, Ar-H), 7.22 (2H, d, J = 8.6, Ar-H), 6.84 (2H, d, J = 8.7, Ar-H), 
4.41 - 4.13 (3H, m, CH2, CH), 3.81 (2H, s, CH2), 2.84 (1H, dd, J = 12.7, 4.7, CHβ), 2.74 
(1H, dd, J = 12.6, 9.4, CHβ). ESI
+ MS (m/z) calculated for C26H25NO5Se 511.09 found 
[MNa]+ 534.08. m.p. 135-138 °C (lit. 138-140 °C).268 
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AEN(GlcNAc(OAc)3)ITTGU(Npys)-NH2 (EPO 22-28 Sec) 15a 
 
Glycopeptide 15a was assembled on Rink amide MBHA resin (0.64 mmol/g loading) 
(156 mg, 0.10 mmol) according to the general peptide synthesis protocols. An 
exception to this was the coupling of selenocysteine 14 and the glycoamino acid 6, 
for which only 5 equivalents were employed. A small sample of the resin (40 mg) 
was treated with TFA/thioanisole (97.5:2.5, v/v, 2.0 mL) in the presence of 2,2'-
dithiobis(5-nitropyridine) (20 mg, 65 µmol, 1.3 equivalents) for 5 hours, filtered and 
washed with neat TFA (1.0 mL) and the crude peptide was precipitated. The peptide 
was purified using semi-preparative (RP)HPLC method 1, (tr 29.0 min). The 
collections were lyophilised to afford 15a as a fluffy white solid (1.5 mg, 8%). ESI+ 
LC-MS (m/z) calculated for C50H75N13O23SSe 1337.23 found [MH]
+ 1338.48. 
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C(Acm)WN(GlcNAc)ETIVENLLANVYHC (IFNβ 78-93 Cys) 16 
 
Fmoc-Cys(Trt)-NovaSyn TGT resin (0.19 mmol/g loading) (263 mg, 0.05 mmol scale) 
was elongated to IVENLLANVYHC by automated synthesis. The pseudoproline 
Fmoc-Glu(OtBu)-Thr(psiMe,Mepro)-OH, glycoamino acid 6, tryptophan and cysteine 
(Acm protected) were coupled manually using 5 equivalents. Peptide cleavage was  
conducted with Reagent K (4.0 mL) for 5 hours, and precipitated in ether. The crude 
peptide was freeze dried before being resuspended in aqueous hydrazine (3.0 mL, 
5% v/v) with DTT (50 mM). After stirring at room temperature for an hour, the 
mixture was subjected to semi-preparative (RP)HPLC method 1 (tr 36.3 min), 
yielding the glycopeptide 16 as a white fluffy solid (7 mg, 6%). ESI+ LC-MS (m/z) 
calculated for C100H151N25O33S2 2294.03 found [MH2]
2+ 1148.73. 
C(Acm)WN(GlcNAc)ETIVENLLANVYH-SCH2CH2SO3H (IFNβ 78-93 thioester)  17 
 
Glycopeptide 16 (7 mg) was dissolved in 6 M Gu.HCl (4.0 mL) containing sodium 
phosphate buffer (0.1 M, pH 5.8), MESNa (10% v/v) and TCEP (0.5% v/v). The 
samples were agitated at 600 RPM in 4 x 1.5 mL microcentrifuge tubes in an 
Eppendorf Thermomixer at 55 °C for 48 hours. The reaction was monitored by LC-
MS at set intervals 0, 24 and 48 hours. The product was purified by semi-
preparative (RP)HPLC method 1 (tr  36.4 min) to yield a white solid (<1 mg). ESI
+ LC-
MS (m/z) calculated for C99H150N24O34S3 2314.99 found [MH2]
2+ 1159.16. 
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APPRLICDSRVLERYLLEAKEAEN(GlcNAc)ITTGC (EPO 1-28 Cys) 18 
 
Glycopeptide 18 was assembled manually on Fmoc-Cys(Trt)-NovaSyn TGT resin 
(0.20 mmol/g loading) (250 mg, 0.05 mmol) according to the general peptide 
synthesis protocols. An exception to this was the glycoamino acid 6 coupling, for 
which only 5 equivalents were employed. After the glycoamino acid coupling, the 
remainder of the peptide was completed by automated synthesis. The peptide was 
cleaved with TFA/EDT/Water (95:2.5:2.5, v/v/v, 4.0 mL) for 5 hours, filtered and 
washed with neat TFA (1.0 mL) and the crude peptide was precipitated. The peptide 
was purified using semi-preparative (RP)HPLC method 1, (tr 32.5 min). The 
collections were lyophilised to afford the glycopeptide as a fluffy white solid (17.2 
mg, 10%). Deacetylation was conducted in aqueous hydrazine (5.0 mL, 5% v/v) with 
DTT (50 mM) before purification of 18 by semi-preparative (RP)HPLC method 1, (tr 
31.5 min) yielding 3.4 mg (35%). ESI+ LC-MS (m/z) calculated for C148H247N41O50S2 
3462.75 found [MH4]
4+ 867.04. 
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APPRLICDSRVLERYLLEAKEAEN(GlcNAc)ITT-NHNH2 (EPO 1-28 hydrazide) 19 
 
Glycopeptide 18 (1 mg) was dissolved in 3 M Gu.HCl (1.0 mL) containing sodium 
phosphate buffer (0.1 M, pH 5.8), MESNa (10% v/v), TCEP (0.5% v/v) and 
hydrazinium acetate. Hydrazinium acetate was prepared as a 50% w/v stock in 7 M 
Hydrochloric acid, added to a final concentration of 5%. The reaction mixture was 
agitated at 600 RPM in a 1.5 mL microcentrifuge tube in an Eppendorf Thermomixer 
at 55 °C for 48 hours. The reaction was monitored by LC-MS at set intervals 0, 24 
and 48 hours. The product was purified by semi-preparative (RP)HPLC method 1 (tr  
31.5 min) to yield a white solid (<1 mg). ESI+ LC-MS (m/z) calculated for 
C145H244N42O48S 3373.76 found [MH4]
4+ 844.77. 
C(Acm)WN(GlcNAc)ETIVENLLANVYH-NHNH2 (IFNβ 78-93 hydrazide) 20a 
 
Glycopeptide 16 (2 mg) was dissolved in 6 M Gu.HCl (1.0 mL) containing sodium 
phosphate buffer (0.1 M, pH 5.8), MESNa (10% v/v), TCEP (0.5% v/v) and 
hydrazinium acetate. Hydrazinium acetate was prepared as a 50% w/v stock in 7 M 
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Hydrochloric acid, added to a final concentration of 5%. The reaction mixture was 
agitated at 600 RPM in 4 x 1.5 mL microcentrifuge tubes in an Eppendorf 
Thermomixer at 45 °C for 120 hours. The reaction was monitored by LC-MS at set 
intervals 0, 24, 48, 72 and 120 hours. The product was purified by semi-preparative 
(RP)HPLC method 1 (tr  36.3 min) to yield a white solid (<1 mg). ESI
+ LC-MS (m/z) 
calculated for C97H148N26O31S 2205.05 found [MH3]
3+ 736.04. 
NovaSyn TGT hydrazine resin 23 
 
Novasyn TGT alcohol resin 21 (500 mg, 0.105 mmol) (0.21 mmol/g loading) was 
washed with DMF (2 x 5.0 mL) , DCM (3 x 5.0 mL) and toluene (3 x 5.0 mL) before 
being transferred to a round bottomed flask equipped with a reflux condenser. Dry 
toluene was added until the resin was covered, followed by the addition of acetyl 
chloride (1.0 mL) and the mixture was heated at 70 °C for 3 hours. The resin was 
transferred to a sintered syringe tube and washed with dry toluene (3 x 5.0 mL) and 
dry DCM (3 x 5.0 mL). The chlorinated resin 22 was immediately treated with a 
solution of hydrazine hydrate (20 µL) in dry THF (5.0 mL) and stirred at room 
temperature for 2 hours. The resin was subsequently washed with 
DCM/MeOH/DIPEA (17:2:1, v/v/v, 3 x 5.0 mL), DCM (3 x 5.0 mL), DMF (2 x 5.0 mL) 
and DCM (2 x 5.0 mL). 23 was employed in peptide synthesis without any further 
purification. 
Alternatively, trityl chloride resin (1.4 mmol/g loading) was purchased directly from 
Novabiochem and functionalised as follows: Trityl chloride resin (500 mg, 0.7 mmol) 
was treated with a solution of hydrazine hydrate (140 µL, 2.8 mmol) in dry THF (5.0 
mL) and stirred at room temperature. The resin was purified according to the same 
procedure used in the previously described method for 23. 
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Hydrazine carboxylate Wang resin 26 
 
Wang resin 24 (1.0 g, 1.3 mmol) (1.3 mmol/g loading)  and N-methyl morpholine 
(467 µL, 4.25 mmol) were stirred at 0 °C in dry DCM (25 mL). 4-nitrophenyl 
chloroformate (840 mg, 3.9 mmol) was added, and the reaction mixture was 
allowed to warm to room temperature before being stirred overnight. The 
following day, the resin was collected by filtration and washed with DCM (2 x 5.0 
mL), DMF (3 x 5.0 mL), MeOH, (3 x 5.0 mL) and DCM (3 x 5.0 mL). The resin 25 was 
allowed to dry in a vacuum desiccator overnight. Assuming quantitative conversion, 
25 (1.3 mmol) was treated with hydrazine hydrate (442 µL, 8.9 mmol) in dry 
DCM/DMF (2:3, v/v, 50 mL) at 0 °C. The reaction was warmed to room temperature 
and stirred overnight under nitrogen. The resin was collected by filtration and 
washed with DCM (2 x 5.0 mL), DMF (3 x 5.0 mL), MeOH, (3 x 5.0 mL) and DCM (3 x 
5.0 mL) before being dried in a vacuum desiccator. 26 was employed in peptide 
synthesis without any further purification. 
CWN(GlcNAc)ETIVENLLANVYH-NHNH2 (IFNβ 78-93 hydrazide) 20b 
 
Glycopeptide 20b was manually synthesised on hydrazine resin 26 according to the 
general peptide synthesis protocols. An exception to this was the glycoamino acid 6 
coupling, for which only 5 equivalents were employed. After cleavage with Reagent 
K (4.0 mL), the product was purified by preparative (RP)HPLC (tr  36.4 min) yielding a 
fluffy white solid (6 mg, 6%). ESI+ LC-MS (m/z) calculated for C94H143N25O30S 2134.02 
found [MH2]
2+ 1068.77.  
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8.3 Chapter 3 experimental details 
Cloning of IFNβ 1-77 intein-CBD fusion 
Primers were designed to allow the cloning of the IFNβ 1-77 gene into vector pTYB1 
between the NdeI/SapI or KpnI restriction sites. 
Forward primer: 
GGTGGTCATATGAGCTACAACTTG 
Reverse primer (SapI cloning): 
GGTGGTTGCTCTTCCGCAGCCGCTAGATGAATCTTG 
Reverse primer (KpnI cloning): 
GGTGGTGGTACCCTTGGCAAAGCAGCCGCTAGATGAATCTTG 
 
The PCR mix was made up as follows: 
Forward primer (10 µM stock) 5 µL  
Reverse primer (10 µM stock) 5 µL  
10 x ThermoPol reaction buffer 5 µL 
dNTP mix (10 mM stock) 5 µL  
Template DNA (IFN 1-166 pKYB1) 1 µL  
Deep Vent Polymerase (New England Biolabs) 1 µL 
Distilled sterile water 28 µL  
PCR was conducted with the following cycling conditions: 
Step Temp Time 
Initial denaturation 95 °C 2 minutes 
30 cycles 95 °C 
54 °C 
72 °C 
30 seconds 
30 seconds 
1 minute 
Final extension 72 °C 5 minutes 
Hold 4 °C   
  
DNA ligation for IFNβ 1-77 intein-CBD fusion 
The vector and PCR product were treated with NdeI/SapI or KpnI to generate sticky 
ends. DNA ligation was performed using a Rapid DNA Ligation Kit (Roche) according 
to the manufacturer’s instructions. 
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Expression and purification of IFNβ 1-77 intein-CBD fusion 27 
The relevant plasmid was transformed into BL21(DE3) cells and a colony was used 
to seed LB medium (200 mL) containing ampicillin (100 µg/ml) and grown  at 37 °C 
overnight. The following day, the overnight culture was used to seed fresh LB 
medium (4 x 500 mL) containing ampicillin (100 µg/ml) and grown to an optical 
density (OD600) of ~ 0.6. At this point, protein expression was induced by the 
addition of IPTG at a final concentration of 1 mM. Expression was carried out at 30 
°C for 5 hours. Cells were harvested by centrifugation at 8000 RPM for 15 minutes 
at 4 °C (Beckman Coulter Avanti J-26XP). The combined cell pellets were 
resuspended in binding buffer (500 mM NaCl, 20 mM Tris pH 8.0, 0.005% PMSF 
w/v, 50 mL) and sonicated on ice for 10 bursts of 30 seconds, with 30 seconds of 
cooling time in between. Cell debris was pelleted at 10000 RPM for 15 minutes at 4 
°C and the supernatant was loaded onto chitin resin (2 x 10 mL) which had been 
pre-equilibrated with 10 volumes of binding buffer). The columns were 
subsequently washed with a further 10 volumes of binding buffer, before being 
washed with 3 volumes of binding buffer containing 50 mM MESNa. Column flow 
was stopped and the cleavage was allowed to proceed over 24 hours at 4 °C. After 
unsuccessful attempts to isolate the product, refolding of the insoluble fusion was 
attempted according to New England Biolabs IMPACT manual (described in section 
3.2.2). 
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Cloning of IFNβ 1-77 thioredoxin intein-CBD fusion 
Primers were designed to allow the cloning of the IFNβ 1-77 intein fusion gene into 
vector pET32XaLIC for ligation independent cloning. 
Forward primer: 
GGTATTGAGGGTCGCATGAGCTACAACTTGCTTGGATTCC 
Reverse primer: 
AGAGGAGAGTTAGAGCCTTATTGAAGCTGCCACAA 
The PCR mix was made up as follows: 
Forward primer (10 µM stock) 5 µL  
Reverse primer (10 µM stock) 5 µL  
10 x ThermoPol reaction buffer 5 µL 
dNTP mix (10 mM stock) 5 µL  
Template DNA (IFN 1-77 pTYB1) 1 µL  
Deep Vent Polymerase (New England Biolabs) 1 µL 
Distilled sterile water 28 µL  
PCR was conducted with the following cycling conditions: 
Step Temp Time 
Initial denaturation 95 °C 2 minutes 
30 cycles 95 °C 
64 °C 
72 °C 
30 seconds 
30 seconds 
2.5 minutes 
Final extension 72 °C 10 minutes 
Hold 4 °C   
 
Ligation independent cloning for IFNβ 1-77 thioredoxin intein fusion 
Ligation independent cloning was carried out according to the manufacturer’s 
instructions (Novagen). 
Expression of IFNβ 1-77 thioredoxin intein-CBD fusion 28 
The protein was expressed in BL21(DE3) cells as before for 27 (2 x 500 mL) at 30 °C 
for 5 hours. After collection of the cells by centrifugation, the whole cell lysate and 
soluble fraction were treated with Bug Buster protein extraction reagent (Novagen) 
and analysed by SDS-PAGE. 
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Cloning of His10 tagged IFNβ 1-77 with C-terminal Gly-Cys 
Primers were designed to allow the cloning of the IFNβ 1-77 terminated with a Gly-
Cys motif into vector pET16b for expression with an N-terminal polyhistidine tag. 
Forward primer: 
GGTGGTCATATGAGCTACAACTTG 
Reverse primer: 
GGTGGTGGATCCTTAACAGCCGCTAGATGAATCTTG 
The PCR mix was made up as follows: 
Forward primer (10 µM stock) 5 µL  
Reverse primer (10 µM stock) 5 µL  
10 x ThermoPol reaction buffer 5 µL 
dNTP mix (10 mM stock) 5 µL  
Template DNA (IFN 1-166 pKYB1) 1 µL  
Deep Vent Polymerase (New England Biolabs) 1 µL 
Distilled sterile water 28 µL  
PCR was conducted with the following cycling conditions: 
Step Temp Time 
Initial denaturation 95 °C 2 minutes 
30 cycles 95 °C 
54 °C 
72 °C 
30 seconds 
30 seconds 
1 minute 
Final extension 72 °C 5 minutes 
Hold 4 °C   
 
DNA ligation for His10 tagged IFNβ 1-77 with C-terminal Gly-Cys 
The vector and PCR product were treated with NdeI/BamHI to generate sticky ends. 
DNA ligation was performed using a Rapid DNA Ligation Kit (Roche) according to the 
manufacturer’s instructions. 
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Expression and purification of His10 tagged IFNβ 1-77 with C-terminal Gly-Cys 29 
The relevant plasmid was transformed into BL21(DE3) cells and a colony was used 
to seed LB medium (200 mL) containing ampicillin (100 µg/ml) and grown  at 37 °C 
overnight. The following day, the overnight culture was used to seed fresh LB 
medium (8 x 500 mL) containing ampicillin (100 µg/ml) and grown to an optical 
density (OD600) of ~ 0.6. At this point, protein expression was induced by the 
addition of IPTG at a final concentration of 1 mM. Expression was carried out at 37 
°C for 3 hours. Cells were harvested by centrifugation at 8000 RPM for 10 minutes 
at 4 °C. The combined cell pellets were resuspended in binding buffer (5 mM 
imidazole, 500 mM NaCl, 20 mM Tris pH 8.0, 0.005% PMSF w/v, 100 mL) and 
sonicated on ice for 10 bursts of 30 seconds, with 45 seconds of cooling time in 
between. Inclusion bodies and cell debris was collected at 10000 RPM for 15 
minutes at 4 °C and the supernatant was saved for analysis. The cell pellets were 
resuspended in denaturing binding buffer (6 M Gu.HCl, 5 mM imidazole, 500 mM 
NaCl, 20 mM Tris pH 8.0, 100 mL) and stirred vigorously at 4 °C for 45 minutes. The 
remaining insoluble material was pelleted at 16000 RPM for 15 minutes at 4 °C. The 
supernatant was stored at -20 °C prior to affinity chromatography. 
Ni-NTA Agarose resin (3.0 mL, Qiagen) was charged with NiSO4 (0.1 M, 15 mL) and 
pre-equilibrated with denaturing binding buffer (30 mL). The cell extract was loaded 
onto the column and unbound proteins were eluted with denaturing wash buffer (6 
M Gu.HCl, 25 mM imidazole, 500 mM NaCl, 20 mM Tris pH 8.0, 30 mL). The target 
protein was eluted with denaturing elution buffer (6 M Gu.HCl, 500 mM imidazole, 
500 mM NaCl, 20 mM Tris pH 8.0, 30 mL), which was subsequently concentrated in 
an Amicon Ultra molecular weight cut off device (3 kDa, Millipore). This method of 
concentration also facilitated buffer-exchange into 6 M Gu.HCl to remove other 
components present in the elution buffer. ESI+ LC-MS (m/z) calculated for 
C514H773N157O146S6 11680.12 found [MH11]
11+ 1062.88. 
Product protein sequence: 
GHHHHHHHHHHSSGHIEGRHMSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIP
EEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSGC 
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His10 tagged IFNβ 1-77 Hydrazide 30 
 
The His10 tagged protein 29 (~ 2 mg) was dissolved in 6 M Gu.HCl (3.0 mL) 
containing MESNa (10% v/v), TCEP (0.5% v/v) and hydrazinium acetate. 
Hydrazinium acetate was prepared as a 50% w/v stock in 7 M Hydrochloric acid, 
added to a final concentration of 5%. The reaction mixture was agitated at 600 RPM 
in 2 x 1.5 mL microcentrifuge tubes in an Eppendorf Thermomixer at 45 °C for 72 
hours. The reaction was monitored by LC-MS at set intervals 0, 24, 48 and 72 hours 
and formation of 30 was observed. ESI+ LC-MS (m/z) calculated for 
C511H770N158O144S5 11590.93 found [MH9]
9+ 1289.19. 
Product protein sequence: 
GHHHHHHHHHHSSGHIEGRHMSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIP
EEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSG-NHNH2 
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Mutagenesis of His10 tagged IFNβ 1-77 with C-terminal Gly-Cys (M36L, M62L) 
Primers were designed to introduce the mutations M36L and M62L to facilitate 
selective cleavage during treatment of the protein with CNBr. 
M36L Forward primer: 
TGCCTCAAGGACAGGCTGAACTTTGACATCCCT 
M36L Reverse primer: 
AGGGATGTCAAAGTTCAGCCTGTCCTTGAGGCA 
The PCR mix was made up as follows: 
Forward primer (10 µM stock) 5 µL  
Reverse primer (10 µM stock) 5 µL  
10 x ThermoPol reaction buffer 5 µL 
dNTP mix (10 mM stock) 5 µL  
Template DNA (IFN 1-77 pET16b) 1 µL  
Deep Vent Polymerase (New England Biolabs) 1 µL 
Distilled sterile water 27 µL  
MgSO4 (100 mM) 1 µL 
PCR was conducted with the following cycling conditions: 
Step Temp Time 
Initial denaturation 95 °C 1.5 minutes 
20 cycles 95 °C 
54 °C 
72 °C 
30 seconds 
30 seconds 
8 minutes 
Final extension 72 °C 10 minutes 
Hold 4 °C   
 
M62L Forward primer: 
TTGACCATCTATGAGCTGCTCCAGAACATCTTT 
M62L Reverse primer: 
AAAGATGTTCTGGAGCAGCTCATAGATGGTCAA 
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The PCR mix was made up as follows: 
Forward primer (10 µM stock) 5 µL  
Reverse primer (10 µM stock) 5 µL  
10 x ThermoPol reaction buffer 5 µL 
dNTP mix (10 mM stock) 5 µL  
Template DNA (IFN 1-77 pET16b M36L) 2 µL  
Deep Vent Polymerase (New England Biolabs) 1 µL 
Distilled sterile water 26 µL  
MgSO4 (100 mM) 1 µL 
PCR was conducted as above. 
Expression and purification of His10 tagged IFNβ 1-77 (M36L, M62L) with C-
terminal Gly-Cys 31 
Protein was expressed and purified as before for 29. ESI+ LC-MS (m/z) calculated for 
C516H777N157O146S4 11643.91 found [MH12]
12+ 971.51. 
Product protein sequence: 
GHHHHHHHHHHSSGHIEGRHMSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRLNFDIPE
EIKQLQQFQKEDAALTIYELLQNIFAIFRQDSSSGC 
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His10 tagged IFNβ 1-77 (M36L, M62L) hydrazide 32 
 
The His10 tagged protein 31 (~ 4 mg) was dissolved in 6 M Gu.HCl (3.0 mL) 
containing MESNa (10% v/v), TCEP (0.5% v/v) and hydrazinium acetate. 
Hydrazinium acetate was prepared as a 50% w/v stock in 7 M Hydrochloric acid, 
added to a final concentration of 5%. The reaction mixture was agitated at 750 RPM 
in 2 x 1.5 mL microcentrifuge tubes in an Eppendorf Thermomixer at 45 °C for 48 
hours. After 48 hours, LC-MS showed partial conversion to the product 32. The 
reaction mixture was diluted with 6 M Gu.HCl (10 mL) and transferred to an Amicon 
Ultra molecular weight cut off device (3 kDa, Millipore). The sample was rigorously 
buffer-exchanged by concentrating to ~ 1 mL and subsequently re-diluting with 6 m 
Gu.HCl (12 mL). This process was repeated 3 times and finally diluted into 6 M 
Gu.HCl (3.0 mL) containing MESNa (10% v/v), TCEP (0.5% v/v) and hydrazinium 
acetate (5% w/v) The reaction was continued for a further 48 hours at 45 °C.  ESI+ 
LC-MS (m/z) calculated for C513H774N158O144S3 11554.80 found [MH12]
12+ 963.88. 
Product protein sequence: 
GHHHHHHHHHHSSGHIEGRHMSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRLNFDIPE
EIKQLQQFQKEDAALTIYELLQNIFAIFRQDSSSGC-NHNH2 
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Cloning of His10 tagged IFNβ 94-166 preceded by Factor Xa recognition site 
Primers were designed to allow the cloning of the IFNβ 94-166 preceded by a Factor 
Xa recognition site allowing the liberation of an N-terminal cysteine on treatment 
with the protease. The gene was cloned into vector pET16b for expression with an 
N-terminal polyhistidine tag. 
Forward primer: 
GGTGGTCATATGATCGAAGGTCGTTGTATAAACCATCTGAAG 
Reverse primer: 
GGTGGTGGATCCTTAGTTTCGGAGGTAACC 
The PCR mix was made up as follows: 
Forward primer (10 µM stock) 5 µL  
Reverse primer (10 µM stock) 5 µL  
10 x ThermoPol reaction buffer 5 µL 
dNTP mix (10 mM stock) 5 µL  
Template DNA (IFN 1-166 pKYB1) 1 µL  
Deep Vent Polymerase (New England Biolabs) 1 µL 
Distilled sterile water 28 µL  
PCR was conducted with the following cycling conditions: 
Step Temp Time 
Initial denaturation 95 °C 2 minutes 
30 cycles 95 °C 
54 °C 
72 °C 
30 seconds 
30 seconds 
1 minute 
Final extension 72 °C 5 minutes 
Hold 4 °C   
 
DNA ligation for His10 tagged IFNβ 94-166 
The vector and PCR product were treated with NdeI/BamHI to generate sticky ends. 
DNA ligation was performed using a Rapid DNA Ligation Kit (Roche) according to the 
manufacturer’s instructions. 
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Expression and purification of His10 tagged IFNβ 94-166 preceded by Factor Xa 
recognition site 
His10 tagged IFNβ 94-166 was expressed and purified as before for 29. ESI
+ LC-MS 
(m/z) calculated for C534H819N169O136S4 11910.53 found [MH16]
16+ 745.35. 
Product protein sequence: 
GHHHHHHHHHHSSGHIEGRHMIEGRCINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHY
LKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN 
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Cloning of IFNβ 94-166 thioredoxin fusion 
Primers were designed to allow the cloning of the IFNβ 94-166 gene into vector 
pET32XaLIC for ligation independent cloning. 
Forward primer: 
GGTATTGAGGGTCGCTGTATAAACCATCTGAAGACAGTCC 
Reverse primer: 
AGAGGAGAGTTAGAGCCTTAGTTTCGGAGGTAACCTG 
The PCR mix was made up as follows: 
Forward primer (10 µM stock) 5 µL  
Reverse primer (10 µM stock) 5 µL  
10 x ThermoPol reaction buffer 5 µL 
dNTP mix (10 mM stock) 5 µL  
Template DNA (IFN 94-166 pET16b) 1 µL  
Deep Vent Polymerase (New England Biolabs) 1 µL 
Distilled sterile water 28 µL  
PCR was conducted with the following cycling conditions: 
Step Temp Time 
Initial denaturation 95 °C 2 minutes 
30 cycles 95 °C 
64 °C 
72 °C 
30 seconds 
30 seconds 
2.5 minutes 
Final extension 72 °C 10 minutes 
Hold 4 °C   
 
Ligation independent cloning for IFNβ 94-166 thioredoxin fusion 
Ligation independent cloning was carried out according to the manufacturer’s 
instructions (Novagen). 
Expression of IFNβ 94-166 thioredoxin intein 33 
The protein was expressed in BL21(DE3) cells as before for 27 (2 x 500 mL) at 30 °C 
for 5 hours. After collection of the cells by centrifugation, the whole cell lysate and 
soluble fraction were treated with Bug Buster protein extraction reagent (Novagen) 
and analysed by SDS-PAGE. 
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Mutagenesis of His10 tagged IFNβ 94-166 (M117L and cleavage site) 
Primers were designed to introduce the mutations M117L and methionine before 
the desired N-terminal cysteine for selective CNBr cleavage. 
M117L Forward primer: 
ACCAGGGGAAAACTCCTGAGCAGTCTGCACCTG 
M117L Reverse primer: 
CAGGTGCAGACTGCTCAGGAGTTTTCCCCTGGT 
The PCR mix was made up as follows: 
Forward primer (10 µM stock) 2.5 µL  
Reverse primer (10 µM stock) 2.5 µL  
10 x ThermoPol reaction buffer 5 µL 
dNTP mix (10 mM stock) 5 µL  
Template DNA (IFN 94-166 pET16b) 0.5 µL  
Deep Vent Polymerase (New England Biolabs) 0.5 µL 
Distilled sterile water 32.5 µL  
MgSO4 (100 mM) 0.5 µL 
PCR was conducted with the following cycling conditions: 
Step Temp Time 
Initial denaturation 95 °C 1.5 minutes 
20 cycles 95 °C 
54 °C 
72 °C 
30 seconds 
30 seconds 
7 minutes 
Final extension 72 °C 10 minutes 
Hold 4 °C   
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Cleavage site (MIEGRC→LIEGMC) Forward primer: 
GAAGGTCGTCATCTGATCGAAGGTATGTGTATAAACCAT 
Cleavage site (MIEGRC→LIEGMC) Reverse primer: 
ATGGTTTATACACATACCTTCGATCAGATGACGACCTTC 
 
The PCR mix was made up as follows: 
Forward primer (10 µM stock) 5 µL  
Reverse primer (10 µM stock) 5 µL  
10 x ThermoPol reaction buffer 5 µL 
dNTP mix (10 mM stock) 5 µL  
Template DNA (IFN 94-166 pET16b M117L) 1 µL  
Deep Vent Polymerase (New England Biolabs) 1 µL 
Distilled sterile water 25.75 µL  
MgSO4 (100 mM) 1 µL 
DMSO 1.25 µL 
PCR was conducted with the following cycling conditions: 
Step Temp Time 
Initial denaturation 95 °C 1.5 minutes 
20 cycles 95 °C 
54 °C 
72 °C 
30 seconds 
30 seconds 
8 minutes 
Final extension 72 °C 10 minutes 
Hold 4 °C   
 
Expression and purification of His10 tagged IFNβ 94-166 CNBr mutant 34 
Protein was expressed and purified as before for 29. ESI+ LC-MS (m/z) calculated for 
C535H820N166O136S3 11849.46 found [MH13]
13+ 912.34. 
Product protein sequence: 
GHHHHHHHHHHSSGHIEGRHLIEGMCINHLKTVLEEKLEKEDFTRGKLLSSLHLKRYYGRILHYL
KAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN 
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IFNβ 94-166 (M117L) 35 
 
The His10 tagged protein 34 (7 mg) was dissolved in 6 M Gu.HCl (1.0 mL) containing 
0.1 M HCl. CNBr was added (~ 5 mg) and the mixture was stirred overnight with the 
exclusion of light. The following day, the sample was treated with DTT (5.0 mg) and 
checked by LC-MS which indicated successful cleavage. The reaction mixture was 
diluted to 5.0 mL in denaturing binding buffer (6 M Gu.HCl, 5 mM imidazole, 500 
mM NaCl, 20 mM Tris pH 8.0) containing 2-mercaptoethanol (5 mM). The mixture 
was adjusted to pH 8.0 with NaOH and applied to Ni-NTA resin (1.0 mL) pre-
equilibrated with denaturing binding buffer (10 mL). The flow-through was 
collected and the resin was washed with further denaturing binding buffer (2 x 2.5 
mL). The washes were combined with the flow-through and concentrated in an 
Amicon Ultra molecular weight cut off device (3 kDa, Millipore) to a final volume of 
1.0 mL. The concentrated protein mixture was diluted with distilled water to a final 
volume of 15 mL and left to precipitate overnight at 4 °C. Precipitated protein was 
collected by centrifugation, resuspended in water/acetonitrile (3:1) and lyophilised 
to yield ~ 6 mg. ESI+ LC-MS (m/z) calculated for C410H646N114O105S2 8916.35 found 
[MH9]
9+ 991.60. 
Product protein sequence: 
CINHLKTVLEEKLEKEDFTRGKLLSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLT
GYLRN 
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8.4 Chapter 4 experimental details 
His10 tagged IFNβ 1-93 (GlcNAc) hydrazide 36 
 
The N-terminal fragment 32 (6 mg) was dissolved in diazotisation buffer (6 M 
Gu.HCl, 0.2 M sodium phosphate pH 3.5, 600 µL) and stirred at -10 °C. NaNO2 (0.2 
M, 60 µL) was added dropwise, and the mixture was stirred at -10 °C for 20 
minutes. Ligation buffer (6 M Gu.HCl, 0.2 M sodium phosphate pH 7.0, 600 µL) 
containing 0.2 M MPAA was added and the pH of the final reaction mixture was 
adjusted to 7.0. IFNβ glycopeptide 20b (3 mg) was added to the stirred mixture 
which was allowed to warm to room temperature. The mixture was transferred to a 
1.5 mL microcentrifuge tube and shaken at 25 °C, 800 RPM. After 2 hours the 
sample was treated with neutralised TCEP solution (200 mM, 120 µL) and the 
reaction was allowed to proceed overnight. 
Product protein sequence: 
GHHHHHHHHHHSSGHIEGRHMSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRLNFDIPE
EIKQLQQFQKEDAALTIYELLQNIFAIFRQDSSSGCWN(GlcNAc)ETIVENLLANVYH-NHNH2 
 
 
 
 
 
 
Semi-synthesis of glycoproteins                                                      Bhavesh Premdjee 
 
169 
 
His10 tagged IFNβ 78-166 (GlcNAc) Acm 37a 
 
Glycopeptide 20a (4 mg) was dissolved in diazotisation buffer (6 M Gu.HCl, 0.2 M 
sodium phosphate pH 3.0, 400 µL) and stirred at -10 °C. NaNO2 (0.2 M, 40 µL) was 
added dropwise, and the mixture was stirred at -10 °C for 15 minutes. To this 
mixture was added the C-terminal fragment 35 dissolved in ligation buffer (6 M 
Gu.HCl, 0.2 M sodium phosphate pH 7.0, 600 µL) containing 0.2 M MPAA and the 
pH of the final reaction mixture was adjusted to 7.0. The reaction was allowed to 
warm to room temperature and after 2.5 hours, TCEP was added from a neutral 
stock (1 M, 50 µL). After a further 30 minutes, LC-MS analysis revealed the 
complete consumption of 35 and the presence of 37a. The product was purified by 
semi-preparative (RP)HPLC method 2 (tr  27.5 min) to yield a white solid (<1 mg). 
ESI+ LC-MS (m/z) calculated for C507H790N138O136S3 11090.74 found [MH10]
10+ 
1110.15. 
Product protein sequence: 
C(Acm)WN(GlcNAc)ETIVENLLANVYHCINHLKTVLEEKLEKEDFTRGKLLSSLHLKRYYGRILHY
LKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN 
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8.5 Chapter 5 experimental details 
Mutagenesis of Endo A (E173Q) 
Primers were designed to introduce the mutation E173Q. 
E173Q Forward primer: 
TGGTTTATTAACCAACAAACAGAAGGGGCAGAC 
E173Q Reverse primer: 
GTCTGCCCCTTCTGTTTGTTGGTTAATAAACCA 
The PCR mix was made up as follows: 
Forward primer (10 µM stock) 2.5 µL  
Reverse primer (10 µM stock) 2.5 µL  
10 x ThermoPol reaction buffer 5 µL 
dNTP mix (10 mM stock) 5 µL  
Template DNA (Endo A pGEX2T) 1 µL  
Deep Vent Polymerase (New England Biolabs) 1 µL 
Distilled sterile water 33 µL  
 
PCR was conducted with the following cycling conditions: 
Step Temp Time 
Initial denaturation 95 °C 1.5 minutes 
30 cycles 95 °C 
60 °C 
72 °C 
30 seconds 
30 seconds 
15 minutes 
Final extension 72 °C 10 minutes 
Hold 4 °C   
 
Expression of Endo A variants 39a and 39b 
The relevant plasmid was transformed into BL21(DE3) cells and a colony was used 
to seed LB medium (10 mL) containing ampicillin (100 µg/ml) and grown  at 37 °C 
overnight. The following day, the overnight culture was used to seed fresh LB 
medium (500 mL) containing ampicillin (100 µg/ml) and grown to an optical density 
(OD600) of ~ 0.6. At this point, protein expression was induced by the addition of 
IPTG at a final concentration of 1 mM. Expression was carried out at 25 °C for 16 
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hours. Cells were harvested by centrifugation at 8000 RPM for 15 minutes at 4 °C 
(Beckman Coulter Avanti J-26XP). The combined cell pellets were resuspended in 
binding buffer (PBS, 1 mM EDTA, 1 mM DTT, 20 mL) and sonicated on ice for 5 
bursts of 30 seconds, with 30 seconds of cooling time in between. Cell debris was 
pelleted at 10000 RPM for 15 minutes at 4 °C and the supernatant was loaded onto 
a glutathione Superflow resin (3.0 mL, Qiagen) which had been pre-equilibrated 
with 10 volumes of binding buffer). The columns were subsequently washed with a 
further 10 volumes of binding buffer, before the proteins were eluted with elution 
buffer (50 mM Tris pH 8.0, 100 mM NaCl, 50 mM reduced glutathione, and 1 mM 
DTT). The eluted proteins were subsequently concentrated in an Amicon Ultra 
molecular weight cut off device (10 kDa, Millipore) to the required concentration. 
Preparation of Endo A variants without GST tag 40a and 40b 
The GST tagged proteins 39a and 39b were dialysed into protease cleavage buffer 
(20 mM Tris pH 8.0, 100 mM NaCl, 2 mM CaCl2) and concentrated to 1.0 mL. 
Thrombin (20 U, Calbiochem) was added to the mixture, which was incubated at 20 
°C for 24 hours. After analysis by SDS-PAGE, further Thrombin (50 U) was added and 
the cleavage was allowed to proceed for a further 24 hours. The cleavage mixture 
was diluted to 5 mL in column buffer (100 mM NaCl, 20 mM Tris pH 7.2) and passed 
through glutathione Superflow resin (3.0 mL, Qiagen) which had been pre-
equilibrated with 10 volumes of column buffer. The flow-through was collected and 
reapplied to the column for a total of five times. Finally, the resin was washed with 
further column buffer (2.5 mL) and the combined flow-through was rigorously 
buffer-exchanged in an Amicon Ultra molecular weight cut off device (10 kDa, 
Millipore) into potassium phosphate buffer (50 mM, pH 6.4). 
Endo A activity assays with RNAse B 
A mixture of RNAse B 41 (300 µM, 2 µL), denaturing buffer (5% SDS, 400 mM DTT, 1 
µL) and distilled water (4 µL) was boiled at 99 °C for 10 minutes. This was followed 
by the addition of 10 x Protease Inhibitor cocktail (1 µL, Roche), sodium phosphate 
(500 mM, pH 7.5, 1 µL), NP-40 (10% w/v, 1 µL) and Endo A or dH2O for control (1 
µL). The mixture was incubated at 37 °C for an hour before analysis by SDS-PAGE. 
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HAEGTFTSDVSSYLEG-NHNH2 (GLP-1 7-22 hydrazide) 43 
 
Hydrazine carboxylate Wang resin 26 (285 mg, 0.2 mmol) was treated with a 
mixture of Fmoc-Gly-OH (100 mg, 0.33 mmol) and Boc-Ala-OH (126 mg, 0.67 mmol) 
in DMF (2.2 mL), 0.45 HBTU/HOBt (2.2 mL) and DIPEA (300 µL). Fmoc analysis 
indicated a loading of approximately 0.35 mmol/g and a scale of 0.1 mmol. The 
remainder of the peptide was manually synthesised according to standard 
protocols before being cleaved with Reagent K (6.0 mL) for 5 hours and purified by 
preparative (RP)HPLC (tr  29.7 min)  yielding 39 mg of the desired peptide 43 (23%). 
ESI+ (m/z) calculated for C73H108N20O28 1712.76 found [MH2]
2+ 857.86. 
CAAKEFIAWLVN(GlcNAc)GR-NH2 (GLP-1 23-36) 44 
 
Glycopeptide 44 was manually assembled on Rink amide MBHA resin using the 
standard protocols. An exception to this was the glycoamino acid 6 coupling, for 
which only 3 equivalents were employed using HATU (3 equivalents) and DIPEA (6 
equivalents). The peptide was cleaved with Reagent K (10 mL) for 4 hours, and 
precipitated in ether. The crude peptide was treated with aqueous hydrazine 
hydrate (5%, 15 mL) containing DTT (50 mM). The glycopeptide was purified by 
preparative (RP)HPLC (tr  36.5 min)  yielding 39 mg of the desired peptide 44 (22%). 
ESI+ (m/z) calculated for C80H126N22O22S 1778.91 found [MH]
+ 1779.68. 
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HAEGTFTSDVSSYLEGCAAKEFIAWLVN(GlcNAc)GR-NH2 (GLP-1 7-36) 45 
 
The GLP-1 peptide hydrazide 43 (19 mg) was dissolved in diazotisation buffer (6 M 
Gu.HCl, 0.2 M sodium phosphate pH 3.0, 2.5 mL) and stirred at -10 °C. NaNO2 (0.2 
M, 250 µL) was added dropwise, and the mixture was stirred at -10 °C for 20 
minutes. Ligation buffer (6 M Gu.HCl, 0.2 M sodium phosphate pH 7.0, 2.5 mL) 
containing 0.2 M MPAA and glycopeptide 44 (29 mg) was added and the pH of the 
final reaction mixture was adjusted to 7.0. The reaction was allowed to warm to 
room temperature and stirred for 3 hours after which the sample was treated with 
neutralised TCEP solution (1 M, 250 µL) and checked by LC-MS. Analysis revealed 
the formation of the product 45 with no trace of the hydrazide 43 and hence the  
mixture was purified by preparative (RP)HPLC (tr  40.7 min). The product co-eluted 
with MPAA yielding a white solid (~ 60 mg). ESI+ LC-MS (m/z) calculated for 
C153H230N40O50S 3459.64 found [MH4]
4+ 866.27. 
HAEGTFTSDVSSYLEGC(capped)AAKEFIAWLVN(GlcNAc)GR-NH2 (GLP-1 7-36) 46 
 
The glycopeptide 45 (~ 60 mg mixture with MPAA) was stirred in NH4HCO3 (50 mM, 
30 mL) and treated with TCEP (1 M, 30 µL). The mixture was stirred under nitrogen 
and after 5 minutes, a solution of freshly prepared iodoacetamide (100 mM, 3.0 
mL) was added. The mixture was stirred at room temperature, after which LC-MS 
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analysis suggested complete conversion to the product 46. The product was 
purified by preparative (RP)HPLC (tr  40.7 min) to yield 12 mg of the capped 
glycopeptide. ESI+ LC-MS (m/z) calculated for C155H233N41O51S 3516.66 found 
[MH4]
4+ 880.62. 
Transfer assays with GLP-1 7-36 and Endo A variants 
 
GLP-1 7-36 46 (700 µg) and Man3GlcNAc oxazoline (1.5 mg, 10 equivalents) were 
dissolved in potassium phosphate buffer (50 mM, pH 6.4, 375 µL). PMSF (100 mM 
in isopropanol) was added to a final concentration of 1 mM and Endo A 39a or 39b 
was added from a 100 µM stock to a final concentration of 1 µM. The reaction was 
incubated at 23 °C and monitored by analytical (RP)HPLC at various time points. In 
the case of the wild type Endo A 39a, product formation was confirmed by LC-MS 
and the GLP-1 pentasaccharide 47 was purified by preparative (RP)HPLC using a 
Phenomenex Jupiter 4 µm Proteo 90 Å, LC Column (diameter = 250 mm × 21.2 mm): 
flow rate 7.0 mL/min, detection at 230, 254 and 280 nm using a gradient of 95% 
water (0.1% TFA)/5% acetonitrile (0.1% TFA), to 40% water (0.1% TFA)/60% 
acetonitrile (0.1% TFA), over 45 min (tr  42.8 min). ESI
+ LC-MS (m/z) calculated for 
C181H276N42O71S 4205.90 found [MH4]
4+ 1053.08. 
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C(Acm)WN(Man3GlcNAc2)ETIVENLLANVYH-NHNH2 (IFNβ 78-93 pentasaccharide 
hydrazide) Acm 48 
 
IFNβ glycopeptide 20a (1 mg) was suspended in potassium phosphate buffer (50 
mM, pH 6.5, 600 µL) and Endo A 39a was added from a 100 µM stock to a final 
concentration of 1 µM, followed by Man3GlcNAc oxazoline (1 mg, 3 equivalents). 
The mixture was agitated at room temperature at 500 RPM and after 15 minutes 
was analysed by LC-MS. After confirmation that the desired glycopeptide 48 had 
been formed, the mixture was immediately subjected to purification by semi-
preparative (RP)HPLC method 1 (tr 34.9 min) yielding (<1 mg). ESI
+ LC-MS (m/z) 
calculated for C123H191N27O51S 2894.29 found [MH3]
3+ 966.19. 
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8.6 Chapter 6 experimental details 
1, 2, 3, 4, 6-Penta-O-acetyl-α-ᴅ-galactopyranose 50 
 
 
Perchloric acid (20 μL) was added to a stirred solution of acetic anhydride (50 mL) in 
an ice bath at 0 °C. Galactose 49 (5.00 g, 27.8 mmol) was added in small portions 
over an hour. TLC indicated completion of the reaction after 4 hours and the 
reaction mixture was concentrated to 20 mL. The reaction mixture was then diluted 
with chloroform (125 mL) and washed with saturated aqueous sodium bicarbonate 
(4 x 30 mL), water (30 mL) and brine (30 mL). The organic phase was dried over 
magnesium sulfate and evaporated under vacuum to afford the peracetylated sugar 
as a white solid (10.0 g, 93%). Rf 0.16 (3:1 petroleum spirit/ethyl acetate). 
1H NMR 
(500 MHz, CDCl3) δ 6.36 (1H, d, J = 1.8, H1), 5.49 (1H, br, H4), 5.33 - 5.31 (2H, m, H2, 
H3), 4.33 (1H, apparent t, J = 6.6, H5), 4.12 - 4.06 (2H, m, H6a, H6b), 2.15 (6H, s, 2 x 
CH3), 2.03 (3H, s, CH3), 2.01 (3H, s, CH3), 1.99 (3H, s, CH3). 
13C NMR (125 MHz, CDCl3) 
δ 170.5, 170.2, 170.2, 170.0, 169.0 (5 x C=O), 89.8 (C1), 68.8 (C5), 67.5 (C4), 67.4, 
66.5 (C2, C3), 61.3 (C6), 21.0, 20.7, 20.7, 20.7, 20.6 (5 x CH3). IR υmax (cm
-1) neat 
1737 (C=O). ESI+ MS (m/z) calculated for C16H22O11 390.12 found [MNa]
+ 413.11.  
m.p. 94-96 °C (lit. 96-97°C).269 
Phenyl 2,3,4,6-Tetra-O-acetyl-1-thio-β-ᴅ-galactopyranoside 51 
 
 
Peracetylated galactose 50 (2.22 g, 5.68 mmol) was stirred in dry dichloromethane 
(40 mL). Thiophenol (1.16 mL, 11.4 mmol) was added and the mixture was stirred at 
room temperature for 20 minutes. The mixture was cooled in an ice bath to 0 °C, 
after which boron trifluoride diethyl etherate (352 μL, 2.84 mmol) was added.  The 
mixture was then refluxed overnight for 16 hours. Dichloromethane (125 mL) was 
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added to dilute the reaction mixture which was then quenched with saturated 
aqueous sodium bicarbonate (50 mL). The organic layer was separated and washed 
with saturated aqueous sodium bicarbonate (50 mL) and brine (50 mL) before being 
dried over magnesium sulfate. The crude mixture was then concentrated under 
vacuum and then purified with silica gel flash chromatography (2:1 petroleum 
spirit/ethyl acetate) to yield the product as a clear oil (1.58 g, 63%). Rf 0.22 (7:3 
petroleum spirit/ethyl acetate) 1H NMR (500 MHz, CDCl3) δ 7.49 - 7.46 (2H, m, 2 x 
Ar-H), 7.29 - 7.27 (3H, m, 3 x Ar-H), 5.39 - 5.38 (1H, m, H4), 5.20 (1H, t, J = 10.1, H2), 
5.03 (1H, dd, J = 9.9, 3.3, H3), 4.70 (1H, d, J = 9.9, H1), 4.18 - 4.13 (1H, m, H6a), 4.11 
- 4.07 (1H, m, H6b), 3.92 (1H, t, J = 7.0, H5), 2.08 (3H, s, CH3), 2.06 (3H, s, CH3), 2.00 
(3H, s, CH3), 1.94 (3H, s, CH3). 
13C NMR (125 MHz, CDCl3) δ 170.4, 170.2, 170.0, 
169.5 (4 x C=O), 132.6, 132.5, 128.9, 128.2 (4 x Ar-C), 86.6 (C1), 74.5 (C5), 72.0 (C3), 
67.3 (C4), 67.3 (C2), 61.7 (C6), 20.9, 20.7, 20.7, 20.6 (4 x CH3). IR υmax (cm
-1) neat 
1739 (C=O). ESI+ MS (m/z) calculated for C20H24O9S 440.11 found [MNa]
+ 463.10. 
m.p. 78-81 °C (lit. 69-73 °C).270 
Phenyl 1-thio-β-ᴅ-galactopyranoside 52 
 
 
The acetylated thiogalactoside 51 (1.58 g, 3.59 mmol) was dissolved in dry 
methanol (20 mL) and stirred under nitrogen. To the stirred mixture was added 
sodium methoxide (10 mg, 190 µmol) and the reaction was then monitored by TLC. 
The pH was also monitored to ensure the catalyst had not been quenched. Further 
sodium methoxide was added when the pH of the reaction was found to be neutral. 
After 2 hours the reaction appeared complete by TLC, and Amberlyst 15 ion 
exchange resin was added until neutralisation of sodium methoxide. The resin was 
separated by filtration and the filtrate was evaporated under reduced pressure to 
afford a white foam (832 mg, 85%). Rf 0.08 (100% ethyl acetate). 
1H NMR (500 MHz, 
MeOD) δ 7.54 (2H, d, J = 7.3, 2 x Ar-H), 7.28 (2H, t, J = 7.3, 2 x Ar-H), 7.21 (1H, t, J = 
7.3, Ar-H), 4.58 (1H, d, J = 9.6, H1), 3.89 (1H, d, J = 3.0, H6a), 3.77 - 3.68 (2H, m, H5, 
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H6), 3.61 (1H, t, J = 9.6, H2), 3.56 (1H, t, J = 6.5, H4), 3.50 (1H, dd, J = 9.1, 3.3, H3). 
13C NMR (125 MHz, MeOD) δ 136.1, 132.1, 129.9, 128.0 (4 x Ar-C), 90.3 (C1), 80.6 
(C3), 76.3 (C4), 71.0 (C5), 70.4 (C2), 62.6 (C6). IR υmax (cm
-1) neat 3339 (OH). ESI+ MS 
(m/z) calculated for C12H16O5S 272.07 found [MNa]
+ 295.06. m.p. 114-116 °C (lit. 
105-107 °C).271 
Phenyl 3-O-(tert-butyloxycarbonyl)methyl 1-thio-β-ᴅ-galactopyranoside 53 
 
 
Thiogalactoside 52 (5.00 g, 18.4 mmol) was refluxed with dibutyltin oxide (6.86 g, 
27.6 mmol) in dry methanol (50 mL) for 4 hours. The mixture was then evaporated 
to give a light yellow foam which was redissolved in dry tetrahydrofuran (150 mL) 
containing 4Å molecular sieves. The mixture was stirred and tetrabutyl ammonium 
bromide (3.00 g, 9.23 mmol) was added in one portion. After a further 30 minutes 
of stirring at room temperature, tert-butyl bromoacetate (16.4 mL, 111 mmol) was 
added with the resulting mixture stirred at 60 °C overnight. The yellow mixture was 
filtered and evaporated under reduced pressure before being purified by silica gel 
flash chromatography (2:1 petroleum spirit/ethyl acetate) to yield the product as a 
white crystalline solid (5.79 g, 82%). Rf 0.63 (100% ethyl acetate). 
1H NMR (500 
MHz, CDCl3) δ 7.56 (2H, d, J = 6.5, 2 x Ar-H), 7.32 - 7.27 (3H, m, 3 x Ar-H), 4.55 (1H, 
d, J = 9.8, H1), 4.22 (1H, d, J = 17.2, CH), 4.11 (1H, d, J = 17.2, CH), 4.03 (1H, d, J = 
2.0, H6a), 3.98 (1H, dd, J = 11.8, 6.6, H2), 3.87 - 3.79 (1H, m, H6b, H4), 3.56 - 3.54 
(1H, m, H3), 3.33 (1H, dd, J = 8.9, 3.2, H5), 1.47 (9H, s, C(CH3)3). 
13C NMR (125 MHz, 
CDCl3) δ 171.4 (C=O), 132.5, 129.0, 127.9 (4 x Ar-C), 88.3 (C1), 85.0 (C5), 83.2 
(C(CH3)3), 78.3 (C3), 68.3 (C4), 67.9 (CH2), 67.1 (C2), 62.8 (C6), 28.1 (C(CH3)3). IR υmax 
(cm-1) neat 3405 (OH), 1720 (C=O). ESI+ HR-MS (m/z) C18H26O7S found [MNa]
+ 
409.1282, calculated 409.1297. m.p. 99-102 °C. 
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Phenyl 2,4,6-Tri-O-acetyl-3-O-(tert-butyloxycarbonyl)methyl 1-thio-β-ᴅ-
galactopyranoside 54 
 
 
Thiogalactoside 53 (1.58 g, 4.10 mmol) was dissolved in dry pyridine (12 mL) and 
stirred at 0 °C in an ice bath. Acetic anhydride (6 mL) was added and the reaction 
was allowed to warm to room temperature and stirred overnight. The yellow 
mixture was then diluted with chloroform (60 mL) and added to crushed ice (20 g). 
The organic layer was then washed with water (50 mL), saturated aqueous sodium 
bicarbonate (50 mL), 2 M aqueous hydrochloric acid (50 mL), water (50 mL) and 
brine (50 mL). The organic extract was dried over anhydrous magnesium sulfate and 
then concentrated under vacuum to afford a yellow solid (2.03 g, 97%). Rf 0.48 (2:1 
petroleum spirit/ethyl acetate). 1H NMR (500 MHz, CDCl3) δ 7.50 - 7.48 (2H, m, 2 x 
Ar-H), 7.27 - 7.26 (3H, m, 3 x Ar-H), 5.47 (1H, dd, J = 3.3, 1.1, H4), 5.12 (1H, t, J = 9.8, 
H2), 4.68 (1H, d, J = 10.1, H1), 4.14 - 4.12 (2H, m, H6a, H6b), 3.95 - 3.94 (2H, m, CH2), 
3.83 - 3.80 (1H, m, H5), 3.71 (1H, dd, J = 9.5, 3.3, H3), 2.15 (3H, s, CH3), 2.07 (3H, s, 
CH3), 2.03 (3H, s, CH3), 1.42 (9H, s, C(CH3)3). 
13C NMR (125 MHz, CDCl3) δ 170.6, 
170.4, 169.9, 168.9 (4 x C=O), 149.1, 132.6, 128.9, 128.0 (4 x Ar-C), 86.4 (C1), 81.8 
(C(CH3)3), 79.0 (C3), 74.6 (C5), 69.0 (C2), 66.7 (CH2), 66.2 (C4), 62.3 (C6), 28.1 
(C(CH3)3), 22.2, 21.1, 20.8 (3 x CH3). IR υmax (cm
-1) neat 1732 (C=O). ESI+ HR-MS (m/z) 
C24H32O10S found [MNa]
+ 535.1621, calculated 535.1614. m.p. 85-86 °C. 
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2,4,6-Tri-O-acetyl-3-O-(tert-butyloxycarbonyl)methyl ᴅ-galactopyranoside 55 
 
 
The acetylated thiogalactoside 54 (620 mg, 1.21 mmol) was stirred at room 
temperature in acetone (5.3 mL) and water (0.6 mL). To the stirred solution was 
added freshly recrystallised N-bromosuccinimide (650 mg, 3.65 mmol) which 
immediately turned the reaction mixture bright red (fading over time). The reaction 
was monitored by TLC and further N-bromosuccinimide was added when the 
reaction appeared to halt. TLC indicated completion within 2 hours. The mixture 
was diluted with ethyl acetate (25 mL) and quenched with saturated aqueous 
sodium thiosulfate (25 mL). The organic layer was then washed with water (25 mL) 
and then washed again with saturated aqueous sodium thiosulfate (25 mL). This 
process was repeated until no more precipitate formed, after which the organic 
layer was washed with water (25 mL) again. The crude product was purified by silica 
gel flash chromatography (1:1 petroleum spirit/ethyl acetate) to yield the product 
as a clear oil (411 mg, 81%). Rf 0.39 (1:1 petroleum spirit/ethyl acetate). IR υmax (cm
-
1) neat 1744 (C=O).  ESI+ HR-MS (m/z) C18H28O11 found [MNa]
+ 443.1519, calculated 
443.1529. 
2,4,6-Tri-O-acetyl-3-O-(tert-butyloxycarbonyl)methyl 1-O-diphenoxyphosphoryl-
α-ᴅ-galactopyranoside 56 
 
 
Galactose derivative 55 (813 mg, 1.93 mmol) was dissolved in dry tetrahydrofuran 
(50 mL) and stirred under nitrogen in a flame dried flask at -78 °C. Lithium 
diisopropylamide (1.8 M solution in tetrahydrofuran/heptane/ethylbenzene) (1.28 
mL, 2.32 mmol) was added and after a further 5 minutes of stirring, tetrabenzyl 
pyrophosphate (1.25 g, 2.32 mmol) in dry tetrahydrofuran (5.0 mL) was added. The 
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reaction was allowed to warm to room temperature and stirred for a further 2 
hours. The reaction was quenched with ethyl acetate (300 mL) and transferred to a 
separating funnel. The mixture was then washed with water (150 mL), 2 M aqueous 
hydrochloric acid (150 mL), saturated aqueous sodium bicarbonate (150 mL) and 
brine (150 mL). The organic extract was then dried over anhydrous magnesium 
sulfate and then concentrated under vacuum to give a clear oil which was 
subsequently purified by silica gel flash chromatography (2:1 to 1:1 petroleum 
spirit/ethyl acetate) to yield a clear oil (952 mg, 72%). Rf 0.45 (1:1 petroleum 
spirit/ethyl acetate). 1H NMR (600 MHz, CDCl3) δ 7.32 - 7.25 (10H, m, 10 x Ar-H), 
5.86 (1H, dd, J = 6.8, 3.4, H1), 5.51 (1H, dd, J = 2.8, 0.9, H4), 5.08 (1H, dt, J = 10.2, 
3.0, H2), 5.05 - 4.98 (4H, m, 2 x CH2), 4.21 (1H, t, J = 6.6, H5), 4.06 - 4.03 (1H, m, 
H6a), 3.98 - 3.89 (3H, m, CH2, H6b), 3.87 (1H, dd, J = 10.2, 3.4, H3), 2.04 (3H, s, CH3), 
1.86 (3H, s, CH3), 1.83 (3H, s, CH3), 1.40 (9H, s, C(CH3)3). 
13C NMR (150 MHz, CDCl3) δ 
170.5, 170.4, 170.2, 168.8 (4 x C=O), 128.9, 128.8, 128.2, 128.1 (4 x Ar-C), 95.0 (d, JC-
P = 6.0, C1), 81.9 (C(CH3)3), 73.5 (C3), 69.7 (C5), 69.2 (d, JC-P = 7.2, CH2), 69.0 (C2), 
67.8 (CH2), 67.2 (C4), 62.0 (C6), 28.2 (C(CH3)3), 20.9, 20.8, 20.7 (3 x CH3). 
31P NMR 
(121MHz, CDCl3) δ -1.44. IR υmax (cm
-1) neat 1747 (C=O). ESI+ HR-MS (m/z) 
C32H41O14P found [MNa]
+ 703.2184, calculated 703.2132. 
2,4,6-Tri-O-acetyl 3-O-(tert-butyloxycarbonyl)methyl 1-O-phosphoryl-α-ᴅ-
galactopyranoside (triethylammonium salt) 57 
 
 
The dibenzyl protected sugar monophosphate 56 (890 mg, 1.3 mmol) was stirred in 
dry methanol (25 mL) in the presence of Palladium on carbon (40 mg, 10% loading) 
under a hydrogen atmosphere at room temperature for 2 hours. Completion of the 
reaction was determined by TLC and the mixture was filtered through celite and 
washed through with methanol (2 x 25 mL). The filtrate was then stirred with 
triethylamine (250 µL) for 5 minutes and then concentrated in vacuo to give an off 
white amorphous solid which was further dried by co-evaporation with toluene to 
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yield a white solid (690 mg, 68% by NMR). Rf 0.5 (4:1 acetonitrile/water). 
1H NMR 
(600 MHz, CDCl3) δ 5.68 - 5.66 (1H, br, H4), 5.53 (1H, d, J = 2.1, H1), 4.98 (1H, d, J = 
10.3, H3), 4.42 - 4.39 (1H, m, H5), 4.09 - 3.94 (5H, m, H2, H6a, H6b, CH2), 2.05 (6H, s, 
2 x CH3), 1.98 (3H, s, CH3), 1.40 (9H, s, C(CH3)3). 
13C NMR (150 MHz, CDCl3) δ 171.1, 
170.8, 170.4, 169.1 (4 x C=O), 92.2 (C4), 81.6 (C(CH3)3), 74.0 (C3), 70.2 (d, JC-P = 7.7, 
C2), 67.8 (d, JC-P = 9.5, C1), 67.2 (CH2), 61.7 (C6), 28.2 (C(CH3)),  21.2, 20.9, 20.9 (3 x 
CH3). 
31P NMR (121MHz, CDCl3) δ -0.66. IR υmax (cm
-1) neat 1740 (C=O). ESI- HR-MS 
(m/z) C18H29O14P found [M-H]
- 499.1257, calculated 499.1217. 
2,4,6-Tri-O-acetyl 3-O-(tert-butyloxycarbonyl)methyl 1-O-uridine-5’-diphosphoryl-
α-ᴅ-galactopyranoside (Na salt) 58 
 
 
Sugar monophosphate 57 (399 mg, 800 µmol) was dissolved in toluene and rotary 
evaporated to dryness. This process was repeated twice more and then dissolved in 
N, N-dimethylformamide (8 mL) under a nitrogen atmosphere. 4Å molecular sieves 
were added followed by uridine 5’-monophosphomorpholidate 4-morpholine-N,N’-
dicyclohexyl carboxamidine salt (657 mg, 960 µmol). The mixture was stirred under 
nitrogen at 60 °C for 24 hours after which water (2.0 mL) was added. The mixture 
was stirred for a further ten minutes before being evaporated to dryness. The 
product was then purified using silica gel flash chromatography (1:20 to 1:4 
water/acetonitrile) to yield the product as an off white crystalline solid (190 mg). 
The purified material was redissolved in water (5 mL) and passed through cation 
exchange resin (2 mL, Na+ form). The flow through was collected and the resin was 
washed with water (10 mL) before the combined fractions were lyophilised. Rf 0.54 
(4:1 acetonitrile/water). 1H NMR (500 MHz, D2O) δ 7.88 (1H, d, J = 8.1, Ur CH), 5.92 - 
5.90 (2H, m, Rib H1, Ur CH), 5.71 - 5.68 (1H, dd, J = 7.7, 3.5, Gal H1), 5.59 - 5.56 (1H, 
m, Gal H4), 5.02 - 4.99 (1H, m, Gal H2), 4.45 (1H, q, Gal H5), 4.28 - 4.05 (10H, m, Rib 
H2, Rib H3, Rib H4, Rib H5a, Rib H5b, Gal H3, Gal H6a, Gal H6b, CH2), 2.11 (6H, s, 2 x 
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CH3), 2.01 (3H, s, CH3), 1.39 (9H, s, C(CH3)3).
 13C NMR (125 MHz, D2O) δ 173.9, 173.5, 
170.9, 166.4, 158.2 152.1 (6 x C=O), 142.1 (Ur C=C), 103.1 (Ur C=C), 92.9 (Gal C1), 
88.9 (Rib C1), 84.3 6 (C(CH3)3), 83.5, 74.1, 70.0 (3 x CH), 69.7 (d, JC-P = 7.7, Rib C2), 
68.4 (CH), 67.8 (d, JC-P = 7.7, Gal C2), 66.3 (CH), 65.3 (d, JC-P = 5.8, Gal C1), 62.3, 54.8, 
27.6 (3 x CH), (C(CH3)3), 20.8, 20.5, 20.5 (3 x CH3).
 31P NMR (121MHz, D2O) δ -9.03 
(d, JP-P = 19.6), -11.01 (d, JP-P = 20.0). IR υmax (cm
-1) neat 1744 (C=O), 1688 (C=O). ESI- 
HR-MS (m/z) C27H40N2O22P2 found [M-H]
- 805.1483, calculated 805.1470. m.p. 210 
°C (decomposed). 
Phenyl 2,4,6-Tri-O-acetyl-3-O-(benzyl)carboxymethyl 1-thio-β-ᴅ-
galactopyranoside 59 
 
The protected thioglycoside 54 (2.96 g, 5.78 mmol) was dissolved with stirring in 
dichloromethane (20 mL) at room temperature before the addition of 
trifluoroacetic acid (5 mL). TLC indicated completion of the reaction within 3 hours. 
The crude reaction mixture was evaporated to dryness, followed by co-evaporation 
with toluene (3 x 10 mL) to yield a brown oil (2.50 g, 95%). The crude product was 
used without further purification and stirred in dry N, N-dimethylformamide (40 
mL) with caesium carbonate (1.34 g, 4.11 mmol). Benzyl bromide (1.96 mL, 16.44 
mmol) was added and the mixture was stirred under nitrogen at room temperature 
overnight. The following day, the reaction mixture was diluted with water (125 mL) 
and extracted with chloroform (2 x 125 mL). The aqueous layer was further acidified 
by the addition of 2 M aqueous hydrochloric acid to a final pH of 2, followed by a 
further extraction with chloroform (50 mL). The combined extracts were rotary 
evaporated to dryness and the crude material was purified by flash 
chromatography (3:1 petroleum spirit/ethyl acetate) to yield a clear oil (2.34 g, 
72%). Rf 0.75 (1:1 petroleum spirit/ethyl acetate).  
1H NMR (500 MHz, CDCl3) δ 7.52 
- 7.50 (2H, m, 2 x Ar-H), 7.35 - 7.28 (8H, m, 8 x Ar-H), 5.47 (1H, dd, J = 3.3, 0.7, H4), 
5.14 - 5.12 (3H, m, H2, CH2), 4.67 (1H, d, J = 10.1, H1), 4.15 - 4.14 (4H, m, H6a, H6b, 
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CH2), 3.81 - 3.78 (1H, m, H5), 3.70 (1H, dd, J = 9.5, 3.4, H3), 2.12 (3H, s, CH3), 2.07 
(3H, s, CH3), 2.04 (3H, s, CH3). 
13C NMR (125 MHz, CDCl3) δ 170.5, 170.4, 169.8, 
169.6 (4 x C=O), 135.3, 132.8, 132.7, 128.9, 128.7, 128.6, 128.5, 128.1, (8 x Ar-C), 
86.5 (C1), 79.3 (C3), 74.6 (C5), 68.8 (C2), 66.7 (CH2), 66.4 (CH2), 66.0 (C4), 62.2 (CH2), 
21.1, 21.0, 20.8 (3 x CH3). IR υmax (cm
-1) neat 1750 (C=O). ESI+ HR-MS (m/z) 
C27H30O10S found [MNa]
+ 569.1446, calculated 569.1457. 
2,4,6-Tri-O-acetyl-3-O-(benzyl)carboxymethyl ᴅ-galactopyranoside 60 
 
To a stirred solution of thioglycoside 59 (2.34 g, 4.28 mmol) in acetone (45 mL) and 
water (5 mL) was added freshly recrystallised N-bromosuccinimide (2.29 g, 12.9 
mmol) at room temperature. TLC analysis suggested a halt in progress of the 
reaction after 2 hours and further N-bromosuccinimide (500 mg, 2.8 mmol) was 
added. After stirring at room temperature for another hour, the reaction mixture 
was concentrated under reduced pressure to 10 mL and the crude residue was 
taken up in ethyl acetate (150 mL). The extract was washed with water (100 mL), 
saturated sodium bicarbonate solution (100 mL) and water (100 mL). The organic 
layer was dried over magnesium sulfate before concentration in vacuo. The crude 
oil was purified by flash chromatography (3:1 petroleum spirit/ethyl acetate) to 
yield a clear oil (1.18 g, 61%). Rf 0.27 (1:1 petroleum spirit/ethyl acetate). IR υmax 
(cm-1) neat 1749 (C=O). ESI+ HR-MS (m/z) C21H26O11 found [MNa]
+ 477.1350, 
calculated 477.1373. 
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2,4,6-Tri-O-acetyl-3-O-(benzyl)carboxymethyl 1-O-diphenoxyphosphoryl-α-ᴅ-
galactopyranoside 61 
 
Galactose derivative 60 (508 mg, 1.12 mmol) was dissolved in dry tetrahydrofuran 
(15 mL) and stirred under nitrogen in a flame dried flask at -78 °C. Lithium 
diisopropylamide (1.8 M solution in tetrahydrofuran/heptane/ethylbenzene) (683 
µL, 1.23 mmol) was added and after a further 5 minutes of stirring, tetrabenzyl 
pyrophosphate (662 mg, 1.23 mmol) in dry tetrahydrofuran (3.0 mL) was added. 
The reaction was allowed to warm to room temperature and stirred for a further 3 
hours. The reaction was quenched with ethyl acetate (150 mL) and transferred to a 
separating funnel. The mixture was then washed with water (75 mL), 1 M aqueous 
hydrochloric acid (75 mL), saturated aqueous sodium bicarbonate (75mL) and brine 
(75 mL). The organic extract was then dried over anhydrous magnesium sulfate and 
then concentrated under vacuum to give a clear oil which was subsequently 
purified by silica gel flash chromatography (2:1 to 1:1 petroleum spirit/ethyl 
acetate) to yield a clear oil (540 mg, 68%). Rf 0.38 (1:1 petroleum spirit/ethyl 
acetate). 1H NMR (500 MHz, CDCl3) δ 7.37 - 7.34 (15H, m, 15 x Ar-H), 5.91 (1H, dd, J 
= 6.6, 3.4, H1), 5.55 (1H, dd, J = 2.2, H4), 5.17 - 5.09 (7H, m, H2, 3 x CH2), 4.25 (1H, t, 
J = 6.4, H5), 4.17 (2H, q, J = 16.6, CH2) 4.09 (1H, dd, J = 11.4, 5.9, H6a), 3.97 (1H, dd, J 
= 11.4, 6.9, H6b) 3.90 (1H, dd, J = 10.3, 3.3, H3), 2.11 (3H, s, CH3), 1.91 (3H, s, CH3), 
1.88 (3H, s, CH3). 
13C NMR (125 MHz, CDCl3) δ 170.4, 170.3, 170.2, 169.5 (4 x C=O), 
135.4, 135.3, 128.8, 128.7, 128.6, 128.5, 128.1, 128.0 (8 x Ar-C), 94.9 (d, JC-P = 6.0, 
C1), 73.8 (C3), 69.7 (d, JC-P = 5.0, CH2), 69.0 (CH2), 69.0 (C5) 68.9 (CH2) 67.3 (C4), 67.0 
(CH2), 66.8 (C2), 61.9 (C6) 20.7, 20.6, 20.6 (3 x CH3). 
31P NMR (121MHz, CDCl3) δ -
1.40. IR υmax (cm
-1) neat 1753 (C=O). ESI+ HR-MS (m/z) C18H29O14P found [MNa
+(-
PO2(OBn)2)]
+ 460.1634, calculated 460.1340. 
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3-O-(tert-butyloxycarbonyl)methyl-1-O-uridine-5’-diphosphoryl-α-ᴅ-
galactopyranoside (Na salt) 62 
  
Sugar nucleotide 58 (13 mg, 19.8 µmol) was stirred in a mixture of methanol, water 
and triethylamine (5:3:1, 900 µL) at room temperature for 7 days. The reaction was 
diluted with water (20 mL) and freeze dried. The crude material was redissolved in 
water (1 mL) and passed through cation exchange resin (1 mL, Na+ form). The flow 
through was collected and the resin was washed with water (5 mL) before the 
combined fractions were lyophilised. ESI+ MS (m/z) calculated for C21H34N2O19P2 
680.44 found [MNa]+ 703.19. HR-MS attempted in ESI+ and ESI- modes, however no 
molecular ion was found by these methods. 
Benzyl 2-acetamido-2-deoxy-3,4,6-tri-O-acetyl-β-ᴅ-glucopyranoside 64 
  
Phthalamido protected GlcNAc 63 (500 mg, 1.05 mmol) was stirred in dry 
dichloromethane (10 mL) with benzyl alcohol (109 µL, 1.05 mmol) under nitrogen 
and cooled to 0 °C. Boron trifluoride diethyl etherate (133 μL, 1.05 mmol) was 
added dropwise and the reaction was allowed to warm to room temperature. After 
stirring overnight, the reaction was diluted with dichloromethane (20 mL) before 
being washed with water (20 mL), saturated sodium bicarbonate (20 mL) and brine 
(20 mL) and dried over magnesium sulfate. The crude reaction mixture was 
concentrated in vacuo to give a yellow foam which was redissolved in n-butanol (20 
mL). Ethylenediamine (232 μL, 1.57 mmol) was added, and the mixture was 
refluxed at 90 °C overnight. After concentration under reduced pressure, the 
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residue was dissolved in pyridine (20 mL) and acetic anhydride (10 mL) was added 
at 0 °C. After stirring under nitrogen overnight, the mixture was diluted with ethyl 
acetate (100 mL) before being washed with water (100 mL), saturated sodium 
bicarbonate (100 mL) and brine (100 mL) and dried over magnesium sulfate. The 
crude product was concentrated in vacuo and purified by silica gel flash 
chromatography (1:1 petroleum spirit/ethyl acetate to 100% ethyl acetate) to yield 
a white solid (205 mg, 45%). Rf 0.56 (100% ethyl acetate). 
1H NMR (500 MHz, CDCl3) 
δ 7.45 - 7.18 (5H, m, 5 x Ar-H), 5.46 (1H, d, J = 8.9, NH), 5.20 (1H, dd, J = 10.5, 9.4, 
H3), 5.08 (1H, t, J = 9.6, H4), 4.88 (1H, d, J = 12.2, CH2a), 4.64 - 4.58 (2H, m, H1, 
CH2b), 4.27 (1H, dd, J = 12.2, 4.8, H6a), 4.16 (1H, dd, J = 12.2, 2.4, H6b), 3.97 (1H, dt, J 
= 10.5, 8.7, H2), 3.67 (1H, ddd, J = 9.9, 4.7, 2.5, H5) 2.09 (3H, s, CH3), 2.01 (3H, s, 
CH3), 2.00 (3H, s, CH3), 1.90 (3H, s, CH3). 
13C NMR (125 MHz, CDCl3) δ 171.0, 170.8, 
170.2, 169.4 (4 x C=O), 137.0, 128.6, 128.1, 128.0 (4 x Ar-C), 99.5 (C1), 72.5 (C3), 
71.9 (C5), 70.7 (CH2), 68.7 (C4), 62.2 (C6), 54.8 (C2), 23.4, 20.8, 20.7, 20.6 (4 x CH3). 
IR υmax (cm
-1) neat 1738 (C=O). ESI+ MS (m/z) calculated for C21H27NO9 437.17 found 
[MH]+ 438.17. m.p. 169-172 °C (lit. 165-166 °C).272 
Benzyl 2-acetamido-2-deoxy-β-ᴅ-glucopyranoside 65 
 
The acetylated glycoside 64 (100 mg, 228 µmol) was stirred in dry methanol (5 mL) 
with sodium methoxide (0.5 M, 50 µL) at room temperature for an hour. TLC 
indicated complete deacetylation and Amberlyst 15 ion exchange resin was added 
to neutralise the mixture. The resin was separated by filtration and the filtrate was 
evaporated under reduced pressure to afford 65 as a white solid (70 mg, 99%). 1H 
NMR (600 MHz, DMSO-d6) δ 7.76 (1H, d, J = 9.1, NH), 7.34 - 7.25 (5H, m, 5 x Ar-H), 
4.78 (1H, d, J = 12.4, CH2a), 4.51 (1H, d, J = 12.4, CH2b), 4.35 (1H, d, J = 8.5, H1), 3.70 
(1H, d, J = 10.8, H6a), 3.55 - 3.42 (2H, m, H2, H6b), 3.28 (1H, dd, J = 10.1, 8.1, H3), 
3.10 - 3.08 (2H, m, H4, H5), 1.81 (3H, s, CH3). 
13C NMR (150 MHz, DMSO-d6) δ 
169.18 (C=O), 138.1, 128.2, 127.4, 127.2 (4 x Ar-C), 100.7 (C1), 77.0 (C5), 74.0 (C3), 
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70.5 (C4), 69.5 (CH2), 61.0 (C6), 55.3 (C2), 23.0 (CH3). IR υmax (cm
-1) neat 3299 (OH), 
1640 (C=O). ESI+ MS (m/z) calculated for C15H21NO6 311.14 found [MH]
+ 312.14. 
m.p. 191-193 °C (lit. 194-196 °C).273 
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1H NMR (500 MHz, CDCl3) Phenyl 3-O-(tert-butyloxycarbonyl)methyl 1-thio-β-ᴅ-
galactopyranoside 53 
 
13C NMR (125 MHz, CDCl3) Phenyl 3-O-(tert-butyloxycarbonyl)methyl 1-thio-β-ᴅ-
galactopyranoside 53 
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1H NMR (500 MHz, CDCl3) Phenyl 2,4,6-Tri-O-acetyl-3-O-(tert-butyloxycarbonyl)methyl 1-
thio-β-ᴅ-galactopyranoside 54 
 
13C NMR (125 MHz, CDCl3) Phenyl 2,4,6-Tri-O-acetyl-3-O-(tert-butyloxycarbonyl)methyl 1-
thio-β-ᴅ-galactopyranoside 54 
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1H NMR (600 MHz, CDCl3) 2,4,6-Tri-O-acetyl-3-O-(tert-butyloxycarbonyl)methyl 1-O-
diphenoxyphosphoryl-α-ᴅ-galactopyranoside 56 
 
13C NMR (150 MHz, CDCl3) 2,4,6-Tri-O-acetyl-3-O-(tert-butyloxycarbonyl)methyl 1-O-
diphenoxyphosphoryl-α-ᴅ-galactopyranoside 56 
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31P NMR (121 MHz, CDCl3) 2,4,6-Tri-O-acetyl-3-O-(tert-butyloxycarbonyl)methyl 1-O-
diphenoxyphosphoryl-α-ᴅ-galactopyranoside 56 
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1H NMR (600 MHz, CDCl3) 2,4,6-Tri-O-acetyl 3-O-(tert-butyloxycarbonyl)methyl 1-O-
phosphoryl-α-ᴅ-galactopyranoside (triethylammonium salt) 57 
 
13C NMR (150 MHz, CDCl3) 2,4,6-Tri-O-acetyl 3-O-(tert-butyloxycarbonyl)methyl 1-O-
phosphoryl-α-ᴅ-galactopyranoside (triethylammonium salt) 57 
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31P NMR (121 MHz, CDCl3) 2,4,6-Tri-O-acetyl 3-O-(tert-butyloxycarbonyl)methyl 1-O-
phosphoryl-α-ᴅ-galactopyranoside (triethylammonium salt) 57 
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1H NMR (500 MHz, D2O) 2,4,6-Tri-O-acetyl 3-O-(tert-butyloxycarbonyl)methyl 1-O-uridine-
5’-diphosphoryl-α-ᴅ-galactopyranoside (Na salt) 58 
 
13C NMR (125 MHz, D2O) 2,4,6-Tri-O-acetyl 3-O-(tert-butyloxycarbonyl)methyl 1-O-
uridine-5’-diphosphoryl-α-ᴅ-galactopyranoside (dicyclohexylcarboxamide salt) 58 
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31P NMR (121 MHz, D2O) 2,4,6-Tri-O-acetyl 3-O-(tert-butyloxycarbonyl)methyl 1-O-
uridine-5’-diphosphoryl-α-ᴅ-galactopyranoside (Na salt) 58 
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1H NMR (500 MHz, CDCl3) Phenyl 2,4,6-Tri-O-acetyl-3-O-(benzyl)carboxymethyl 1-thio-β-
ᴅ-galactopyranoside 59 
 
13C NMR (125 MHz, CDCl3) Phenyl 2,4,6-Tri-O-acetyl-3-O-(benzyl)carboxymethyl 1-thio-β-
ᴅ-galactopyranoside 59 
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1H NMR (500 MHz, CDCl3) 2,4,6-Tri-O-acetyl-3-O-(benzyl)carboxymethyl 1-O-
diphenoxyphosphoryl-α-ᴅ-galactopyranoside 61 
 
13C NMR (125 MHz, CDCl3) 2,4,6-Tri-O-acetyl-3-O-(benzyl)carboxymethyl 1-O-
diphenoxyphosphoryl-α-ᴅ-galactopyranoside 61 
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31P NMR (121 MHz, CDCl3) 2,4,6-Tri-O-acetyl-3-O-(benzyl)carboxymethyl 1-O-
diphenoxyphosphoryl-α-ᴅ-galactopyranoside 61 
 
